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Abstract 
 
Telomerase is present in over 90% of tumour tissues and immortalized cells and is 
tightly regulated in most normal somatic cells. This suggests the existence of 
regulatory mechanisms repressing telomerase in normal cells that somehow have 
become inactive during cancer development. In this project, I used genetic 
complementation in the form of microcell-mediated monochromosome transfer 
(MMCT) to search for chromosomes that repress telomerase activity in a prostate 
cancer cell line, PC-3. Microcell hybrids generated by introducing normal human 
chromosome 11 strongly inhibited telomerase. Telomerase is regulated primarily at 
the level of hTERT transcription, its catalytic subunit. Consequently, endogenous 
hTERT mRNA levels were measured by quantitative RT-PCR in microcell hybrids 
generated by transferring normal human chromosomes into a PC-3 sub-clone (PC-
3/hTERT) ectopically expressing hTERT cDNA to prevent senescence. Only hybrids 
constructed with transferred chromosome 11 showed strong transcriptional 
repression of hTERT. Next, hybrids were constructed by the MMCT transfer of 
chromosome 11 fragments (X-ray-induced). FISH analysis of clones with completely 
silenced endogenous hTERT transcription revealed in all cases a discrete 
chromosome 11 fragment with both the p-arm and q-arm material. A randomly 
selected hTERT-repressed clone was treated with ganciclovir to select against the 
HyTK marker and reverse the phenotype. hTERT expression in majority of GCV-
resistant clones returned to levels comparable to the parent PC-3/hTERT cells. 
Collectively, these results provide strong functional evidence for the presence of a 
powerful telomerase repressor sequence on the fragment. Transfer of one repressive 
fragment back into mouse A9 cells was then carried out to facilitate fine-structure 
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mapping of its sequence content. High density STS mapping of the fragment in each 
of the clones revealed a considerable DNA content heterogeneity across the panel. 
These content maps, together with a further round of MMCT to confirm hTERT-
repressive activity, enabled me to identify three candidate regions on the q-arm of 
chromosome 11 where the repressor sequence may be located: the first region lies 
between map positions 64.70Mb to 65.42Mb and the other two regions each flank a 
single positive STS marker at 69.71Mb and 127.32Mb. KAT5, a histone modifying 
gene has been identified as a potential candidate for repressing hTERT. 
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NCBI  National Center for Biotechnology Information. 
PBS  Phosphate Buffered Saline 
PCR  Polymerase Chain Reaction 
PEG  Poly Ethylene Glycol 
PHA-P  Phytohaematogglutinin-P 
PIA  Proliferative Inflammatory Atrophy 
PIN  Prostatic Intraepithelial Neoplasia 
PMSF  PhenylMethylSulphonylFluride 
PSA  Prostate Specific Antigen 
Rb  Retinoblastoma gene. 
RNA  Ribonucleic acid 
Rpm  Revolutions per minute.  
RQ  Relative Quantification. 
RT-PCR Reverse Transcription Polymerase Chain Reaction. 
SETD2  SET Domain Containing protein 2 
SFM  Serum Free Medium.  
STS  Short Tagged Sequences. 
SV40  Simian Virus 40 
TBE  Tris Borate EDTA 
TRAP  Telomerase Repeat Amplification Protocol 
TSG  Tumour Suppressor Gene. 
XMMCT Irradiated Microcell Mediated Chromosome Transfer 
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Background and the aim of the project 
Telomeres are special nucleoprotein structures consisting of tandem repeats of DNA 
hexamers at the end of linear human chromosomes (Moyzis et al., 1988). Normal 
somatic cells progressively lose their telomeric repeats with each cell division due to 
incomplete DNA replication (Harley et al., 1990). When the telomeres become 
critically short the cells senesce and this is thought to act as a tumour suppressor 
mechanism in normal cells (reviewed in Campisi and di Fagagna, 2007). However, 
immortal and cancer cells overcome the end replication problem by expressing 
telomerase. Telomerase is a ribonucleoprotein that can add hexameric repeats of 
nucleotides to the ends of chromosomes during replication and maintain telomere 
length (Greider and Blackburn., 1985). Telomerase activity is detected in over 90% 
of all human cancers and it is undetected in normal somatic cells (Kim et al., 1994) 
except in rapidly self renewing tissue cells such as stem cells, human germ cells, 
lymphocytes and endometrial cells (reviewed in Kyo and Inoue, 2002). Therefore, 
telomerase has become a preferential target for anticancer drug development. 
 
In humans, the two main components of telomerase are the RNA template (hTR) and 
the catalytic subunit which is a reverse transcriptase (hTERT). The human 
telomerase RNA template is ubiquitously expressed in most cells (Feng et al., 1995) 
whereas hTERT is exclusively expressed in immortal cells and cancerous tissues 
(Kim et al., 1994). Thus hTERT is the limiting component in controlling telomerase 
activity. A strong correlation between telomerase activity and hTERT transcription 
exists in numerous cancers (Meyerson et al., 1997). This suggests that hTERT 
repressors are present in normal somatic cells that are inactivated in cancerous 
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tissues. Human TERT expression is predominantly regulated at the transcriptional 
level but differential splicing of the hTERT transcript and post-translational 
modification of the hTERT protein also contribute to its regulation (reviewed in Kyo 
and Inoue, 2002). Since the cloning of the upstream hTERT proximal promoter, 
many transcription factors have been identified that regulate its expression either 
directly or indirectly (Kilian et al., 1997; Cong et al., 1999). Several groups have 
identified regions on normal human chromosomes that may harbour hTERT repressor 
sequences in various cancers by using the microcell mediated chromosome transfer 
(MMCT) technique (Horikawa et al, 1998; Cuthbert et al., 1999; Nishimoto et al., 
2001; Steenbergen et al., 2001; Backsch et al., 2001). Our own group has used this 
methodology to identify a region on chromosome 3p that represses hTERT mRNA 
expression in 21NT, a breast ductal carcinoma cell line (Cuthbert et al., 1999). 
 
In our laboratory, MMCT is a well established technique that allows individual 
transfer of normal human chromosomes, tagged with the selectable HyTK fusion 
gene, into any recipient cell line. We have available a complete panel of normal 
human:mouse monochromosomal hybrids, in which the individual human 
chromosome exists as an intact stable entity in a mouse background. The introduced 
chromosome is maintained in the recipient cells by drug selection. The selectable 
HyTK marker provides a potent tool in the search for novel genes by function 
analysis, since it can be selected “in” by culturing the cells in hygromycin B or 
selected “out” by treating the cells with ganciclovir (Cuthbert et al., 1995). Different 
chromosomes have been implicated in various cancers indicating that telomerase 
regulation is tissue specific (Horikawa et al, 1998; Cuthbert et al., 1999; Nishimoto 
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et al., 2001; Steenbergen et al., 2001; Backsch et al., 2001). Chromosome(s) that may 
carry a gene for repressing telomerase are yet to be identified for prostate cancer. 
Therefore, the aim of this project was to identify gene(s) on normal human 
chromosome(s) that repress telomerase activity involved in prostate cancer. In the 
present study, I made use of the MMCT technique to individually transfer normal 
human chromosomes of the complete donor panel into PC-3, a prostate cancer cell 
line. This potentially permitted me to screen the whole genome in search of gene(s) 
that may repress telomerase activity. Furthermore, use of molecular and cytogenetic 
techniques allowed me to identify the regions on the transferred normal human 
chromosome where the telomerase repressor sequence may be located. 
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General introduction 
1.1 The prostate gland 
The prostate gland is a male muscular organ situated directly below the bladder in 
front of the rectum. At birth the prostate gland weighs only a few grams and it is 
roughly the size of a pea. Enlargement to adult size starts at puberty from the effects 
of androgen hormones and stops at the age of about 20. The approximate size of a 
normal adult prostate gland is 1.5inches long. The prostate gland consists of 
approximately 30-50 smaller glands and stroma that are surrounded by a fibrous 
tissue known as the prostatic capsule. The main function of the prostate gland is to 
produce secretions that form part of the semen; the rest of the seminal fluid is 
produced by a pair of glands, attached to the prostate, called seminal vesicles 
(http://library.med.utah.edu; http://www.upmccancercenters.com). 
The prostate gland can cause major problems in men above the age of about 50, 
enlargement of the gland being the main medical concern. Since the urethra is 
completely surrounded by the prostate gland, enlargement of the latter restricts the 
flow of urine as the urethra gets squeezed. Both benign prostatic hyperplasia (BPH) 
and prostate cancer result in enlarged prostate, often showing similar symptoms. 
(http://www.upmccancercenters.com). 
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1.1.1 Prostate Cancer (CaP) 
There has been an enormous increase in incidence rates of prostate cancer over the 
past 20 years and this has made CaP the sixth most common cancer in the world and 
the third most common amongst men. In Europe, North America and some parts of 
Africa it is the most commonly diagnosed malignant neoplasm and the second 
leading cause of cancer deaths in USA and Europe (Kumar et al., 2004; reviewed in 
Gronberg, 2003). The clinical behaviour of CaP is extremely unpredictable. The 
most typical features of CaP include its very slow growth compared with breast or 
colon cancers. CaP is highly associated with age, typically diagnosed in men aged 
over 70 years. Other distinct traits of CaP include heterogeneity in its morphology 
and genotype, suggesting the involvement of multiple pathways in its development, 
(reviewed in Bostwick et al., 2004). 
 
1.1.1.i Symptoms, diagnosis, prognosis and treatment 
Most early prostate cancers cause no symptoms but progression of the disease can 
cause changes in urination flow, frequency of urination, pelvic, hip or back pain. 
Nevertheless these symptoms may also occur in other diseases not related to CaP 
(Cancer Research UK, website). The two most important tests used in conjunction 
with each other to diagnose early CaP are the prostate specific antigen (PSA) blood 
test and the digital rectal examination (DRE). However, the changes observed by 
these tests are not specific for prostate cancer and, in the event of elevated PSA 
and/or abnormal DRE, a needle biopsy has to be performed. The prostate specific 
antigen (PSA) blood test has been used widely for over 25 years to diagnose CaP but 
it fails as a reliable test because it often leads to false positive and false negative 
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results. PSA is not a specific test for CaP as elevated levels are also observed in 
individuals with benign prostatic hyperplasia (BPH) and prostatitis. BPH is the 
enlargement of the prostate gland, a non-cancerous condition associated with aging 
and prostatitis is the inflammation of the prostate gland (Cancer Research UK, 
website). There is no specific PSA level that can distinguish CaP from BPH 
(Thompson et al., 2005). Therefore, men with high PSA levels need to undergo 
repeated biopsies to rule out CaP as these individuals are at a greater risk of 
developing CaP as they get older. A need for a more specific test to evaluate the 
requirement of biopsies in these patients has led to the recent development of the 
PCA3 (prostate cancer gene 3) molecular biomarker. The PCA3 gene encodes a 
prostate-specific mRNA that is highly over expressed in CaP cells compared with 
BPH (Marks et al., 2007). The PCA3 gene is detected in the nuclear material 
collected from cancer cells that have been shed into the urine after the prostate is 
massaged three times on each lobe during DRE (Groskopf et al., 2006). The PCA3 
urine assay has very recently been introduced clinically in the UK. 
 
Patients with localised CaP show considerable heterogeneity in biological 
aggressiveness and prognosis. Even though CaP is normally an indolent disease, 25-
30% of the tumours behave aggressively (Crawford 2003). Presently there is no 
accurate way to predict the course of the disease in individual patients and no 
consensus on the most appropriate means of treating localized disease. However, 
radical prostatectomy is an effective treatment for patients whose cancer is confined 
to the prostate and has not spread to the seminal vesicles. Over 90% of men remained 
cancer free five years after the surgery (http://www.upmccancercenters.com). 
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Radiation therapy is used to treat patients whose cancers are confined to the prostate 
gland or has spread to nearby tissues. It is also used in advanced forms of cancers to 
reduce the size of the tumour. Androgen deprivation is the main treatment given to 
patients with locally advanced and early metastatic disease. Initially, between 70-
80% of the patients respond to the therapy but the tumour eventually becomes 
hormone independent and more aggressive, leading to a poor prognosis (Crawford 
2003; Cancer Research UK, website). 
 
1.1.2 Epidemiology of prostate cancer 
There are 32,000 cases of prostate cancer diagnosed in the UK every year, which is 
12% of all cancers, causing 10,000 deaths. One in every 4 male cancers diagnosed in 
the UK is prostate cancer making it the most commonly diagnosed cancer in men. 
This may be explained by the fact that men are living longer and that there is 
enhanced usage of the PSA test (Cancer Research UK, website). Various exogenous 
(diet, geography and socio-economics situation) and endogenous (hormonal 
imbalance, epithelial and stroma interaction and family history) risk factors 
contributing to prostate cancer development have been suggested (Bostwick et al., 
2004; Crawford, 2003). 
 
1.1.2.i Age, ethnicity and diet 
Age is the major risk factor with incidence rate increasing sharply as men get older. 
The highest numbers of cases diagnosed in men are between the ages of 70 and 79 
and CaP is rarely found in men under the age of 50 (Crawford, 2003; Cancer 
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Research UK, website). Prostate cancer is usually evident in men in their 60s or 70s 
even though pre-neoplastic lesions known as prostatic intraepithelial neoplasia (PIN) 
can be found in younger men and are quite common in men in their fifties. The 
incidence of PIN is much more extensive, affecting 1 in 3 men compared to the 
incidence of carcinoma which affects approximately 1 in 9 men. Morphological 
changes related to the initiation of the disease are commonly observed, occurring 
early in life whereas advancement of the disease to metastatic state affects a fewer 
number of older men (reviewed in Abate-Shen and Shen, 2000). 
 
Geographical distribution of CaP cases also varies considerably, with the highest 
incidences of CaP in the western world and lowest in Asia. USA has twice the 
incidence rate of CaP than that of the UK but this may be due to higher usage of PSA 
testing in the USA (Collin et al., 2008; Shibata and Whittemore, 2001). Within the 
USA, African Americans have a higher incidence rate of CaP than white Americans, 
and the Chinese and Japanese have the lowest rate in the world, leading to the idea 
that dietary and environmental factors may play a significant role in prostate 
carcinogenesis (reviewed in Bostwick et al., 2004; Cancer Research UK, website). 
Effects of diet and environment have been shown by studies conducted on Japanese 
immigrants to the USA. The risk of prostate cancer correlated with the age of the 
individuals at the time of relocation to the USA and the period spent in the new 
environment (Cook et al., 1999). Adapting to a Western lifestyle has been proposed 
to account for higher risk of prostate cancer, especially high intake of food rich in 
saturated fat such as red meat and dairy products which are known to increase 
prostate cancer incidence and mortality (reviewed in Bostwick et al., 2004). High 
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intake of soybean, which is rich in isoflavones such as genistein and daidzin, is 
thought to possibly be related to low incidences of prostate cancer in Japan. It has 
been proposed that tyrosine-specific kinases, which are proteins involved in cell 
proliferation and transformation can be inhibited by genistein and thus constrain the 
progression of prostate tumours (Akiyama et al., 1987). It has been reported that 
daily intake of selenium, mainly found in grains and fish may have protective effects 
against prostate cancer in humans. Long term supplementation with α tocopherol (a 
form of vitamin E) has also been reported to lower the risk of CaP (Shirai et al., 
2002; reviewed in Gronberg, 2003). 
 
1.1.2.ii Mortality 
Significant variations exist between mortality rates due to CaP throughout the world. 
High rates of mortality are observed in the USA especially amongst the African 
Americans while mortality rates are much lower in China and Japan. African 
American men have more than double the rate of mortality compared to white 
Americans and approximately 10 times greater mortality than that for men in Hong 
Kong and Japan (Bostwick et al., 2004). This variation in the mortality rate may be 
explained by the differences in socioeconomic status of the patients which seems to 
be higher in lower status individuals. However, when healthcare is equally available 
to the African American men and white men, certain patient population may not 
avail the opportunities equally (reviewed by Hass and Sakr, 1997). In the UK 10,209 
deaths were recorded in 2004 which was 13% of all male cancer deaths. Ninety three 
per cent of the prostate cancer deaths were in men aged 65 years or more (Cancer 
Research UK, website). Mortality has decreased in the USA and the UK, but the rate 
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of decline is much faster in the USA than in the UK. This could be due to intensive 
use of the PSA test for screening and monitoring the therapeutic efficacy or it may be 
due to the differences in the treatment of the disease or both (Collin et al., 2008; 
Shibata and Whittemore, 2001). The fact that most men with prostate cancer die from 
other causes rather than directly from it is well established. There is a 3% risk of an 
American man dying of prostate cancer and a 72% risk of dying with the disease but 
of unrelated causes (reviewed Bostwick et al., 2004). The main predictors of death 
due to prostate cancer is related to the disease being diagnosed at a young age, being 
of African American race, or disease at an advanced stage when diagnosed 
(Crawford, 2003). 
 
1.1.2.iii Genetic susceptibility 
The chance of developing prostate cancer doubles for individuals that have either 
their father or a brother affected by the disease. The risk is further increased if 
multiple relatives have prostate cancer and the onset of the disease is usually 6-7 
years earlier in life compared with the sporadic form of the disease (Carter et al., 
1992). Approximately 40% of patients of less than 55 years of age have hereditary 
CaP when diagnosed with the disease. Hereditary prostate cancers account for 5-10% 
of the disease incidence and there are no known clinical differences between 
hereditary and sporadic prostate cancer (Bratt, 2002). Familial prostate cancer is 
thought to occur from inheriting one or more susceptibility genes or being exposed to 
the same environmental factors (Crawford, 2003; Gronberg, 2003). Linkage analysis 
and refined mapping has identified 3 strong candidate genes for hereditary prostate 
cancer (HPC). RNASEL (1q25), believed to be a tumour suppressor gene involved in 
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regulating cell proliferation and apoptosis is found within the HPC1 (1q24-25) locus 
(Carpten et al., 2002). The other germline mutations are in the MSR1 (8p22-23) and 
HPC2/ELAC2 (17p12) genes. The involvement of these 3 putative susceptibility 
genes was very infrequent in sporadic CaP (Porkka and Visakorpi, 2004).  
 
Linkage analysis and epidemiological studies of familial prostate cancer have 
identified other susceptibility loci on chromosomes X, 8, 17 and 20, but these loci 
have not yet been linked to any specific candidate genes (Simard et al., 2002). The 
search for CaP susceptibility genes has been difficult because the disease is usually 
diagnosed at an advanced age which often means it is impossible to obtain DNA 
samples from living relatives of more than one generation; also problematic is the 
complexity in identifying hereditary and sporadic forms of the cancers in individuals 
with high risk phenotypes and genetic heterogeneity (Simard et al., 2002). 
 
Recently, Eeles et al (2008) employed genome-wide association study (GWAS) to 
investigate genetic susceptibility in CaP patients that were either diagnosed with the 
disease at ≤60 years or had family history of the disease. The control for this study 
consisted of individuals with very low PSA levels of <0.5ηg/ml. The authors 
analysed over half a million SNPs (single nucleotide polymorphisms) in the two 
populations and they identified seven new loci on chromosomes 3, 6, 7, 10, 11, 19 
and X associated with CaP. In these new regions, the authors identified three 
candidate susceptibility genes for CaP. These are MSMB (microseminoprotein beta-
which codes for an immunoglobulin binding factor family and is synthesized by the 
epithelial cells of the prostate) on chromosome 10, LMTK2 (lemur tyrosine kinase 2) 
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on chromosome 7 and KLK3 (kallikrein-related peptidase 3) on chromosome 19. It 
has been proposed that these candidate genes and their products may be used to 
screen CaP and potentially be used as therapeutic targets. 
 
1.1.2.iv Effects of hormones on prostate cancer 
There is strong evidence to suggest that steroid hormones play a significant role in 
the pathogenesis of prostate cancer but the precise mechanisms by which androgens 
affect this process is not clear. The growth and differentiation of the prostate gland 
which is composed of stromal and epithelial cells is regulated by androgens. The 
enzyme 5-alpha-reductase reduces testosterone to dihydrotestosterone (DHT), an 
active metabolite that controls the development of the prostate (reviewed in Haas and 
Sakr, 1997). Inhibition of the enzyme 5-alpha-reductase causes benign prostatic 
hyperplasia (BPH) whereas androgen ablation either surgically or with hormone 
agonists is used as therapy for advanced prostate cancer (reviewed by Crawford, 
2003). Men who have congenital abnormalities in androgen metabolism do not 
develop prostate cancer or BPH nor do those men who were castrated before puberty 
(Haas and Sakr, 1997). Conflicting studies have been reported on the plasma levels 
of testosterone and DHT in prostate cancer patients and healthy controls of similar 
age (Ghanadian et al., 1979; Meikle and Stanish, 1982). In one study, African 
American men had 15% higher serum testosterone level compared with white 
Americans, reflecting increased risk of prostate cancer in that ethnic group (Ross et 
al., 1986). In another, Japanese men had lower levels of 5-alpha-reductase and 
therefore decreased levels of DHT compared with American men (Ross et al., 1992). 
Recently, Marks et al (2006) investigated serum and tissue testosterone and DHT 
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levels in normal African American men and white men and found no significant 
difference between the two groups.  
 
1.1.3 Pathological and molecular mechanisms underlining prostate cancer 
The molecular pathology of prostate cancer is extremely complex, involving multiple 
genes and environmental factors. Currently, the cellular and molecular events 
associated with the initiation, development and progression of the disease are 
unknown. However, identification of genetic alterations involved in these stages of 
CaP is gathering pace with the aid of modern molecular tools, raising expectations 
that soon it will be possible to distinguish the indolent cancers from the life 
threatening aggressive tumours by molecular analysis of suitably validated 
biomarkers (Hughes et al., 2005). Inherited prostate cancer is estimated to constitute 
less than 10% of CaP with the majority of cases being sporadic (Konishi et al., 
2005). Therefore, only the most consistent cellular, biochemical and molecular 
changes that occur in sporadic prostate cancer will be reviewed here.  
 
1.1.4 Cellular biology of benign prostate growth 
Morphological characterization of prostate epithelium has revealed the existence of 
three distinct types of cells (Fig.1.1). The most prevalent cell type is the androgen 
dependent secretory luminal cell which secretes prostatic proteins such as PSA 
(prostate specific antigen). These cells express androgen receptor (AR), cytokeratins 
8 and 18 and CD57 (a surface marker-cluster differentiation 57). The second 
epithelial cell type is the basal cell; these are situated between the luminal cells and 
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the basement membrane of the prostate gland. Basal cells mediate attachment to the 
stroma and they express p63 (a nuclear protein that has high homology to the tumour 
suppressor protein p53), cytokeratins 5 and 14, CD44 and low levels of AR; these do 
not secrete prostatic proteins. The third type of prostatic epithelial cell is the 
neuroendocrine cell; these support the growth of luminal cells. Neuroendocrine cells 
are androgen independent and express serotonin and several other peptide hormones 
(reviewed in Abate-Shen and Shen, 2000). There are now reports describing the 
existence of certain prostatic epithelial cells that co-express both luminal and basal 
associated markers, the prostate stem cell antigen marker first appears on these rare 
intermediate cells (Kelly and Yin, 2008). Stem cells express high levels of p63 and 
its expression by the basal cells has led to consensus that epithelial stem cells reside 
in the basal compartment of the prostate (Tokar et al., 2005). 
 
Figure 1.1: Different types of cells found in the human prostatic duct. The neuroendocrine cells are 
morphologically identical to the basal cells. Diagram reproduced from Abate-Shen and Shen, 2000. 
 
Even though the three types of prostate epithelial cells differ in their marker 
expression and biological function they do originate from common pluripotent stem 
cells that are located in the basal cell layer (reviewed by Konishi et al., 2005; Abate-
Shen and Shen, 2000; Foster et al, 2000). In normal prostate, there are only a small 
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number of neuroendocrine cells scattered along the basal cells. However, increased 
numbers of cells with neuroendocrine differentiation are present in more aggressive 
forms of prostate cancer (Cussenot et al., 1998). 
 
1.1.5 Initiation and progression of prostate cancer 
Prostatitis, Benign prostatic hyperplasia (BPH) and adenocarcinoma are the three 
major forms of prostatic disease. Although prostate cancer patients often have 
inflammation of the prostate, association between the two has not been clearly 
demonstrated (De Marzo et al., 2004; Karan et al., 2003). Seventy percent of CaP 
occurs in the peripheral zone of the prostate with 10-20% occurring in the transition 
zone and 5-10% arises in the central zone (Fig 1.2), whereas BPH (which is not a 
pre-malignant lesion or a precursor of prostate cancer) mainly evolves in the 
transition zone (Konishi et al., 2005). 
 
Figure 1.2: Anatomy of the human prostate. Diagram reproduced from Abate-Shen and Shen, 2000. 
 
Prostate cancer in its initial stage is confined to the prostate gland and is androgen 
dependent. At this stage, the cancer is normally curable by surgical and/or radiation 
therapy. In most men, the disease is indolent but the aggressive form of CaP first 
invades the seminal vesicles and then metastasises to other organs, especially to the 
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regional lymph nodes and the bone system. Metastatic cancer is generally androgen 
independent and is the main cause of mortality, with the cancer spreading to bones in 
more than 70% of patients (Karan et al., 2003; Abate-Shen and Shen, 2000). 
Prostatic intraepithelial neoplasia (PIN) is the first morphologically recognizable 
stage of prostate cancer. Both PIN and advanced forms of CaP are multi foci lesions 
and have similar chromosomal abnormalities (Konishi et al., 2005). Genetic 
alterations in PIN have been linked to the development of CaP (Foster et al., 2000). 
PIN is normally divided into high and low grade using the Gleason grading system, 
with the high grade associated with the metastatic disease. However, high grade PIN 
is not an in situ carcinoma, in spite of being so closely associated with CaP, because 
PIN has intact basement membrane and does not invade into the stroma and produces 
small amounts of PSA (Konishi et al., 2005). 
 
Figure 1.3: Histological images of prostate tissue stained with hematoxylin-eosin stains. A is a low 
magnification image showing heterogeneity of prostate tissue that contains BPH, PIN and CaP 
regions. B is a higher magnification view of the same image showing the BPH and PIN regions. 
Arrows are pointing towards the basal layer that surrounds the ducts at the BPH region, which is 
absent in the PIN region. Images reproduced from Abate-Shen and Shen, 2000. 
 
Recently, proliferative inflammatory atrophy (PIA) has been identified as a possible 
precursor to PIN, making PIA an even earlier stage in the evolution of CaP. There 
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are several defined stages in the progression of normal prostate or BPH to metastatic 
CaP. These stages include PIA, followed by PIN, leading to localised CaP and 
subsequently to metastatic and/or hormone refractory prostate cancer (De Marzo et 
al., 1999). 
 
Currently, the method used for predicting the grade for prostate cancer is the Gleason 
score where the most predominant cancer pattern and the next leading cancer pattern 
are given a grade of 1-5, with 1 being the most differentiated and 5 being the least 
differentiated. The two grades are added together. If there is only one principal 
histological pattern present in both cancers then the same grade is given so that the 
Gleason score ranges from 2 to 10 (Gleason et al, 1974). 
 
1.1.6 Molecular mechanism of sporadic prostate cancer 
The heterogeneity of CaP is a major factor that has made the identification of genetic 
alterations extremely difficult. Heterogeneity may be the result of multifocal tumours 
growing very close to each other and eventually terminating in fusion of separate 
lesions, creating difficulties in obtaining pure sample of cells from patients (Latil and 
Lidereau, 1998). Prostate cancer cells possess numerous somatic genomic alterations 
like all other epithelial cancers. Although genetic alterations in CaP have been 
widely studied little is known of the mechanisms that are involved in the progression 
of primary CaP to metastatic CaP. Therefore, distinguishing the indolent form of the 
disease from an aggressive form with current technology has not been possible so far 
(Saric et al., 1999). 
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1.1.6.i Chromosomal aberration associated with prostate cancer 
Several methods, such as conventional cytogenetics (G banding), fluorescence in situ 
hybridization (FISH), comparative genomic hybridization (CGH) and loss of 
heterozygosity (LOH) have all been employed to study chromosomal aberrations in 
prostate cancer. The most successful technique has been comparative genomic 
hybridization (CGH) which allows loss and gain of DNA copy number to be 
detected. CGH studies have revealed that the loss of genetic material is higher than 
the gain in the early stages of prostate cancer, implying loss of tumour suppressor 
genes is involved in prostate tumorigenesis. Gains were observed in metastatic 
hormone-independent cancer indicating the activation of oncogenes at a later stage of 
the disease (Visakorpi et al, 1995). The most frequently recorded chromosomal 
losses are on 2q, 5q, 6q, 8p, 10q, 13q, 16q and 18q. More than 50% of the samples 
studied had losses in 8p and 13q chromosomal regions and these regions were also 
lost in high grade PIN, suggesting these chromosomal regions harbour one or more 
tumour suppressor genes. Gains have been recorded in metastatic CaP on 
chromosomal regions 2p, 11p, 1q, 3q, 4q, 7q, 8q, 11q, 12q and Xq (Porkka and 
Visakorpi, 2004; Karan et al, 2003). 
 
1.1.6. ii The most commonly altered genes in prostate cancer 
Heterogeneity in CaP found at the histological and clinical level is reflected at the 
molecular level too. There are no clearly defined genetic events that occur in its 
progression but different stages of CaP may possibly be associated with inactivation 
of one or more tumour suppressor genes (TSG) and functional activation of certain 
oncogenes (Ozen and Pathak, 2000). Not many CaP share all the same genetic 
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alterations but there are various genes that are most frequently altered in different 
stages of prostate cancer (Fig 1.4) (Jhavar et al., 2008; Tomlins et al., 2006; Hughes et 
al., 2005; Konishi et al., 2005; Porkka and Visakorpi, 2004). 
 
 
Figure 1.4: Proposed pathway for human prostate cancer progression. Different stages of CaP are 
associated with inactivation of candidate tumour suppressor genes and activation of oncogenes. 
 
1.1.7 Chromosomal instability 
The karyotype of prostate cancer has revealed both numerical and structural changes 
in a variety of chromosomes. Chromosomal instability contributes to molecular 
transformation of many epithelial cancers (Cahill et al, 1999), and one of the causes 
of chromosomal instability is dysfunctional telomeres (Counter et al, 1992). 
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Telomeres and telomerase, the ribonucleoprotein required to maintain telomere 
length, play an important role in prostate cancer. The biology of telomeres and 
telomerase and their involvement in cancer will therefore be reviewed next. 
 
1.2 Cellular senescence: a tumour suppressor mechanism 
Renewable tissues are essential for the viability of complex organisms such as 
mammals. However, these tissues are at risk of developing cancers because dividing 
cells acquire mutations much more easily than non-dividing cells. There is a greater 
possibility of mutations occurring during DNA replication leading to accumulation 
of genetic alterations that can result in tumorigenesis (reviewed in Deng and Chang, 
2007). There is an association between human cancer development and advanced 
age. Adult cancers are predominantly carcinomas of epithelial origin arising in 
tissues that are continually being renewed throughout life. Tumour suppressor 
mechanisms have evolved to ensure the longevity of organisms and one such 
mechanism is replicative cellular senescence (reviewed in Campisi and di Fagagna, 
2007; Kuliman and Peeper, 2009). 
 
Cells from multicellular organisms were originally thought to possess an ability to 
proliferate indefinitely in culture. However, more than 40 years ago Hayflick and 
Moorehead (1961) discovered that human fibroblasts, when propagated in culture 
underwent robust cell division initially and thereafter cell proliferation gradually 
declined. All the cells in the culture eventually lost the ability to divide even though 
the cells were viable and there was ample space, nutrients and growth factors in the 
medium. This proliferative barrier was initially termed “the Hayflick limit” but is 
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now known as cellular or replicative senescence. The replicative capacity of cells 
depended on the origin of the tissue and the age of the organism from which the cells 
were isolated. A molecular clock was thought to exist in normal cells that registered 
the number of cellular replications and after a certain number of population 
doublings the cells underwent senescence (Harley et al., 1990). These observations 
generated two contradictory hypotheses at the time. The first theory stemmed from 
the fact that numerous cancerous cells proliferate indefinitely in culture, therefore 
cellular senescence was considered beneficial since it acted as a tumour suppressor 
mechanism in organisms to protect them from cancer. The second theory stemmed 
from the fact that tissue regeneration and repair deteriorates with age and cellular 
senescence was seen as a detrimental mechanism that led to the loss of regenerative 
capacity of cells in vivo (Reviewed in Campisi and di Fagagna, 2007; Stewart and 
Weinberg, 2006). 
 
1.2.1 Senescence and immortalization prior to telomere discovery 
Prior to the discovery of the involvement of telomeres with senescence and 
telomerase with immortalization, it was known that normal human fibroblasts 
proliferate between 50 to 80 population doublings. Subsequently, the cells senesce as 
they had reached a proliferative barrier, termed mortality stage 1 (M1). Replicative 
senescence is dependent on the presence of p53 and pRb tumour suppressor genes 
(Shay et al., 1991). M1 can be bypassed by transfecting the pre-senescent cells with 
viral genes such as the gene encoding the large T antigen of SV40 (simian virus) or 
co-transfection of genes encoding the HPV16 E6 and E7 transforming proteins 
(reviewed in Newbold, 2005). The HPV16 E6 and E7 viral proteins inactivate the 
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p53 and pRb tumour suppressor proteins respectively as does the large T antigen of 
SV40. Abrogation of both the p53 and pRb pathways is required to bypass 
senescence while inactivation of one of the two pathways did not suffice to bypass 
senescence. Evading the M1 barrier increases the proliferative capacity of the 
fibroblasts by 20 to 30 population doublings, rather than immortalizing the cells. The 
cells then enter another proliferative phase known as crisis or mortality stage 2 (M2), 
where their number remains approximately constant because successful cell division 
is balanced by cell death due to critically short telomeres (Wright et al,. 1989). 
Rarely, cells escape the crisis and form colonies of immortal cells but this a very 
infrequent event, occurring at 10-6 in epithelial cells and 10-7 in human fibroblasts 
(Shay and Wright, 2006) (Fig 1.5). The above findings indicate that SV40-LT 
antigen expression is essential but not sufficient for immortalization and that 
immortalization is a two-stage mechanism i.e. normal human somatic cells need to 
overcome the 2 proliferative barriers, senescence and crisis to become immortal 
(Wright et al., 1989; reviewed in Newbold, 2002; Newbold, 2005; Stewart and 
Weinberg, 2006). 
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Figure 1.5: The two step model of cellular senescence: showing the two independent proliferative 
barriers, M1 and M2 that limit the indefinite division potential of normal cells.  
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1.2.2 Telomeres 
Telomeres are composed of unique sequence of DNA and associated proteins at the 
ends of each chromosome. They allow cells to distinguish natural chromosome ends 
from DNA breaks by capping the 3’ end, so prevent inappropriate DNA repair such 
as exonucleolytic degradation and ligation of one chromosome end to another 
(Smogorzewska and De Lange, 2004). In normal human cells, telomeres can consist 
of 5 to 15kbp of tandem repeats of TTAGGG (Moyzis et al., 1988). With every cell 
cycle an average of 50-150bp of nucleotides are lost due to the end replication 
problem at the 3’ end (Fig 1.6) (Harley et al., 1990). This shortening of telomeres 
limits the cells from indefinite cell division hence acting as a potent tumour 
suppressor mechanism. In normal cells, once the length of a single or a few 
telomeres reaches a critical level the cells undergo replicative senescence and 
withdraw from the cell cycle (Reddel, 2003). However, germline cells and 
unicellular organisms have acquired telomerase activity to overcome the telomere 
shortening that leads to senescence (Shippen-Lentz and Blackburn, 1989). Telomere 
lengths in human germline cells are significantly longer than those of somatic cells 
and they are stable regardless of the age of the donor (Allsopp et al., 1992). 
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The end replication problem 
 
Figure 1.6: Diagram of the “end replication problem” which results in loss of DNA sequence with 
each cycle of DNA replication. (A) Double stranded parental DNA. (B) Parental strands open up to 
act as template to synthesize the daughter strands using DNA polymerase and the latter requires an 
RNA primer to initiate synthesis in the 5’-3’ direction. The leading strand can be synthesized 
continuously until the end of the linear chromosome. (C) The lagging strand is synthesized as a 
sequence of fragments known as “Okazaki fragments” all of which require the RNA primer. (D) RNA 
primers are degraded. (E) The gaps left by the RNA primers between the newly replicated fragments 
are filled by DNA ligase, the exception being the gap at the very terminal 5’end which cannot be 
filled. (F) This gap is further increased by an apparent 5’-3’ exonuclease which degrades 130-210 
nucleotides that result in the further shortening of the 5’ end of the telomere and a 3’ G-rich overhang 
on the parental strand. 
 
1.2.2.i Telomere dysfunction and senescence 
Recent advances in molecular biology have revealed the involvement of telomeres 
with senescence and telomerase with immortalization. When cells are cultured in 
vitro they tend to senesce at a point when they still have an average of several kb of 
repeats remaining at each telomere (Counter et al., 1992). Unfolding of the T-loop 
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structure in these short telomeres is seen as a double strand break by the p53 
mediated pathway resulting in replicative senescence. It is postulated that the cells 
stop dividing because the anti-proliferative mechanism, M1, has been activated 
(Shay et al., 1991). It has been hypothesised that in normal somatic cells telomere 
shortening in one or more of the 92 (23 pairs of chromosome in a normal cell with 
telomere at each end results in 92 telomeres) telomeric repeats may induce M1, even 
when an average of several kb of repeats remains on each of the other telomeres 
(Levy et al., 1992). Tumour suppressor proteins p53 and pRb, involved in cell cycle 
checkpoints for DNA damage are induced when a single chromosome of limited 
telomeric repeats produces a DNA damage signal (Wright and Shay, 1995). Cells 
that bypass the M1 mortality stage due to inactivation of p53 and pRb signalling 
pathways continue to divide with decreasing telomere lengths. When the telomeres 
become critically short they cannot protect the chromosome ends from being 
detected as double strand breaks and enter M2 or crisis (Newbold, 2005). M2 is 
characteristic of uncapped chromosome ends, end to end chromosomal fusions, 
anaphase bridges and a high number of apoptotic cells. End to end chromosome 
fusion resulting in dicentric chromosomes can initiate chromosomal instability 
through repeated breakage-fusion-bridge (BFB) cycles. During mitosis the two 
centromeres of a dicentric chromosome are pulled towards the opposite poles of the 
spindle causing the chromosome to break. These broken chromosomes can either 
translocate or form new dicentric chromosomes to continue the process of 
chromosomal instability. Such genomic instability is associated with extensive cell 
death making M2 distinguishable from M1 (reviewed in Stewart and Weinberg, 
2006). Hence, crisis provides a potent barrier to tumour development but rarely a cell 
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in the M2 stage escape crisis and become immortal by reactivating or up-regulating 
telomerase resulting in infinite cell proliferation (Fig 1.5). Between 80 to 90% of 
tumour derived cells that have detectable telomerase activity also have short 
telomeres suggesting that telomerase activation leading to telomere stabilization, by 
arresting telomere shortening and stabilizing the frequency of dicentric 
chromosomes, occurs late during oncogenesis (Counter et al., 1992). The majority of 
immortalized cells express telomerase (Kim et al., 1994) and the rest use an 
alternative mechanism (ALT) to maintain the telomeric length with each cellular 
division (Reddel, 2003; Newbold, 2005; Shay and Wright, 2005; Stewart and 
Weinberg, 2006; Feldser et al., 2003). 
 
1.2.2.ii Telomere function 
Early cytogenetic studies revealed that chromosomes with broken ends fused 
together to form dicentric, ring or some other unstable form of chromosome i.e. 
inappropriate recombination (reviewed in Stewart and Weinberg, 2006). However, 
the natural linear ends of a normal chromosome were found to be stable, so this led 
to the theory that telomeres are specialised DNA structures at the ends of eukaryotic 
chromosomes which provide a protective cap and hence stability to the chromosomes 
(Shampay et al., 1984). The other very important function of telomeres is to prevent 
the loss of terminal bases at the 5’end of each newly synthesized strand of the DNA 
by allowing the linear ends to be replicated completely. This can only be achieved in 
the presence of telomerase but in its absence telomeres gradually get shorter with 
each successive cell division until they reach a critical threshold where cell 
replication is arrested. This phenomenon was termed replicative senescence by 
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Olovnikov (1973). Replication of the linear chromosomes presents a problem, known 
as the end replication problem first recognized by Watson in 1972 (Fig 1.6). The 
difficulty arises due to linear DNA being exclusively replicated in 5’ to 3’ direction 
and DNA polymerase requiring an RNA primer to initiate DNA replication. This 
results in a single strand overhang of the 3’ end consisting of approximately 30-110 
nucleotides in humans. Olovnikov (1973) first purposed replicative senescence to be 
attributed to the end replication problem due to telomere shortening which serves as 
an intrinsic clock like mechanism of aging that counts the number of cell division 
before growth arrest. 
 
1.2.2.iii Telomere structure 
Telomeres were originally thought to be linear structures but electron microscopy has 
shown that telomeres are in fact a large duplex structures consisting of 2 loops 
(Griffith et al., 1999). Telomere folds back onto itself to form a large telomere loop 
(T-loop) and the 3’ end overhang binds to the double stranded telomeric sequence of 
the 5’end to form a displacement loop (D-loop) (Fig 1.7; Page 44). It is thought that 
T and D loops may cover the overhang structure so as to cap the telomeres and 
provide stability and capping may protect the telomeres from being recognized as 
DNA damage (Wright and Shay, 2005).  
 
Alternative studies using the NMR (nuclear magnetic resonance) have shown that the 
single strand G rich 3’overhang can provide structural stability to the chromosome 
by folding back on itself to form a four stranded structure called G-quadruplex. G-
quadruplexes can be stabilized by ligands such as Na+ and K+. Formation of the G-
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quadruplex prevents the synthesis of further telomeric DNA repeats because the 3’ 
end cannot be recognized by the RNA template of telomerase (Ambrus et al., 2006; 
Gilbert and Feigon. 1999). Both the T-loop and the G-quadruplex structures of 
telomeres have been observed in vitro. However, in vivo structures of telomeres are 
yet to be established, i.e. whether the telomeres form T-loops, G-quadruplexes or 
other structures is not yet clear. 
 
1.2.3 Telomere, a multi-protein complex 
The number of proteins being discovered in association with mammalian telomeres is 
constantly increasing. In humans, TRF1, TRF2, hRap1, TIN2, TPP1 and POT1 are 
the six proteins that form a multi protein complex at the telomeres known as 
“Shelterin” (de Lange, 2005). Shelterin is involved in telomere length control and it 
may inhibit telomerase from accessing the 3’ overhang by forming a T-loop. The 
three main proteins that bind directly to the telomeres are TRF1, TRF2 (telomeric 
repeat-binding factors 1 and 2) and POT1 (protection of telomeres). TRF1 and TRF2 
bind to the double stranded telomeric sequence of the T loop (van Steensel and de 
Lange, 1997; Smogorzewska et al., 2000), and POT1 binds to the 3’ single stranded 
telomeric DNA overhang (Baumann and Cech, 2001). The structures of TRF1 and 
TRF2 are very similar but the TRF1 complex is involved in regulating telomere 
length whereas the TRF2 complex influences the length of the telomere as well as 
being involved in telomere capping. TIN2 binds to TRF1, TRF2 and TPP1 and these 
three proteins interact with each other through TIN2. In addition TPP1 binds to 
POT1 hence recruiting POT1 to the double stranded part of telomere and hRap1 
interacts with TRF2 (reviewed in Smogorzewska and de Lange, 2004). 
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Figure 1.7: Telomeres form a protective t-loop structure in which the single stranded 3’ G-rich 
overhang folds into the double stranded DNA forming a displacement loop. TRF1 and TRF2 bind 
specifically to the double stranded telomeric DNA and POT1 binds to the single stranded DNA. There 
are many additional proteins that bind to these core components forming a capped telomere. Diagram 
reproduced from Colgin and Reddel, 2004.  
 
1.2.4 Telomerase 
Telomerase is a ribonucleoprotein that functions as a reverse transcriptase to 
completely replicate the telomeric DNA and hence, by maintaining telomere length 
provides unlimited proliferative potential to the cells (Greider and Blackburn, 1985) 
(Fig 1.8). Telomerase activity is present in 90% of human cancers (Kim et al., 1994) 
making it the most common tumour marker (Shay and Bacchetti, 1997). Although 
most normal somatic cells do not express detectable levels of telomerase, mitotically 
active cells such as skin, hair follicle cells, lymphocytes, endometrial and cells of the 
colonic crypt express low levels of telomerase (Hiyama et al., 1995; Harle-Bachor et 
al., 1996; Yasumoto et al., 1996). Expression of telomerase is also associated with 
male germ cells, stem cells and embryonic cells whereas inhibition of telomerase is 
involved in apoptosis, cellular senescence and aging (Hahn et al., 1999). Telomerase 
is active during early embryonic development and it is progressively repressed 
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through differentiation in most somatic cells. Telomerase is switched off in the 
majority of cells starting at 20 weeks of gestation in the human embryo (Ulaner et al, 
1998). 
 
 
Figure 1.8: Simplified diagram of telomere extension by telomerase: the incomplete synthesis of the 
lagging strand in the replication fork uses telomerase to synthesize the G rich telomeric DNA 
sequence. 
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Telomerase is a large complex that is approximately 1000kDa. In humans, it has two 
main components; a functional RNA (hTR) that serves as a template for the addition 
of telomeric DNA to the 3’ chromosomal ends and telomerase reverse transcriptase 
(hTERT) which is the catalytic subunit of telomerase with reverse transcriptase 
activity (Meyerson et al., 1997). There are additional proteins associated with 
telomerase including TEP1, hsp23 and hsp90, hStau and dyskerin. Hsp90 and hsp23 
are required for the assembly of telomerase in the nucleolus and defects in dyskerin 
lead to dyskeratosis congenita (DC) (reviewed in Pendino et al, 2006). DC is a rare 
congenital disorder in which bone marrow failure is the major cause of premature 
mortality. Another feature of DC is predisposition to cancer. The principal cause of 
DC is the mutations in the hTR and hTERT genes resulting in defective telomere 
maintenance through telomerase (reviewed in Walne and Dokal, 2009). 
 
1.2.4.i Human TR (hTR) 
A single copy of the hTR gene is localized on chromosome 3q26.3 and it is 
transcribed by RNA polymerase II, which produces a mature transcript of 451 
nucleotides (Soder et al., 1997). Human TR is found in both normal and cancerous 
cells and it contains 11bp sequence (5’-CUAACCCUAAC-3’) template coding for 
the telomere repeats (TTAGGG)n (Feng et al., 1995). Even though the length and the 
sequence of the mature telomerase RNA has diversified between species, i.e. 153-
192 nucleotides in ciliates and 1.3kb in Saccharomyces cerevisiae, the secondary 
structure has been largely conserved (Romero and Blackburn, 1991). As well as 
providing a template for the telomeres, telomerase RNA contains binding sites for 
the protein subunits (Gilley and Blackburn., 1999). Yi et al (1999) showed that the 
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level of hTR expression is five fold higher in tumour cells compared with normal 
cells and they suggested this increase in expression is due to upregulation of hTR 
transcription and a longer half-life of the transcribed RNA. The catalytic activity of 
telomerase is dependent on several factors involving hTR. These include its 
interaction with hTERT, its binding with the telomeric DNA and its role in the 
folding and assembly of telomerase (Holt et al, 1999). 
 
1.2.4 ii Human TERT (hTERT) 
Two related proteins, Est2p and p123, were initially identified as the catalytic 
subunit of telomerase in yeast Saccharomyces cerevisiae and in ciliate Euplotes 
aediculatus, respectively. Enzymatic activity of telomerase was abolished if these 
motifs were disrupted (Lingner et al., 1997). Substitution of a single amino acid in 
the reverse transcriptase motif of telomerase in yeast resulted in telomere shortening 
and senescence. This indicated the significance of these motifs in elongating 
telomeres via telomerase activity (Counter et al., 1997). Est2p and p123 homologues 
have since been identified in many organisms. Meyerson et al (1997) prepared cDNA 
encoding the human catalytic subunit of telomerase (hTERT) based on the conserved 
sequence information within the reverse transcriptase motifs of p123. Detectable 
levels of hTERT mRNA is found in telomerase positive tissues, cancer cell lines and 
tumours but not in cells and tissues that lack telomerase activity. Furthermore, the 
hTERT mRNA expression is induced when telomerase is activated during cellular 
immortalization (Kilian et al., 1997) and its expression is down regulated with 
telomerase activity when HL60, promyelocytic leukaemia cells were differentiated in 
vitro (Meyerson et al., 1997). These observations suggest hTERT mRNA is the rate-
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limiting step in determining telomerase activity. Additional evidence exists that 
suggest hTERT is the most essential component required for functional telomerase. 
Transfection of the hTERT gene into telomerase negative cells resulted in cells 
expressing telomerase activity comparable to the levels seen in immortal telomerase 
positive cells (Counter et al., 1998). Weinrich et al (1997) demonstrated that mixing 
transcribed hTR and translated hTERT in vitro with rabbit reticulocyte lysate 
resulted in telomerase activity, indicating hTERT is the rate limiting factor for 
telomerase activity missing in normal somatic cells. Alternatively, a single amino 
acid change in any of the 8 RT specific motifs reduced or abolished telomerase 
activity providing direct evidence of hTERT being the catalytic subunit of telomerase 
(Cong et al., 2002, Wyatt et al., 2010). 
 
1.2.4.iii Multimerization of hTR and hTERT to form functional human 
telomerase  
Separate in vitro syntheses of hTR and hTERT from human cell and rabbit 
reticulocyte lysate extracts have been co-assembled to produce functional 
telomerase. The level of telomerase activity produced by the hTR region spanning 
between +33 to +325 is comparable to the activity produced by the 451 nucleotide 
full length sequence (Tesmer et al., 1999). The authors also identified two fragments 
within this region which ranged between +33 to +147 and +164 to +325 nucleotides. 
Combining either of these fragments individually with hTERT failed to produce 
telomerase activity suggesting both are essential for the assembly of functional 
telomerase. Wenz et al (2001) later confirmed human telomerase contains two 
cooperating telomerase RNA molecules. The authors demonstrated that telomerase is 
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barely active when it consists of a heterodimer reconstituted from a mutant and wild-
type telomerase RNA compared with a homodimer. 
 
In another study, Beattie et al (2001) reported that two hTERT protein subunits are 
required to form functional hTERT. Functional hTERT multimerization occurs when 
the N terminus of one hTERT protein forms an association with a second full length 
hTERT protein that has an intact RT domain and a C terminus. These findings 
suggest that the catalytic activity of telomerase is achieved by two hTR and two 
hTERT subunits to form a tetramer complex (Weinrich et al., 1997). 
 
1.2.5 Alternative telomere lengthening 
Telomere length is maintained by upregulating telomerase activity in 90% of 
cancerous cells (Kim et al., 1994). The other 10% of cancers maintain their telomere 
lengths by one or more mechanisms referred to as an alternative lengthening of 
telomeres, ALT (Bryan et al., 1995). In vitro cells that have escaped crisis and 
become immortal maintain their telomere lengths by ALT mechanism. These cells 
have a mixture of variable telomere lengths, ranging from short to very long (Bryan 
et al., 1995). It is not known whether all telomerase negative immortal cell lines 
utilise the same ALT mechanism. Recombination as seen in the mutant yeast, in the 
absence of telomerase, has been proposed by McEachern and Blackburn (1996) as 
one of the alternative mechanisms. All the human cell lines examined either have 
telomerase activity or show evidence of ALT indicating the importance of telomere 
length maintenance in immortalization (Bryan and Reddel, 1997).  
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A recent study by Atkinson et al (2005) has suggested that the mechanism used for 
maintaining telomere length is determined by the chromatin environment of the 
telomerase promoters. Cells that utilize telomerase may reactivate the telomerase by 
chromatin remodelling of the hTR and hTERT promoters allowing a favourable state 
for transcription to occur. In contrast, the ALT mechanism might arise due to the 
tight repression of the hTR and hTERT promoters, caused by chromatin remodelling 
of the promoter sequence.  
 
1.2.6 Telomerase and cancer 
The development of cancer is a multi-step process that involves accumulation of 
numerous genetic and epigenetic alterations that have occurred to transform cells 
over a time period (Newbold, 1985). Multi-step carcinogenesis occurs through a 
process called clonal evolution where variant cells with increasing number of genetic 
abnormalities are repeatedly selected because they display a greater strength of 
survival and proliferate in a certain environment (reviewed by Newbold, 2005). This 
complexity of cancer development was not observed in a murine model where 
introduction of two cooperating oncogenes were sufficient for transformation (Land 
et al, 1983). However, epidemiology studies carried out by Armitage and Doll (2004) 
suggested 4 to 6 rate limiting events are required for cancer formation in humans. 
These findings have since been confirmed by cloning of the hTERT gene. 
Telomerase is the key enzyme required by cells to acquire immortality and this is 
reflected by its functional presence in over 90% of cancer cells (Kim et al., 1994). 
Significant levels of hTERT expression have also been reported in 90% of tumours 
whereas its absence from most normal somatic cells suggests transcriptional 
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activation of hTERT is required for cellular transformation (Kilian et al., 1997). 
Ectopic expression of hTERT and subsequent activation of telomerase activity, in 
telomerase negative cells, is sufficient to prevent telomere shortening that allows 
cells to overcome crisis. Therefore, activation of hTERT appears to be a critical step 
in tumour progression (Counter et al., 1998). It is essential, for this reason, to 
investigate the regulation of the hTERT gene so that molecular mechanisms of 
telomerase regulation, cellular senescence, immortalization and carcinogenesis in 
humans can be elucidated. 
 
1.2.7 Human TERT regulation  
The hTERT transcript was found to be absent in normal fibroblasts, pre-crisis cells 
and in telomerase negative immortalized (ALT) cells, but present in a large number 
of tumours that were surveyed. Matched pairs of pre- and post-crisis fibroblast and 
epithelial cells showed conversion from an hTERT negative to an hTERT positive 
status in parallel with telomerase activity (Kilian et al., 1997). These findings 
indicate that telomerase activity is tightly regulated by repressing the hTERT gene in 
normal cells and that its de-repression leads to activation of telomerase in tumour 
cells. The correlation between the hTERT mRNA expression and telomerase activity 
has strongly suggested that the hTERT gene is regulated at the transcriptional level 
(Meyerson et al, 1997). Multiple mechanisms seem to play roles in activation and 
repression of hTERT in cancer and normal cells respectively. Transcriptional, post-
transcriptional and epigenetic modifications of the hTERT gene all seem to regulate 
its expression but transcription overwhelmingly predominates (reviewed by Kyo and 
Inoue, 2002). 
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1.2.8 Features of the hTERT gene and its promoter 
The organization of the hTERT gene and its promoter region has been characterized 
by several groups (Kilian et al., 1997; Cong et al., 1999; Horikawa et al., 1999; 
Takakura et al., 1999). A single copy of the hTERT gene has been located on 
chromosome band 5p15.33 in human diploid cells and it is approximately 2Mb away 
from the telomeres (Leem et al., 2002). The hTERT gene is composed of 16 exons 
and 15 introns extending over 35kb and all the splice junctions at exon/intron 
boundaries conform to GT/AG sequence except for the last intron (Cong et al., 
1999). The hTERT gene encodes a protein that consists of 1132 amino acids with a 
MW of 127kDa. Seven of the 8 hTERT protein motifs are the conserved form of the 
reverse transcriptases and the eighth is the non-RT but telomerase specific T motif 
(Meyerson et al., 1997) (Fig 1.9). 
 
 
Figure 1.9: Organization of the hTERT gene showing the localization of 16 exons (shaded regions) 
and 15 introns. The hTERT gene encodes for a protein that has seven conserved motifs of the reverse 
transcriptases and a non-RT telomerase specific T motif 
 
Sequence analysis immediate upstream of the hTERT promoter has shown the region 
to be GC rich without TATA or CAAT boxes but it does possess binding sites for 
several transcription factors (Fig 1.10). Two E-boxes (CACGTG) within the 
promoter region of hTERT, binding sites for the Myc/Max/Mad network, have been 
identified at 5’ upstream of the initiating ATG at -165/-160 bp and at +44/+49 bp. 
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There are 5 GC-boxes that are binding sites for the general transcription factor Sp1 
(stimulating protein 1) localized within 110 bp of the hTERT transcription initiating 
site, situated between the two E-boxes. The transcription initiation site maps to 60-
120 bp upstream of the translation start site (Horikawa et al., 1999; Cong et al., 1999; 
reviewed in Janknecht R, 2004). Two binding sites for the estrogen receptor ER exist 
in the hTERT proximal promoter region. The first one is at -2677 to -2665 bp and the 
second at -873 to -859 bp upstream of the ATG. The latter consists of a half site for 
ER binding and has a Sp1 site adjacent to it. Complexes of ER and Sp1 often bind 
together to the DNA at this site (Cong et al., 1999; reviewed in Janknecht R, 2004). 
 
Figure 1.10: Representation of the hTERT promoter region showing the binding sites of selected 
transcription factors, +1 indicates the transcription initiation site (TIS) and the translation initiation 
codon ATG. 
 
1.2.9 Transcription regulators of hTERT 
Like telomerase, the hTERT promoter is inactive in normal and pre-immortal cells 
but active in immortal and cancer cells suggesting telomerase is regulated via hTERT 
at the transcriptional level (Cong et al., 1999; Takakura et al., 1999). In order to fully 
understand how telomerase is regulated by repressing the hTERT promoter, negative 
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transcription factors need to be identified. Several known transcription factors are 
involved in the positive and negative regulation of the hTERT gene and some of the 
major ones will be reviewed (Fig 1.11). 
 
1.2.9.i c-Myc/Max/Mad network  
Myc is a proto-oncogene that is a key regulator of cellular proliferation and 
differentiation. Myc encodes for a universally expressed nuclear phosphoprotein, 
Myc which consists of 439 amino acids and it is expressed in various human cancers. 
The c-Myc protein acts as a transcription factor by forming a heterodimer with the 
Max protein to activate hTERT expression by binding to the E-boxes, whereas Mad, 
an antagonist of c-Myc forms a heterodimer with Max to repress hTERT expression 
(Gunes et al., 2000; Grandori et al., 2000). Being antagonists, the levels of c-Myc 
and Mad are inversely regulated with c-Myc gene being active in proliferating and 
cancerous cells and Mad expressed in differentiating and resting cells (Grandori et 
al., 2000; Luscher B., 2001). A switch from Myc/Max to Mad/Max at the hTERT 
promoter down-regulates hTERT expression in promyelocytic leukemic HL60 cells 
during differentiation (Xu et al., 2001). Casillas et al (2003) reported a reverse switch 
when foetal lung fibroblasts were transformed causing the cells to acquire telomerase 
activity. These finding suggest antagonism between Myc and Mad may be an 
important factor in determining hTERT expression and telomerase activity. 
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1.2.9.ii Sp1 
A large number of genes are activated by the general transcription factor Sp1 which 
binds to the GC-boxes located in the promoter and enhancer regions (Suske G., 
1999). Sp1 sites in the core promoter of the hTERT are essential for its activity as it 
lacks a TATA box and mutation in these sites leads to the termination of promoter 
activity (Kyo et al., 2000). The exact regulatory mechanism of Sp1 is yet to be 
determined but Sp1 does seem to cooperate with cMyc to activate hTERT 
transcription. This cooperation is specific to the type of cells indicating that other 
transcription factors may be involved. Correlation between c-Myc and Sp1 
expression levels and telomerase activity has been reported in SV40 LT antigen 
transformed fibroblasts at different stages of transformation during multi-step 
carcinogenesis (Kyo et al., 2000). c-Myc expression has been observed in a large 
number of tumours but some tumours lack this expression even in the presence of 
telomerase. Transfer of normal human chromosome 3 into a breast cancer cell line 
repressed hTERT expression without affecting c-Myc or Mad expression levels 
(Ducrest et al., 2001). Sp1 is also found in numerous normal cells where telomerase 
is absent suggesting c-Myc and Sp1 expression may be insufficient in inducing 
cancer specific telomerase activation. 
 
1.2.9.iii Steroid hormones 
Detectable telomerase activity in normal human endometrial cells correlates with its 
proliferative activity indicating steroid sex hormones may tightly regulate telomerase 
(Kyo et al., 1997). Estrogen acts as a positive transcriptional regulator of the hTERT 
gene by binding directly to the hTERT promoter in hormone sensitive tissues (Kyo et 
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al., 1999). Estrogen-induced proliferation is inhibited by its antagonist, progesterone 
which has been used to treat estrogen dependent cancers (Henderson et al., 1993). 
Estrogen-induced expression of the hTERT gene can be inhibited by exposure to 
progesterone (Wang et al., 2000). The negative effect of progesterone on hTERT 
regulation may be indirect through inducing the expression of p21, which is a cyclin 
dependent kinase inhibitor that negatively regulates the cell cycle (Holt et al., 1997). 
Depriving prostate cancer cells of androgens reduces telomerase activity in androgen 
sensitive cells. However, this effect is not observed in androgen insensitive cells 
(Soda et al., 2000). Conversion of androgens to estrogen is one possible mechanism 
that may be employed to activate telomerase; the precise mechanism is yet to be 
elucidated. 
1.2.9.iv Cell cycle regulators 
The p53 protein is a well documented transcriptional factor involved in many 
biological processes such as DNA damage, hypoxia and oncogene activation that 
results in cell cycle arrest and/or apoptosis. Absences of functional p53 allow cells to 
immortalize that may lead to neoplastic transformation (Asker et al., 1999). 
Inactivation of p53 and activation of telomerase is a common feature observed in 
many cancers indicating cell cycle regulators may be involved in regulating 
telomerase. Co-transfection of an hTERT promoter construct with wild type p53 in 
HeLa cells resulted in inhibition of hTERT expression (Xu et al., 2000). 
Transcriptional repression of hTERT by p53 occurs through direct binding to TATA 
binding protein, CAAT binding factor and Sp1 (Bargonetti et al., 1997). The hTERT 
promoter lacks TATA and CAAT boxes but does possess 5 Sp1 binding sites, 
making it possible for p53 to form a complex with Sp1 and repress hTERT activity. 
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Mutation in Sp1 binding sites in the core promoter terminates hTERT repression by 
p53 (Xu et al., 2000). Telomerase inhibition is also observed by p21, p15 and p16 but 
this inhibition may be a secondary effect following the induction of cell cycle arrest 
(Kagawa et al., 1999). 
 
1.2.9.v E2F-1 
It has been reported that over-expression of pRb and E2F-1 in a human squamous 
cell carcinoma cell line represses telomerase. The mechanism by which these 
proteins exert their effect is unknown but several mechanisms have been proposed. 
pRb and E2F may possibly repress hTERT directly or cooperatively (Crowe and 
Nguyen, 2001). Crowe et al (2001) later reported two putative E2F-1 binding sites 
proximal to the transcriptional start site of the hTERT promoter. Mutation in these 
sites resulted in increased promoter activity whereas its overexpression repressed 
hTERT promoter activity in reporter gene assay, suggesting E2F-1 to play an 
important role in hTERT repression.  
 
1.2.9.vi Wilms’ tumour 1 tumour suppressor gene 
Wilms tumour 1 (WT1) is a tumour suppressor protein that represses hTERT by 
directly binding to the core promoter region located at approximately -352 bp 
upstream of the ATG. Mutation in the DNA binding site of WT1 resulted in 
increased hTERT promoter activity in 293 renal cells but not in HeLa cells. Over-
expression of the gene WT1 in 293 cells led to the inhibition of mRNA expression 
and telomerase activity (Oh et al., 1999) indicating that WT1 may be a negative 
 61 
transcription regulator. However, WT1 is limited to the tissues in which it is 
expressed i.e. kidney, gonad and spleen suggesting its role as a repressor will also be 
limited (Kyo and Inoue, 2002). 
 
1.2.9.vii Multiple Endocrine Neoplasia type 1 (MEN-1) tumour suppressor 
MEN-1 is a tumour suppressor gene, located at 11q13 that encodes for a protein 
called Menin. Mutations in the MEN1 gene leads to multiple endocrine neoplasia 
type 1 disease. Development of tumours in patients with mutated MEN1 may be a 
direct result of the loss of hTERT repression activity. Menin acts as a negative 
regulator of hTERT expression by binding to several positive transcription factors. It 
is not known through which protein menin exerts its effects but JunD and/or NF-ĸB 
are thought of as possible candidates for mediating this activity (Lin and Elledge, 
2003). 
 
1.2.9.viii Myeloid specific zinc finger protein 2 (MZF-2) 
Transient transfection experiments using luciferase reporter assays on the hTERT 
promoter identified a silencer region between -776 to -378bp upstream from the 
ATG site. Cellular differentiation was found to increase the inhibitory effects of the 
silencer. Sequence analysis has shown MZF-2 to have multiple binding sites in the 
silencer region and its over-expression results in repression of hTERT promoter 
activity whereas mutation of these sites activates it (Fujimoto et al., 2000). However, 
MZF-2 is expressed in normal as well as cancerous cells therefore it is probably not a 
specific hTERT transcriptional repressor. 
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Figure 1.11: Binding sites of some of the main transcription regulators on the hTERT promoter. 
 
1.2.9.ix E-Box mediated regulation of hTERT 
Some of the hTERT transcription regulators mentioned above were identified by over 
expressing the proteins in question rather than the physiological protein levels that 
exist in the cells. Horikawa et al (2002) searched for an endogenous factor that 
caused differential hTERT transcription in a renal cell carcinoma cell line that was 
hTERT positive (RCC23) and the same cell line with transferred chromosome 3 
which was hTERT negative (RCC23/chr 3). The authors claim that the proximal E-
box downstream of the transcription initiation site is responsible for the hTERT 
differential transcription between the two cell lines. Even though over-expression of 
c-myc and Mad proteins did mediate their effect through this E-box, endogenous 
levels or binding activity of these proteins did not control hTERT transcription in the 
two similar renal cell lines. A different endogenous E-box mediated binding protein 
repressed hTERT transcription in RCC23/chr 3 cell line but not in RCC23 suggesting 
the inactivation of this repressor during carcinogenesis. This E-box mediated hTERT 
repression was also observed in normal fibroblasts and epithelial cells and inactive in 
some of the telomerase/hTERT positive cancer cells. However, when the hTERT 
promoter region was PCR amplified between -261 and +80 in 15 cell lines 
originating from breast, prostate and cervical carcinomas in our laboratory, no 
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mutations were observed, suggesting that the repression through the downstream E-
box may possibly be specific to renal cell carcinoma. 
 
Table 1.1: Summary of all the well documented hTERT transcription regulators 
 
hTERT transcription factor Proposed status of the hTERT regulator 
c-Myc/Max/Mad network c-Myc/Max - activator 
Mad/Max – repressor 
Sp1 Activator 
Steroid hormones Estrogen - activator 
Progestrone – repressor 
Androgen – activator in CaP cells 
Cell cycle regulators Repressor  
E2F-1 Repressor 
Wilms’ tumour suppressor gene (WT1) Repressor 
Multiple Endocrine Neoplasia type 1  
(MEN-1) 
Repressor 
 
Myeloid specific zinc finger protein 2  
(MZF-2) 
Repressor 
 
E-Box mediated regulation of hTERT Repressor – probably specific for only renal cell 
carcinoma 
hTERT repression by normal human 
chromosomes 
Various chromosomes implicated in different cancers. 
See Table 1.2 
 
1.2.9.x Repression of hTERT transcription by normal human chromosomes 
Fusion of telomerase-positive immortal cells with normal somatic cells results in 
hybrids that have repressed telomerase activity. This indicates the loss, mutation or 
inactivation of telomerase repressor genes in the immortal cells which are required 
for the normal cells to senesce (Wright et al., 1996). In most somatic cells the 
absence of telomerase activity is due to the hTERT gene being repressed and it is 
proposed to be the loss of this hTERT gene repressor that allows the upregulation of 
hTERT expression which is normally observed in cancerous cells. Many groups have 
reported the repression of hTERT transcription and downregulation of telomerase 
activity in various cancer cell lines, following microcell mediated transfer of specific 
human chromosomes. These findings suggest the presence of transcriptionally active 
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hTERT repressor gene(s) that could be identified on normal human chromosomes 
using such an approach (Oshimura and Barrett, 1997). 
 
Introduction of chromosome 3 into RCC23, a human renal carcinoma cell line, led to 
the repression of telomerase activity, gradual shortening of telomere length, and 
induction of cellular senescence. In contrast, microcell transfer of chromosome 7 and 
11 into RCC23 resulted in hybrid cells that maintained their telomerase activity and 
telomere length as in the parental RCC23 cell line (Oshimura and Barrett., 1997). 
Horikawa et al (1998) reported that telomerase repression in RCC23 chromosome 3 
hybrids is due to down-regulation of the hTERT gene. Our own group, (Cuthbert et 
al., 1999) described similar repressor activity after the transfer of chromosome 3 into 
21NT, a breast cancer cell line. Powerful repression of telomerase activity and 
permanent growth arrest was observed with chromosome 3 after 10-18 population 
doublings. However, transfer of chromosome 8, 12 and 20 into 21NT cells did not 
repress telomerase activity. These findings suggest the presence of a telomerase 
repressor gene(s) on normal human chromosome 3 that induce cellular senescence in 
cancer cells. Tanaka et al (2005) used whole cell fusion to demonstrate that the 
defects in telomerase repression are corrected by different regions of chromosome 3 
in breast and renal carcinoma. Hybrid cells generated from self-fusion of two renal 
cell lines, KC12 and RCC23 and the breast cancer cell line 21NT expressed 
telomerase activity as in the parental cells. Similarly, hybrids from whole cell fusion 
of KC12 and RCC23 also expressed telomerase activity indicating the same genetic 
defect is shared by the two renal cell carcinoma cell lines. However, fusion of 21NT 
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with KC12 and 21NT with RCC23 generated a significant number of hybrids that did 
not possess telomerase activity. 
 
Another group reported that the transfer of normal human chromosome 7 into a 
telomerase positive human mesothelial cell line (MeT5A), resulted in telomerase 
repression which was associated with telomere shortening (Nakabayashi et al., 1999). 
In order to investigate which component was responsible for telomerase repression, 
the authors investigated mRNA levels of telomerase related genes. The expression of 
hTERT was markedly lower in telomerase repressed hybrids compared with non-
repressed and revertants whereas there was no significant difference in the 
expression levels of hTR and TEP1 between the hybrid clones, suggesting lower 
expression of the hTERT gene is responsible for reduced telomerase activity. 
 
Nishimoto et al (2001) transferred chromosome 2, 4, 5, 10 and 16 into a telomerase 
positive hepatocellular carcinoma cell line, Li7HM. Only chromosome 10 repressed 
telomerase activity and the growth of the hybrid cells was arrested after 50 
population doublings. Transfer of defined fragments of chromosome 10p narrowed 
down a region of 28.9cM on 10p15.1, which led to immediate telomerase repression 
and telomere shortening, strongly suggesting the presence of hTERT repressor 
gene(s) in this region. Another group reported the transfer of chromosome 6 and 11 
into a HPV16-immortalized keratinocyte cell line, FK16A, and a cervical cancer cell 
line SiHa. Hybrid clones generated from the transfer of chromosome 6 for both cell 
lines underwent growth arrest which was associated with telomere shortening, 
suggesting the presence of a telomerase repressor (Steenbergen et al., 2001). 
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In contrast, Backsch et al (2001) transferred normal human chromosomes 3, 4, 6, and 
11 into HeLa cells and found strong repression of telomerase activity in chromosome 
3 and 4 hybrid cells but not 6 and 11, even though functional loss of chromosome 6 
and 11 are implicated in cervical cancer. From these studies it can be concluded that 
telomerase activity and hTERT mRNA expression can be abolished in telomerase-
positive cell lines by the transfer of a normal human chromosome, suggesting that 
normal human cells possess hTERT transcriptional repressors that may be tissue-
specific and form part of a complementation series.  
 
Table 1.2: Summary of the MMCT studies showing repression of either telomerase 
activity or hTERT transcription repression due to individual transfer of normal 
human chromosome into cancer cell lines originating from various different cancers. 
Name 
of cell 
line 
Tissue origin of 
the human cell 
line 
Transferred 
chromosomes 
Measured 
parameter 
Reference 
RCC23 Renal carcinoma 
cell line 
3, 7, 11 Chromosome 3 
repressed telomerase 
activity 
Oshimura and Barrett. 
Eur J Cancer. 1997 
Apr; 33(5):710-5 
RCC23 Renal carcinoma 
cell line 
3 Repression of hTERT 
transcription with 
chromosome 3 
Horikawa et al. 
Mol Carcinog. 1998 
Jun; 22(2):65-72 
21NT Breast 
adenocarcinoma 
cell line 
3, 8, 12, 20 Chromosome 3 
repressed telomerase 
activity 
Cuthbert et al.  
J Natl Cancer Inst. 
1999 Jan 6; 91(1):37-
45 
Li7HM Hepatocellular 
carcinoma cell line 
2, 4, 5, 10, 16 Chromosome 10 
repressed telomerase 
activity 
Nishimoto et al.  
Oncogene. 2001 Feb 
15; 20(7):828-35 
FK16A 
 
 
SiHa 
Keratinocyte cell 
line 
 
Cervical carcinoma 
cell line 
6, 11 
 
 
6, 11 
Chromosome 6 
repressed telomerase 
activity in both cell 
lines 
Steenbergen et al. J 
Natl Cancer Inst. 2001 
Jun 6; 93(11):865-72. 
HeLa Cervical carcinoma 
cell line 
3, 4, 6, 11 Chromosomes 3 and 4 
repressed telomerase 
activity 
Backsch et al.  
Genes Chromosomes 
Cancer. 2001 Jun; 
31(2):196-8. 
 
MeT5A Mesothelial cell 
line 
7 Chromosome 7 
repressed telomerase 
activity and hTERT 
expression 
Nakabayashi et al. 
Expt Cell Research. 
1999  
252, 376-382. 
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1.2.10 Splice variants of hTERT gene 
Regulation of the hTERT gene is tissue-specific in eukaryotes and also involves 
alternative splicing of the mRNA (Adams et al., 1996). Several transcripts of the 
hTERT gene exist in human cells (Fig 1.12). They include the full length transcript 
and the well characterized α and β deleted variants. The α-spliced transcript has 36 
nucleotides deleted from the 5’ end of exon 6 including motif A, and the β-spliced 
transcript has 182 nucleotides deleted from exons 7 and 8 including motif β, and α-
and β-spliced transcripts. Other splice variants include 159 nucleotides insertion of 
intron 14, a 38 nucleotide insertion of intron 4 and the replacement of exon 15 and 
part of exon 16 with the 600 nucleotides of intron 14. The proteins coded by these 
transcripts are not detected in tissue cultured cells but it is thought that these 
transcripts may be expressed during human development and are possibly tissue and 
age specific (reviewed in Pendino et al, 2006). It is only the full length transcript that 
is associated with telomerase activity (Ulaner et al., 2000). Alternative splicing of the 
hTERT gene removes critical reverse transcriptase motifs and hence provides an 
important mechanism of regulating telomerase activity. Suppression of telomerase 
activity during human foetal kidney development is thought to employ this 
mechanism (Ulaner et al., 1998). Lack of telomerase activity in some normal tissues 
containing both α-and β-spliced transcripts suggests the presence of a post-
transcriptional mechanism and mRNA splicing has been lost during neoplastic 
transformation (Ulaner et al., 2000). 
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Figure 1.12: Splice variants of the hTERT gene. Only the full length transcript (A) is associated with 
telomerase activity. The location of translation initiation codon ATG and the stop codon are indicated 
as are telomerase specific T motif and the seven RT motifs. There are three types of deletion variants 
namely α, β and αβ (B) and various intronic insertions as mentioned in the text (C and D). 
 
1.2.11 Epigenetic regulation of hTERT transcription 
There are two types of epigenetic modifications involved in regulating gene 
expression. One is methylation of cytosine at the CpG dinucleotide by DNA 
methyltransferase (DNMT), which is the only known epigenetic modification of 
DNA in mammals and the other is the post-translational modification of histones 
(Robertson, 2005). Human cancers are often associated with irregular methylation 
leading to activation of proto-oncogenes, such as c-Myc, Ha-ras, K-ras, c-Fos and 
Bcl-2 or repression of tumour suppressor genes such as pRB, p16, BRCA1 and 
hMLH1 (Laird and Jaenisch, 1994). 
 
1.2.11.i. DNA methylation status of the hTERT promoter 
Large CpG islands in the GC rich hTERT promoter are usual sites for DNA 
methylation and alterations in chromatin structure involved in regulating the hTERT 
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expression. However, conflicting reports about this have been published in recent 
years. When Dessain et al (2000) analysed a number of cell lines and tissues for the 
methylation status of the hTERT promoter, no correlation between methylation and 
hTERT expression was established. In contrast, Guilleret et al (2002) found a positive 
correlation between hypermethylation of the hTERT promoter, mRNA expression 
and telomerase activity in various human tumour cell lines and in normal and tumour 
tissues derived from different organs. Furthermore, the same group conducted a 
demethylation study where 3 telomerase-positive cell lines, with hypermethylated 
promoters were treated with a demethylation agent 5aza-2’-deoxycytidine (5azadC). 
Strong repression of hTERT mRNA was observed with hTERT demethylation 
suggesting hypermethylation of the hTERT promoter is required for its expression 
(Guilleret and Benhattar, 2003). These finding are in complete contrast to general 
regulation of gene expression where promoter hypermethylation represses 
transcription (Robertson, 2005). Choi et al (2007) recently reported a complex 
pattern of hTERT promoter methylation, and they suggest methylation status of 3 
specific CpG sites might be significant in activation of hTERT expression in 
colorectal carcinoma. They claim two CpG sites are more hypermethylated and a 
proximal exon region is hypomethylated in cancerous tissues compared with normal 
tissues. Zinn et al (2007) recently confirmed that the hTERT promoter is densely 
hypermethylated in most cancer cell lines. However, they found methylation of the 
hTERT promoter is very heterogeneous and the transcription start site lacks 
methylation in three different types of cell lines that were examined. The authors 
claim that the region around the transcription site of the hTERT promoter remains 
unmethylated for the gene to be expressed and that DNA methylation and hTERT 
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expression in cancerous cells conform to the well established concept of promoter 
methylation with gene silencing 
 
1.2.11.ii Chromatin structure 
Gene transcription is dependent on the structure of the chromatin, which in turn 
depends on the post-transcriptional modification of nucleosomal histones by the two 
enzymes histone acetyltransferase (HAT) and histone deacetylase (HDAC). Human 
TERT transcription can be induced by HDAC inhibitors in normal cells, indicating 
the importance of HDAC activity in repressing hTERT (Cong and Bacchetti, 2000). 
 
Chromatin immunoprecipitation (ChIP) experiments have demonstrated that the 
switch from Myc/Max to Mad1/Max at the hTERT promoter during differentiation of 
HL60 cells is accompanied by a decrease in histone acetylation. In the promoter 
region of proliferating HL60 cells, the E-boxes are mainly occupied by c-Myc and a 
high level of acetylated histones H3 and H4. This suggests that c-Myc activates 
hTERT transcription by engaging HAT to the promoter region. Alternatively, in 
differentiating HL60 cells, Mad1 replaces c-Myc on the E-boxes and reduces 
acetylation of histones at the hTERT promoter considerably (Xu et al., 2001). These 
findings suggest that the Myc/Max/Mad network regulates hTERT expression by 
modifying the chromatin at the promoter for transcriptional activation or repression 
(Cong et al., 2002). However, mutation in the E-boxes of the hTERT promoter is able 
to respond to HDAC inhibitor in the same way as the wild type promoter (Cong and 
Bacchetti, 2000) indicating that HDAC may be directed to the hTERT promoter by 
more than one repressor. 
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In order to identify the hTERT regulatory mechanism in normal and tumour cells,  
Szutorisz et al (2003) scanned the hTERT gene for nuclease sensitive sites. Treating 
the chromatin of telomerase positive tumour cells and telomerase negative fibroblasts 
with DNase 1 and micrococcal nuclease (MNase) revealed a nuclease-sensitive site 
in the second intron of the hTERT gene in the telomerase positive tumour cells that 
was absent in the chromatin of normal fibroblasts. The authors examined the state of 
the chromatin at the second intron in 21NT, a breast cancer line and in hTERT 
repressed hybrids of 21NT that were generated by the transfer of a normal human 
chromosome 3. The 21NT cell line exhibited similar patterns of MNase sensitivity to 
telomerase positive cell lines whereas the 21NT chromosome 3 hybrids revealed 
similar patterns to the normal fibroblast. Hybrids that had lost the transferred normal 
copy of chromosome 3 showed MNase sensitivity patterns that were observed in 
telomerase positive cells and some of these hybrids reexpressed the hTERT gene. 
Therefore, the authors claim that the hTERT expression in tumour cells depends on 
an open state of chromatin at intron 2. 
 
Wang and Zhu (2003) reported a similar study where they showed telomerase and 
hTERT mRNA could be induced in telomerase negative pre-crisis cells and ALT 
cells by treating the cells with HDAC inhibitor trichostatin (TSA). The hTERT 
expression was accompanied by an increase in the chromatin sensitivity to DNase 1 
digestion with the appearance of a hypersensitivity site near the hTERT transcription 
initiation site. These results suggest that the hTERT promoter in telomerase-negative 
cells is repressed by a mechanism that involves chromatin organization and 
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immortalization of cells by activating telomerase may possibly involve chromatin 
remodelling resulting in loss of repression (Wang and Zhu, 2003). 
 
1.2.12 Post-translational regulation of hTERT 
It is indisputable that hTERT is regulated mainly at the transcriptional level but there 
is evidence to suggest posttranslational modification of the hTERT protein occurs as 
an additional step in controlling telomerase activity. Some normal ovarian and 
uterine leiomyoma cells had no detectable telomerase activity even when the cells 
expressed hTR and the full length transcript of hTERT (Ulaner et al., 2000). 
Similarly, Rohde et al (2000) found no correlation between hTERT mRNA 
expression and telomerase activity in normal and malignant renal tissue. These 
findings suggest hTERT expression is not always sufficient to induce telomerase 
activity in certain types of cells and posttranslational modification of the hTERT 
protein may determine the status of telomerase activity (reviewed by Cong et al., 
2002). 
 
1.2.12.i Phosphorylation of the hTERT protein  
Phosphorylation of the hTERT protein might be one way of activating telomerase. 
Protein kinase C and Atk kinases have been reported to phosphorylate the hTERT 
protein that is required for its translocation to the nucleus leading to telomerase 
activation (Kang et al., 1999). Activation of T-lymphocytes by hTERT 
phosphorylation leading to telomerase activity has been reported by Liu et al (2001). 
The authors discovered that the induced telomerase activity in CD4 T cells was 
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independent of the hTERT level but instead depended on the phosphorylation and 
translocation of hTERT from the cytoplasm to the nucleus. This indicates that 
telomerase activity may be regulated by translocation of phosporylated hTERT from 
the non-functional cytosolic location to a functional nuclear compartment, providing 
another mechanism of controlling telomerase activity that is independent of hTERT 
protein level. 
 
In summary, telomerase regulation is highly complex with a range of regulators 
controlling its activity at various levels. The conclusion that can be drawn from this 
review is that the key transcriptional repressor(s) of hTERT have yet to be identified. 
The status of telomeres and telomerase and the involvement of known telomerase 
regulators implicated in prostate cancer will be briefly reviewed next. 
 
1.3 Telomere shortening in prostate cancer 
Recent data has confirmed that telomere dysfunction plays a significant role in 
genetic instability in prostate cancer (Meeker, 2006). Telomere lengths were 
measured in normal, BPH and CaP samples obtained from human radical 
prostatectomy specimens from the same patients. Cells from CaP tissue consistently 
possessed shorter telomere lengths compared with the telomere lengths of cells 
obtained from neighbouring normal tissue and BPH tissue (Sommerfeld et al., 1996).  
 
Meeker at al., (2002) found telomere lengths were very short in 93% of high grade 
PIN (HGPIN) foci obtained from radical prostatectomy. Telomere shortening was 
also observed in HGPIN samples taken from needle biopsy from patients without 
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evidence of CaP. In another study, telomere lengths were reported to be short in 63% 
of HGPIN samples increasing to 80% in foci located 2mm away from the 
adenocarcinoma (Vukovic et al., 2003). The reduced telomere lengths observed in 
PIN is beyond the stage where the cell cycle checkpoint can respond suggesting a 
defective checkpoint in PIN. One of the checkpoints that may be damaged in PIN is 
14-3-3 sigma, which is a protein induced by p53 in response to DNA damage 
(Hermeking, 2003). The expression of 14-3-3 sigma protein is decreased in 91% of 
prostate cancers compared with the non malignant areas (Lodygin et al., 2004). 
 
1.3.1 Telomerase in prostate cancer 
Detectable telomerase activity is reported in 84% of CaP samples (Sommerfeld et al., 
1996). Telomerase activity is rarely found in normal or BPH tissues and the levels of 
telomerase activity reported are much lower than the CaP tissue. It is questionable if 
these normal and BPH tissues adjacent to CaP are truly positive or if it is 
contamination of these tissues by a few telomerase positive CaP cells. Normal and 
BPH tissue obtained from cancer-free prostate are always negative for telomerase. 
Inflammation of the prostate is a common phenomenon and the presence of activated 
lymphocytes may be another source of contaminating telomerase activity in non-
cancerous cells (Sommerfeld et al., 1996). Around 10-20% of prostate cancers are 
negative for telomerase. These tumours may have a better prognosis as the tumour 
cells may have a limited proliferative capacity. Currently, there is not enough data to 
determine if there is a correlation between telomerase activity and tumour grade 
(Meeker, 2006). 
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1.3.2 Telomerase and hTERT regulation in prostate cancer 
There are several known transcription regulators of hTERT, of which the positive 
regulators are the c-myc and CBX7 and the negative regulators include Mad1, SIP1, 
and menin (Lin and Elledge, 2003). One of the most frequently reported positive 
regulator in prostate cancer is the c-myc oncogene. High levels of c-myc expression 
have been reported in prostate cancer cell line, LNCaP and in prostatic 
adenocarcinomas (Nag and Smith, 1989). Latil et al (2000) investigated the effects of 
myc expression on hTERT regulated mRNA expression levels in 33 sporadic prostate 
cancer samples by real time quantitative PCR. myc was detected in 58% and hTERT 
in 67% of tumour samples. A significant correlation was observed between myc 
over-expression and increased levels of hTERT expression, suggesting the 
upregulation of telomerase activity is in part due to transactivation of hTERT by myc 
in prostate cancer. However, the authors observed no correlation between over-
expression of myc or hTERT expression and the pathological stage of the disease. 
 
Immortalization of normal human epithelial cells requires the inactivation of the 
p16INK4a/Rb pathway and maintenance of telomere length (Kiyono et al., 1998). Gil 
et al (2005) investigated the role of hTERT, c-myc and other viral oncoproteins in 
prostate cancer progression by introducing a combination of genes into primary 
human prostate epithelial cells (HPrEC) to simulate different stages of cancer. The 
authors discovered that overexpression of c-myc alone resulted in complete 
immortalization of HPrEC. This immortalization was due to c-myc having the ability 
to upregulate hTERT expression and hence activating telomerase to maintain 
telomere lengths and also to suppress the proteins that regulate the cell cycle, such as 
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p16INK4a/Rb. Vitamin D3 and retinoic acid have both been reported to reduce hTERT 
mRNA expression and telomerase activity in two prostate cancer cell lines PC-3 and 
LNCaP (Ikeda et al., 2003). 
 
Recently, several regulators of hTERT expression have been reported in CaP. The 
demethylation reagent, 5-azacytidine (5-aza-CR) was shown to act as an 
antineoplastic drug in prostate cancer. Telomerase activity was significantly reduced 
by 5-aza-CR in TSU-PR1 but not in DU145 prostate cancer cell line. RT-PCR 
revealed telomerase inhibition was related to down-regulation of hTERT mRNA 
expression in TSU-PR1 cells. Transient expression assays have shown 5-aza-CR 
repressed transcriptional activity of the hTERT promoter through the E-box. The 
authors demonstrated by western blot analyses that 5-aza-CR reactivates p16 
expression and represses c-myc expression in TSU-PR1 cells but not in DU145 cells 
(Kitagawa et al., 2000). Jagadeesh et al (2006) showed genistein, an abundant 
isoflavone found in soybean, has antiproliferative effects on prostate cancer. 
Genistein decreased hTERT and c-myc expression and transcriptional activity in a 
dose dependent manner indicating genistein represses hTERT by down regulating c-
myc expression. 
 
1.4 Telomerase: a target for cancer therapeutics 
Maintenance of telomeres through the expression of telomerase is a hallmark of 
cancer cells. Absence of telomerase expression in most normal cells has allowed 
telomerase to become a universal marker for human cancers for a number of years. 
This fact has made inhibition of telomerase an attractive target for cancer therapy. 
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The approaches that have been used to target telomeres and telomerase include 
oligonucleotide based therapeutics, immunotherapy, gene therapy and combination 
therapy (Shay and Wright, 2006). 
 
Human TERT and hTR, the two main components of telomerase, have been 
independently targeted using dominant mutants of hTERT and hTR. Small molecule 
nucleoside AZT and the most extensively studied non-nucleoside BIBR1532 both 
inhibited telomerase. BIBR1532 has advantage over AZT because the former inhibits 
telomerase specifically whereas AZT lacks selectivity for telomerase compared with 
other polymerases (reviewed in Zimmermann and Martens, 2007). RNA template of 
telomerase has directly been targeted with GRN163 which is a potent antagonist of 
hTR. GRN163L is a derivative of GRN163 that contains a palmitoyl lipid carrier to 
facilitate its transport into the cells. GRN163L is currently being used in clinical 
phase I/II trials for chronic lymphocytic leukaemia but current data suggests it has 
the potential to be a universal anticancer agent (reviewed in Zimmermann and 
Martens, 2007; Shay and Wright, 2006). 
 
Telomeres have also been targeted for cancer therapeutics. Formation of G-
quadruplex structures at the ends of telomeres has made it a legitimate target for 
cancer therapy. Acridine derivatives are very potent inhibitors of telomerase and a 
trisubstituted acridine compound BRACO-19 has been developed as a ligand to 
stabilize the G-quadruplex structures. BRACO-19 binds to the single stranded 3’ 
overhang and displaces POT1 thereby uncapping the 3’ telomere ends. The growth 
inhibition and senescence response to BRACO19 was observed in human cell lines 
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within days rather than weeks (Gunaratnam et al., 2007). Another potent G-
quadruplex ligand that is used to stabilize telomeres is telomestatin. TRF2 and POT1, 
the two telomeric proteins that are involved in the capping the telomere by forming a 
t-loop are modulated by telomestatin. In vitro exposure of tumour cells to 
telomestatin causes rapid degradation of the telomeres and delocalization of POT1 
and TRF2 from the telomeres (Gomez et al., 2006). 
 
The argument against targeting telomerase is that it can also affect the proliferative 
cells such as the germ cells, stem cells and lymphocytes, but these cells have longer 
telomeres than tumour cells therefore the damage would be limited (Zimmermann 
and Martens, 2007). Therapies targeting telomerase is a novel approach that has seen 
rapid progress in the past 2 years and it could lead to an effective cancer treatment 
without side effects. 
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General materials and methods 
2.1 General equipment used for routine cell culture 
All cell culture was performed in a LaminAir HB2448 (Heraeus Instruments) safety 
cabinet that had been cleaned and swabbed with 70% industrial methylated sprit 
(IMS) prior to any cell manipulation. Cells were cultured in fully humidified 
incubators. Hera Cell (Heraeus) incubators were set at either 6.5% or 10% CO2 and at 
37°C. An inverted phase contrast microscope, Olympus CK40, was used for 
visualizing the cells. Digital images of cells were captured using an Olympus IX71 
microscope attached to a coolSNAP cf camera (Photometrics). Cells were routinely 
spun down at 1500rpm for 5min in a Sorvall Legend T bench centrifuge. Foetal 
Bovine Serum (FBS-European) was purchased from Sigma and it was batch tested 
and reserved if suitable. 
 
2.2 Details of cell lines used 
2.2.1 PC-3 
PC-3, a prostate epithelial cell line established from a human prostatic grade IV 
adenocarcinoma from a 62 year old male Caucasian, was used as a model system for 
locating telomerase repressor gene(s) on normal human chromosomes that may be 
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involved in prostate cancer. PC-3 was cultured in Ham’s F-12 Nutrient mix with 7% 
FBS and 2mM L-glutamine. Cells were cultured in 6.5% CO2 at 37°C in a fully 
humidified incubator. Confluent cultures were split 1:2 to 1:6 and routinely fed every 
3 days if sub-culturing was not required. PC-3 cells were kept in culture for a 
maximum of 3 weeks and thereafter a new batch was thawed out.  
 
2.2.2 Human: rodent monochromosomal cell hybrids  
Human: rodent monochromosomal hybrid panel was constructed by Professor R. 
Newbold’s group for use in human gene mapping and gene function. These hybrids 
were used to individually transfer normal human chromosomes into PC-3 cells. The 
normal human chromosome tagged with the HyTK fusion gene allowed positive 
selection of cells that had incorporated the tagged chromosome by culturing the cells 
in hygromycin B. The nomenclature used for the human: rodent hybrid panel is 
A9HyTK1, A9HyTK2 etc. The number and HyTK denote the chromosome number 
tagged with the hygromycin resistant gene in a mouse fibroblast, A9, background. 
The human: rodent hybrid panel was routinely cultured in DMEM containing 10% 
FBS, 2mM L-glutamine and 400U/ml of hygromycin B and cultured in 10% CO2 at 
37°C in a fully humidified incubator. The cells were routinely sub-cultured at 1:6 to 
1:8 when 80% confluent and fed every 3 days if sub-culturing was not required. 
 
2.3 Cryopreservation of cells 
Healthy cells growing in log phase were fed with fresh culture medium 24 hr prior to 
freezing them down. The culture medium was aspirated off and the adherent cells 
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washed once with appropriate volume of Versene (0.04% EDTA in PBS). The cells 
were detached with warm 0.05% trypsin made up in EDTA. The detached cells in 
trypsin were neutralised with complete cultured medium and the cells spun down at 
1500rpm for 5min. The supernatant was aspirated off and the cell pellet flicked and 
resuspended in freezing medium consisting of 90% FBS and 10% DMSO. Aliquots 
of 0.5 or 1.0ml of cells were frozen down in 2ml ampoules by placing them into 
gaseous phase of liquid nitrogen before transferring them into liquid phase. Cells 
were routinely frozen down at 3-5x106 from P-100 dishes and at 1-2 x106 from P-60.  
 
2.4 Recovery of cells from liquid nitrogen 
Ampoules of cells were taken out of liquid nitrogen and swabbed with 70% IMS. 
Caps were loosened to release the pressure before rapidly thawing the cells at 37°C. 
Cells were transferred into 10ml of warm complete culture medium and centrifuged 
at 1500rpm for 5min. The supernatant was aspirated off and the pellet gently flicked 
to disperse the cells before resuspending them into appropriate volume of complete 
medium. 
 
2.5 Testing cells for mycoplasma contamination 
2.5.1 The Hoechst 33258 stain method 
Antibiotics can suppress the growth of mycoplasma in cells therefore cells were 
cultured for at least 2 weeks in the absence of all antibiotics including hygromycin, 
geneticin, neomycin etc. After 2 weeks, cells were seeded onto sterile glass cover-
slips placed in Petri dishes or in slide chambers. Cells were fixed directly with 
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freshly made Carnoy’s fixative (methanol and acetic acid 3:1 ratio) when they were 
approximately 70% confluent. Three millilitres of fixative was added to 5ml cultures 
for 2min at room temperature. The medium and the fixative was aspirated off and 
5ml of fixative was added to the cells and left to incubate at room temperature for 
5min. The cells were fixed once more with fresh fixative and left to air-dry. The cells 
were stained with 0.05µg/ml of Hoechst 33258 made up in PBS pH 7.0 for 5min in 
the dark at room temperature in a coplin jar. The slides were rinsed twice with PBS 
pH 7.0 and visualized under a fluorescence microscope.  
 
2.5.2 The nested PCR method 
The parental cell lines and hybrids that were routinely used in the laboratory were 
subjected to mycoplasma contamination tests at regular intervals. Genomic DNA was 
isolated from the cells using a DNA isolation kit (Wizard, Promega). 
 
For the first round amplification of the mycoplasmal DNA, we used the GPO1 
primer (5’ACTCCTACGGGAGGCAGCAGTA 3’) and MGSO primer 
(5’TGCACCATCTGTCACTCTGTTAACCTC 3’). For a 20µl reaction volume, 
1.0µl (100ηg) of DNA was added to 1.0µl (0.4µM) each of the GPO1 and MGSO 
primers and 17µl of Reddymix Mastermix. The amplification was carried out for 35 
cycles with denaturing at 95oC, annealing at 55oC and extension at 72oC. A final 
extension step at 72oC for 10min was added. 
 
For the second round amplification of the mycoplasmal DNA, we used the GPO2 
primer (5’CTTAAAGCAATTGACGGGAACCCG 3’) and MGSO primer. For a 
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20µl reaction volume, 1.0µl of the product from the first round of amplification was 
added to 1.0µl (0.4µM) each of the GPO2 and MGSO primers and 17µl of Reddymix 
Mastermix. PCR amplification conditions and cycles were the same as above. The 
PCR products from both rounds were run on a 1.5% agarose gel containing ethidium 
bromide.  
 
A strong positive sample produces a band at 720bp from the first round of 
amplification and a band at 145bp from the second amplification. A weak positive 
sample produces a single band at 145bp form the second round of amplification. 
Only the cells negative for both rounds of amplifications were used in my study. 
 
2.6 Harvesting colonies 
Plates were examined under an inverted microscope in order to locate colonies. Once 
the colonies were identified they were circled with a marker at the bottom of the 
plate. Culture medium was aspirated off and an appropriate sized cloning cylinder 
was pressed into a plate of autoclaved Vaseline using a pair of sterile forceps. The 
cylinder was carefully lowered onto a colony and pressed down firmly. Trypsin, 100-
200µl depending on the size of the cylinder being used was pipetted and cells were 
left to incubate at room temperature until they detached. The cells were retropipetted 
using a Pasteur pipette and diluted into 5ml of complete culture medium, containing 
appropriate drug if required, into a P-60 plate. 
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2.7 RNA extraction using Trizol reagent 
Monolayer of cells, at approximately 80% confluence, was washed twice with 5ml of 
PBS. One millilitre of Trizol reagent (Sigma) was added to the cells and left for at 
least 1min at room temperature. The cell lysate was pipetted well and the content 
stored in 1.5ml microcentrifuge at -80°C until required. Once all the samples had 
been collected for extraction they were thawed at room temperature and incubated 
for 5min at 15-30oC. Two hundred microlitres of chloroform was added to the 
samples and the tubes were shaken vigorously by hand for at least 15sec. The 
samples were then incubated for 2-3min at 15-30oC prior to spinning them at 
13000rpm for 20min at 4°C in a bench centrifuge (Eppendorf centrifuge 5415R). The 
clear upper aqueous phase that contains RNA exclusively was carefully pipetted into 
a fresh microcentrifuge tube. Isopropyl alcohol, 750µl, was added to each sample and 
mixed gently prior to incubation for 10min at 15-30oC. Samples were centrifuged at 
13000rpm for 10min at 4°C. RNA precipitate forms a gel-like pellet normally on the 
side of the tube. The supernatant was poured off and the RNA pellets washed once 
with 75% ethanol. The samples were mixed well by vortexing prior to centrifugation 
at 8000rpm for 5min at 4°C. The 70% ethanol was poured off and the RNA pellets 
air-dried at room temperature for 10-15min. RNA was dissolved in 20µl of DEPC 
treated water for a minimum of 1hr on ice and absorbance was read at 260ηm. 
 
 
 
 
 
 85 
          
 
 
 
Generation of human monochromosome hybrids by 
microcell-mediated chromosome transfer (MMCT) 
 
3.1 Introduction 
MMCT is a well established technique in our laboratory that allows individual 
normal human chromosomes tagged with a selectable marker to be transferred into 
any mammalian cell. The transferred chromosome is maintained in the recipient cells 
as an intact functional and structural entity. Individual transfer of the complete 
complement of normal human chromosomes into any mammalian cells permits the 
entire genome to be scanned for the existence of active genes that could be identified 
by a particular phenotype on the basis of genetic complementation (Cuthbert et al., 
1995; Newbold and Cuthbert, 1998; Saxon et al., 1985). The structural characteristics 
of the introduced chromosome can easily be defined by STS mapping and 
chromosome painting in a heterospecific human: rodent hybrid (Newbold and 
Cuthbert, 1998). This fact was taken into account when the monochromosomal 
hybrid panel was constructed by Professor Newbold’s group. 
 
We have used genetic complementation studies to locate telomerase/hTERT 
repressor genes in breast cancer cells and, in the present study, in a prostate cancer 
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cell line. Identifying the telomerase repressor gene required the whole genome to be 
screened for repressive function. This was made possible by the availability of the 
complete panel of human: rodent monochromosomal hybrids in our own laboratory 
(Cuthbert et al., 1995). Each hybrid contained a single intact human chromosome 
tagged with the selectable HyTK fusion gene. The HyTK bifunctional gene was 
constructed by fusing the bacterial hygromycin phosphotransferase (hph) gene with 
the herpes simplex virus type 1 (HSV-1) thymidine kinase (TK) gene. The reason for 
choosing the HyTK fusion gene as a mammalian selectable marker was to promote 
the facility for the transferred chromosome to be selected “in” or “out” of the 
recipient cells. Positive selection (to maintain the transferred chromosome in the 
recipient cells) of the integrated HyTK marker is achieved by adding hygromycin B 
in the culture medium and negative selection (loss of the transferred chromosome) by 
culturing cells in a synthetic prodrug called ganciclovir (Newbold and Cuthbert, 
1998). The reverse selection makes use of the fact that the HSV thymidine kinase 
(TK) on the HyTK selectable marker phosphorylates the non-toxic prodrug 
ganciclovir (GCV) to GCV-phosphate. The latter is further phosphorylated to GCV-
triphosphate by endogenous kinases which causes DNA chain termination and single 
strand breaks once it is integrated into the DNA inducing apoptosis in the target cells 
(Beltinger et al., 1999). The dual properties of the HyTK marker allows a specific 
phenotype associated with the transferred chromosome (in my case telomerase 
activity and hTERT transcription determined by TRAP assay and quantitative RT-
PCR respectively) to be confirmed by the loss of the phenotype by reverse selection 
of the transferred chromosome in the hybrid clones (Cuthbert et al., 1995). 
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3.1.1 Construction of human: rodent monochromosomal hybrid panel 
The HyTK fusion gene was inserted into a small (approximately 4.2 kb) Moloney-
based retrovirus (tgLS(+)HyTK) which was placed under the transcriptional control 
of the proviral 5’ long terminal repeat (LTR) (Lupton et al, 1991). The initial step in 
tagging normal human chromosomes with the selectable fusion gene involved the 
transvection of the producer cell line PA317 with the retroviral vector tgLS(+)HyTK. 
Amphotropic pseudotype viral supernatants collected from PA317 cells were used to 
infect the normal diploid adult human male fibroblast strain IBR.2; the cells were 
subsequently selected with hygromyin B and cryopreserved before utilizing them as 
human chromosome donors. Our monochromosomal hybrid panel was constructed 
by direct microcell transfer of the virus-infected human IBR.2 cells into A9, a mouse 
fibroblast cell line. A9 clones resistant to hygromycin B were cryopreserved prior to 
cytogenetic and molecular analysis. Monochromosomal hybrids were further 
analysed by STS-PCR using primers that amplified the telomeric proximal regions 
on the p and q arms. Clones that were positive for both markers were selected for 
more thorough characterization, essentially to remove the likelihood of the clones 
containing a chimeric chromosome. The identity and integrity of the transferred 
chromosome was additionally confirmed by G-banding and FISH analysis using 
whole chromosome specific paints after 40 population doublings, to confirm the 
presence of a stable single human chromosome (Cuthbert et al., 1995). 
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Figure 3.1: Diagram showing the main steps involved in the MMCT technique. 
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In the past, the MMCT has proved to be an invaluable tool in successfully identifying 
several genes in various disorders by using the donor panel constructed by Professor 
Newbold’s team. These include the MMADHC gene which is responsible for defects 
in cobalamin metabolism (Coelho et al., 2008); SUMF1 gene which is involved in 
multiple sulphatase deficiency (Cosma et al., 2003) and SURF1 gene which plays a 
role in biogenesis of cytochrome c oxidase in a human neurological disorder (Zhu et 
al., 1998). Our donor panel has also been successfully used in cancer studies. A 
number of chromosomal regions have been identified where tumour suppressor 
(Dafou et al., 2009) and telomerase repressor gene(s) (Steenbergen et al., 2001; 
Cuthbert et al., 1999) may possibly be located. 
 
The initial aim of this study was to identify a chromosome that may have a repressive 
effect on telomerase activity when transferred into a prostate cancer cell line. This 
was achieved by individually transferring the 22 autosomal chromosomes and the X 
chromosome into PC-3 cells to screen the whole genome for the telomerase repressor 
gene(s). 
 
3.2 Materials and Methods 
3.2.1 Microcell Mediated Chromosome Transfer (MMCT) 
Human: rodent monochromosomal cells, referred to as a “donor” cell line, were 
seeded at the cell number shown in Table 3.1. The cells were set up in 12x24cm2  
flasks (NunclonTM Surface, Nunc) in DMEM containing 20% FBS without 
hygromycin B, in a final volume of 5ml. The cells were incubated at 37oC for 24hr in 
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a fully humidified incubator with 10% CO2. PC-3; the recipient cell line was seeded 
at 3, 3.5 and 4x106/10cm dish in duplicate in 15ml of complete culture medium on 
the same day as the donor cells. The PC-3 cells were incubated at 37oC for 72hr in a 
fully humidified incubator with 6.5 % CO2. After approximately 24hr of incubation, 
colcemid (for concentrations refer to Table 3.1) was added to the donor cells and the 
cells were left to micronucleate for 48hr. The cell seeding number and the colcemid 
concentrations had previously been optimized for each donor cell line. I had 
optimized the cell number to produce 70-80% confluent monolayer cells after 24hr 
of incubation and the colcemid concentration was optimized to produce a maximum 
number of micronuclei with the least number of non-viable cells after 48hr of 
incubation. The culture medium was aspirated off from each of the 24 flasks and 
30ml of 10µg/ml of cytochalasin B (Sigma) prepared in serum free DMEM was 
pipetted into each flask. The flasks were weighed accurately to two decimal places 
and paired to 0.03g differences. 75ml of warm water was poured into each bucket of 
the pre-warmed rotor (Sigma, 6X250ml) and the paired flasks placed opposite each 
other into the rotor at 45 degrees with the cell monolayer facing inwards. The flasks 
were centrifuged at 9500g for 1hr 10min at 37°C in a Sigma laboratory centrifuge 
6K15 (Philip Harris). The flasks were weighed again and any loss or gain in weight 
of more than 0.02g was discarded. DMEM containing the cytochalasin B was poured 
out of the flasks leaving behind 1-2ml. The pellets at the two corners of the flasks 
were flicked and microcells from 6 flasks were pooled into one 15ml conical tube. 
The microcells were spun down at 4500rpm for 5min. The supernatant was aspirated 
off and the pellet flicked before adding 2ml of warm serum free DMEM. The 
microcells were pipetted thoroughly in order to obtain single cell suspension. The 
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volume was made up to 12ml in each tube with serum free DMEM and the 
microcells mixed well prior to sequentially filtering through an 8µm and two 5µm 
polycarbonate filters (Whatman: Nucleopore Track-Etch Membrane, Swinlock 
Holders 25mm diameter) to maximize the yield of microcells carrying only a single 
chromosome. The microcells were spun at 4500rpm for 5min. The supernatant was 
aspirated off and the pellet flicked and resuspended in 3ml of serum free Ham’s F-12 
medium, containing 100µg/ml Phytohaemagglutanin (PHA-P, Sigma). Meanwhile 
the plate containing the most evenly distributed PC-3 cells was selected and washed 
three times in warm SF Ham’s F-12 medium and the microcells pipetted on to the 
recipient cells. The plate was incubated at 37oC and 6.5%CO2 for 25min to allow the 
microcells to attach to the recipient cells. Microcells that had not attached were 
carefully aspirated off and 3ml of PEG solution containing 42.5% polyethylene 
Glycol 1000 (Sigma) and 8.5% DMSO in SF Ham’s F-12 medium was added slowly 
to the edge of the plate. After exactly one minute at room temperature the PEG 
solution was carefully aspirated off and the plate was washed three times with warm 
SF Ham’s F-12 medium with each wash lasting 1min. Fifteen ml of complete 
medium was added to the plate and the cells were incubated at 37oC and 6.5% CO2 
overnight. The next day, the cells were subcultured into ten P-100 dishes and 
incubated for 3 days before gradual selection with 100U/ml of hyg B for 3 days and 
thereafter with 200U/ml of hyg B until colonies appeared. Clones were picked and 
cultured with half the dose of hyg B for maintaining the transferred chromosome in 
the recipient cells. Two ampoules of each clone were cryopreserved in liquid 
nitrogen. A mock fusion was also performed as a control for the MMCT. 
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Table 3.1: Monochromosomal hybrids were seeded at the densities shown for 
MMCT experiments, and the colcemid dose used for each hybrid is the optimum that 
produced maximum micronucleation with the least number of non-viable cells. 
Human:rodent 
monochromosomal hybrids 
Cell seeding density 
Number of cells/flask (x106) 
Colcemid dose (µg/ml) 
A9HyTK1 2.0 0.12 
A9HyTK2 1.5 0.05 
A9HyTK3 1.75 0.075 
A9HyTK4 1.5 0.15 
A9HyTK5 1.5 0.10 
A9HyTK6 1.5 0.075 
A9HyTK7 1.5 0.06 
A9HyTK8 2.0 0.10 
CHOHyTK9 1.0 0.05 
CHOHyTK9 (del p) 1.0 0.05 
A9HyTK10 1.75 0.10 
A9HyTK11  1.25 0.05 
A9HyTK12  1.5 0.05 
A9HyTK13 1.5 0.065 
A9HyTK14  1.5 0.06 
A9HyTK15 1.25 0.04 
A9HyTK16 2.25 0.075 
A9HyTK17 1.5 0.075 
A9HyTK18 2.0 0.10 
A9HyTK19 2.0 0.06 
A9HyTK20  2.0 0.075 
A9HyTK21 1.0 0.05 
A9HyTK22 1.0 0.05 
A9HyTKX 2.0 0.10 
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3.3 Results 
3.3.1 Microcell mediated chromosome transfer of all 22 autosomal normal 
human chromosomes and the X chromosome into PC-3, a prostate cancer cell 
line  
Heterospecific human: rodent hybrids containing a single copy of a normal human 
chromosome in mouse A9 cells were used as microcell donors. A complete, well 
characterized panel, consisting of 22 autosomal chromosomes plus the X 
chromosome, has been constructed by Professor Newbold’s group (Cuthbert et al., 
1995). The donor cell lines available for transfer in our laboratory were all at under 
passage 15. Microcells isolated individually from each of these donor cells were 
fused into PC-3, a prostate epithelial cell line (see Materials and Methods) and 
hybrids were selected with 200U/ml of hygromycin B; colonies appeared 3 to 4 
weeks after fusion. Hybrid colonies were marked whilst being examined under the 
microscope after approximately two weeks. On average 2-3 colonies per plate were 
formed within this time period. Any colonies appearing thereafter were considered to 
be satellites. The possibility of satellite colonies forming within the two weeks was 
deemed to be low since the colonies are very small. Often a dozen or more colonies 
were observed on a plate after 4 to 5 weeks. The previously marked colonies were 
picked using disposable plastic cloning cylinders once they were large enough to fill 
the x5 magnification viewing field. The hybrid colonies were expanded as separate 
cell lines to be assayed for telomerase activity. 
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3.3.2 Microcell Mediated Chromosome Transfer (MMCT) 
The initial step in MMCT involved micronucleation of the donor cells (Fig 3.2). This 
was achieved by incubating the donor hybrids with the mitotic inhibitor colcemid 
which blocks the cells in metaphase by preventing the formation of a functional 
spindle. The donor cells were treated with colcemid for 48hr at concentrations that 
had produced the highest number of micronuclei with the lowest number of non-
viable cells in the pilot study (refer to Table 3.1). The non-viable cells were 
determined by the number of cells that had detached from the plate. Incubating the 
donor cells with the correct concentration of colcemid is vital to the success of the 
MMCT procedure as high dose of this mitotic inhibitor resulted in increased cell 
toxicity and decreased number of micronucleated cells. 
 
 
Figure 3.2: Incubating the donor cells with colcemid for 48hr results in micronucleation of the 
majority of cells. Example of micronucleated A9HyTK 11 donor cells is shown above. (Magnification 
of the image is x20). 
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Incubating the micronucleated cells with cytochalasin B resulted in nuclear extrusion 
(Fig 3.3). Centrifuging these micronucleated cells attached to the plastic culture 
surface at high speed in the presence of cytochalasin B caused extruded nuclei to 
break away from the cells, grasping a small amount of cytoplasm to produce 
microcells. 
 
  
Figure 3.3: Incubating the micronucleated cells in cytochalasin B for approximately 20min caused 
nuclear extrusion which later helps the micronuclei to break away from the cell when they are being 
centrifuged. (Magnification of the image is x20). 
 
Microcells produced by enucleation of the micronucleated cells were size-selected by 
serially filtering through a single 8µm followed by twice through 5µm polycarbonate 
filters to enrich the population of microcells containing a single normal human 
chromosome and to remove the contaminating whole A9 cells and cell debris (Fig 
3.4). 
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Figure 3.4: Microcells are filtered through 1x 8µm and 2 x 5µm polycarbonate filters prior to fusion 
with the recipient cells. Image of filtered microcells prepared from A9HyTK 11 cells. (Magnification 
of the image is x40). 
 
An evenly distributed recipient (PC-3) monolayer was used for fusion when the cells 
were approximately 90% confluent (Fig 3.5). 
 
 
Figure 3.5: A monolayer of PC-3, a prostate cancer cell line used as recipient cells. The arrows are 
pointing at the “ruffles” in the cytoplasm and should not be confused with microcells (an image of 
microcells is shown in Fig 3.6). (Magnification of the image is x10). 
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Microcells were incubated with the recipient cells in the presence of 
phytohaemagglutinin (PHA-P) prior to fusing them using polyethylene glycol (PEG). 
Treating cells with PHA before exposure to 44% PEG results in reduced cytotoxcity 
caused by PEG. McNeil and Brown (1980) demonstrated the combined effects of 
PHA with PEG increases the fusion capacity of microcells with whole cells. PHA 
also helps microcells to adhere to the recipient cells so that the fusion with PEG is 
more efficient (Fig 3.6). 
 
 
Figure 3.6: Image of microcells co-incubating with the recipient PC-3 cells in the presence of PHA, 
before fusing them with PEG. (Magnification of the image is x20). 
 
Transfer of a tagged normal human chromosome into the recipient cells confers 
resistance to hygromycin B in the hybrids, which then proliferate to form a clone 
(Fig 3.7). Cells that do not possess the chromosome with the selectable HyTK 
marker are not resistant to hygromycin B and hence fail to proliferate into colonies. 
Hybrid clones were picked and each cultured as a separate cell line. 
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Figure 3.7: Image of a typical highly proliferative clone of PC-3 microcell hybrid cells resistant to 
hygromycin B. (Magnification of the image is x5). 
 
With certain normal human chromosomes (Table 3.2) occasional hybrids were found 
to undergo senescence after they were picked and cultured in a P-60 plate to 
proliferate as an independent cell line (Fig 3.8). A possible reason for recipient cells 
undergoing senescence in this way is the presence of a telomerase repressor sequence 
in the transferred chromosome. Alternatively, there is also a possibility that the 
transferred chromosome possesses other senescence-inducing gene(s). However, in 
my study, the infrequent occurrence of these senescent colonies suggests that this is 
probably a phenomenon observed in cell culture where cells rarely undergo 
senescence. 
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Figure 3.8: Image of a PC-3/chr 11 hybrid clone that underwent senescence. The difference in the 
morphology of senescent and normal proliferating cells is very evident. Senescent cells are much 
larger, flatter, and granular; they are metabolically active cells that have lost the ability to divide. 
(Magnification of the image is x10). 
 
A complete set of hybrid clones was generated from the transfer of each normal 
human chromosome (Table 3.2) and cultured as independent cell lines. However, 
chromosome Y could not be transferred into PC-3 cells because a donor cell line 
containing an individual normal human chromosome Y was unavailable in our 
laboratory. During the construction of the “donor” panel Cuthbert et al (1995) were 
unable to isolate a Y chromosome, possibly due to lack of integration of the 
retrovirus carrying the HyTK marker.  
 
The panel of hybrids generated by individual transfer of normal human chromosomes 
is a very valuable resource to screen the entire normal human genome for any gene 
of interest for which there is a clear cellular phenotype, i.e. tumour suppressor genes 
can be identified by either in vitro or in vivo growth suppression assays, metastasis 
suppressor genes by migration assay and telomerase repressor genes, as in this study, 
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can be identified by the TRAP assay or by the repressed expression levels of hTERT, 
the catalytic subunit of telomerase. 
 
Table 3.2: Summary of the number of hybrid clones generated by MMCT (a single 
experiment was performed with each transferred chromosome) to study genetic 
complementation in PC-3, a prostate cancer cell line. The number of clones that 
underwent senescence from each MMCT is shown in the last column. 
 
Hybrids Number of colonies picked 
and cultured as separate 
cell lines 
Number of clones that 
senesced  
on the P-60 plate 
PC-3/chr1  19  
PC-3/chr2 25  
PC-3/chr3 17 1 
PC-3/chr4  20  
PC-3/chr5  15 1 
PC-3/chr6  18 1 
PC-3/chr7  16  
PC-3/chr8  26  
PC-3/chr9  1  
PC-3/chr9 (del p-arm)  23  
PC-3/chr10  20 2 
PC-3/chr11 17 1 
PC-3/chr12 18 2 
PC-3/chr13 38  
PC-3/chr14 28 1 
PC-3/chr15 21  
PC-3/chr16 24  
PC-3/chr17 23  
PC-3/chr18 26  
PC-3/chr19 5  
PC-3/chr20 28  
PC-3/chr21 30  
PC-3/chr22 18  
PC-3/chrX 21  
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3.4 Discussion  
On average, transfer of most normal human chromosomes into PC-3 cells produced 
15-30 hybrid clones from microcells prepared from 12x24cm2 flasks. The two 
chromosomes that gave a markedly reduced number of clones were chromosomes 9 
and 19 (Table 3.2). It is a phenomenon well known in this kind of work that some 
chromosomes are easier to transfer than others. Generally, I found many 
experimental factors that can influence the efficiency of a transfer and produce a 
higher number of clones; these included: (i) the use of donor cells of the lowest 
passage number possible (because, in my hands, with increasing passage number, 
donor cells generally produced fewer micronuclei) and (ii) employing an optimal 
colcemid concentration that produced the highest number of micronuclei with the 
lowest number of nonviable cells. Later in the project when fragmented chromosome 
11 was transferred into the telomerized PC-3 cell line (see section 7.2.1) fewer 
hybrid colonies were obtained. However, I found that increasing the number of 
microcells available for fusion with the recipient cells resulted in a larger number of 
colonies. This was achieved by preparing the microcells from donor cells seeded in 
24 flasks compared with 12 flasks for whole chromosome transfers. 
 
The presence of a powerful anti-proliferative gene on human chromosome 9 became 
evident during the construction of the monochromosomal hybrid panel in our 
laboratory. Cuthbert et al (1995) were unable to recover intact human chromosome 9 
in mouse A9 background when it was directly transferred from diploid human 
fibroblast into the A9 cells. However, Chinese hamster ovarian (CHO) cells could 
tolerate intact human chromosome 9 and it was available in our laboratory as part of 
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the human monochromosome hybrid panel. Later, England et al (1996) provided 
strong evidence by STS-PCR deletion mapping of segregants generated from 
monochromosome transfer experiments that it was the p16INK4a (CDKN2A) gene that 
was responsible for growth suppressive effect of chromosome 9 in A9 cells. The 
anti-proliferative effect of chromosome 9 was not confined to A9 cells alone. 
Transfer of chromosome 9 into 5XH11, an X-ray-induced Syrian hamster dermal 
(SHD) cell line produced one clone. The authors provided further evidence of 
p16INK4a involvement in rapid growth suppression by transfecting CDKN2A cDNA 
into 3 human malignant melanoma cell lines.  
 
In my study, MMCT of chromosome 9 generated only a single clone and this is most 
likely to be due to the presence of the cyclin dependent kinase (cdk) inhibitor gene 
p16INK4a located on chromosome 9p21 that blocks the cell cycle at G1 resulting in 
senescence. This pathway is often inactivated in the development of epithelial 
cancers including prostate cancer. Perinchery et al (1999) reported LOH on 9p21 in 
72.5% of prostate cancer samples and they found the expression of the p16 protein to 
be either absent or very low suggesting the loss of p16 may be involved in prostate 
carcinogenesis. However, when Tamimi et al (1996) investigated the frequency of 
p16INK4a mutations/deletions in 20 primary prostate tumours and four established 
prostate cancer cell lines, they only found two mutations; one in DU145 cell line and 
the other in a primary tumour, suggesting that mutation of p16INK4a gene is not a 
frequent event in prostate cancer. Nevertheless, when I transferred chromosome 9 
with a deleted p-arm into PC-3 cells, 23 clones were produced, providing further 
evidence that the p16INK4a tumour suppressor gene or some other gene located on 
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chromosome 9p may have contributed to the low colony number when whole 
chromosome 9 was transferred. 
 
Transfer of chromosome 19 produced the second lowest number of clones (5). Gao et 
al (1999) had earlier reported a region on chromosome 19p13.1-13.2 that is 
responsible for suppressing in vitro and in vivo growth of both human (TSU-pr1) and 
rat (Dunning-R3327 AT6.1) prostatic cancer cells. Therefore, there is a possibility 
that the low colony number may be due to the presence of a growth suppressor 
gene(s) in the 19p13.1-13.2 region. 
 
Even though the human chromosomes are intact and stable in our donor cell lines, as 
characterized by comprehensive cytogenetic and molecular analyses such as G-
banding, FISH analysis and STS mapping (Cuthbert et al., 1995), the MMCT 
technique can result in either large or small deletions of the transferred chromosome 
once it has been fused into the recipient cells. This fact can be turned into a useful 
advantage in any gene mapping exercise, since heterogeneity in the genetic content 
of clones that are generated (with respect to the transferred chromosome) can permit 
sub-chromosomal localization of a gene of interest. With respect to a telomerase 
repressor sequence, one might therefore expect to see a mixture of hybrid clones that 
were repressed and others that were not. This of course assumes that the gene of 
interest is not positioned in close proximity to the selectable marker. 
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Identification of the chromosome that may carry a gene (or 
genes) involved in telomerase repression in prostate cancer 
4.1 Introduction  
 
Normal human somatic cells undergo only a limited number of cell divisions before 
entering replicative senescence (RS). RS is an irreversible growth arrest that has been 
suggested to act as a protective barrier against cancerous transformation (Collado et 
al., 2007). In contrast, tumour cells overcome replicative senescence and grow 
indefinitely i.e. become immortal (reviewed in Campisi and di Fagagna., 2007). 
Telomeres are specialized DNA structures at the ends of linear chromosomes and 
their maintenance is a prerequisite for immortalization and cancer formation that 
commonly occurs through activation of telomerase (reviewed in Shay and Wright, 
2005, Newbold 2005). Telomerase is tightly regulated in normal human somatic cells 
but the majority of tumour and immortal cells have elevated levels of telomerase 
activity in order to maintain telomere lengths (Kim et al., 1994). Inactivation or loss 
of both alleles of a critical gene that functions to repress telomerase could be an 
important event in the transition of normal cells into cancerous cells. Several studies 
have shown that introduction of a normal copy of a specific human chromosome by 
MMCT can be used to induce repression of telomerase activity in various cancers 
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(Horikawa et al., 1998; Cuthbert et al., 1999; Steenbergen et al., 2001; Nishimoto et 
al., 2001). The purpose of this part of my study was to measure telomerase activity in 
hybrids that I previously generated (Chapter 3) by the individual transfer of normal 
human chromosomes into PC-3 cells and hence identify a chromosome(s) that can 
repress telomerase activity in prostate cancer cells. 
 
4.2 Materials and Methods 
4.2.1 Determination of telomerase activity by conventional TRAP assay 
4.2.1.i Sample preparation 
The surface of the hood and the pipettes were cleaned with RNase-Away solution 
before protein isolation. Cell hybrids from MMCT were cultured in P-60 dishes and 
trypsinized as normal when 50-80% confluent. The cell pellet was flicked and 
resuspended at approximately 3-5x105 in complete culture medium containing 
0.1mM PMSF. Cells were counted and 2 times 105 cells for each hybrid were spun 
down in 0.5ml microcentrifuge tubes. The supernatant was carefully removed with a 
Gilson pipette and the pellets frozen down immediately on dry ice. The samples were 
stored at -80oC until required. 
 
4.2.1.ii Protein isolation 
The samples to be assayed were thawed out on wet ice and 200µl of cold x1 CHAPS 
lysis buffer was added to each 105cell pellet. Pellets were retropipetted vigorously 
and left to incubate on ice for 30min. Samples were centrifuged at 13000rpm for 
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20min at 4oC. Approximately 160µl of the supernatant was pippeted into a 
microcentrifuge tube and rapidly frozen down on dry ice for telomerase activity 
measurement. Twenty microlitre of the supernatant was used for protein 
determination. 
 
4.2.1.iii Protein assay 
Coomassie protein assay reagent (Pierce Solution) was used to determine the protein 
concentration in the samples. A standard curve was set up with BSA (Bovine serum 
albumin), dissolved in x1 CHAPS lysis buffer between 0 to 20µg protein. One 
millilitre of the Pierce solution was added to each tube set up for the standard curve 
and the unknown samples (20µl). The standards and the samples were incubated for 
exactly 5min at room temperature. The absorbance was read at 595ηm. The protein 
concentration of the unknown samples was determined from the standard curve and 
the samples were diluted to 50ηg/µl in CHAPS lysis buffer. 
 
4.2.1.iv Telomeric repeat amplification protocol (TRAP) assay 
TRAPeze, a telomerase detection kit (Intergen Company) was used to determine 
telomerase in actively dividing cells. All the samples to be assayed were thawed out 
on ice. TS primer was End labelled with γ-32P-ATP (Amersham Biosciences) using 
the following reagents provided in the kit:  
For 10 assays  TS primer  10µl 
   10x KinaseA buffer 2µl 
   T4 Poly Kinase 0.5µl (10U/µl) 
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   dH2O   5µl 
   γ 32P-ATP  2.5µl 
The tube was placed in a PCR block for 20min at 37oC and for 5min at 85oC.  
The PCR mastermix was prepared for the number of samples to be assayed in 1.5ml 
eppendorf tube using the following reagents: 
For each assay  10x TRAP buffer  5µl 
   50x dNTP   1µl 
   TRAP primer mix  1µl 
   Taq (5units/µl)  0.4µl (2 Units) 
   ddH2O    38.6µl 
   γ 32P TS primer (end label) 2µl 
 
Radioactive end label was added to the master mix at the very end and mixed well.  
To 46µl of master mix 4µl of the sample to be assayed, 4µl of x1CHAPS lysis buffer 
(negative control), 2µl of H 2O and 2µl of TSR8 (positive control) was added to the 
PCR tubes. The tubes were placed into a PCR machine (Tetrad, Peltier Thermal 
Cycler PTC-225) and the samples incubated at 30oC for 30min and amplified using a 
two-step PCR at 94°C for 30sec, 59°C for 30sec for 30 cycle. 
4.2.1.v Polyacrylamide gel electrophoresis 
Non-denaturing 12.5% polyacrylamide gels were prepared in x0.5 TBE buffer and 
poured into 16 x 16cm plates. Ten microlitre of loading buffer was added to the PCR 
products and 30µl samples were loaded onto the vertical gel. The gel was allowed to 
run at constant 200V for approximately 3 to 3.5hr or until the bromophenol blue ran 
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out of the gel and xylene cyanol blue ran 70-75% of the gel length. Cold water was 
circulated through the system to prevent overheating of the gel; this prevents 
distortion of bands from excessive heat. The gel was dried and exposed overnight 
onto a phosphorimager screen in a cassette at room temperature before scanning the 
screen in the phosphorimager (Storm 820, Amersham Pharmacia Biotech). 
 
4.3 Results 
4.3.1 Effects of normal human chromosomes on telomerase activity in a prostate 
cancer cell line, PC-3, following microcell fusion 
There was no published data available concerning the involvement of normal human 
chromosomes in telomerase repression in prostate cancer cells. Therefore, the entire 
chromosome panel was transferred into PC-3 as a complete screen of the human 
genome. There was no indication as to which chromosome may harbour a telomerase 
repressor from the number of hybrid clones recovered after MMCT or indeed the 
growth rate of hybrid cells collected from different transfers.  
 
The hybrids generated from transferring normal human chromosome 3, 4, 10, 11, 17 
and 21 into PC-3 cell line were selected to determine the level of telomerase activity 
in their respective clones. The reason for selecting these hybrids in the first phase of 
the study was because: (i) a region on the small (p) arm of chromosome 3 has already 
been found to repress telomerase activity in human breast cancer cell line in our 
laboratory (Cuthbert et al., 1999) and a different region on chromosome 3 had been 
found to repress telomerase in a human renal carcinoma cell line (Oshimura and 
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Barrett., 1997); (ii) chromosome 4 had been shown previously to repress telomerase 
in HeLa, a cervical cancer cell line (Backsch et al., 2001) and Bertram et al (1999) 
had identified a senescence gene on chromosome 4q; (iii) chromosome 10 had been 
shown to repress telomerase activity in hepatocellular carcinoma cell line (Nishimoto 
et al. 2001); (iv) chromosome 17 hybrids were selected because loss of the TP53 
gene is common in a variety of human cancers possibly leading to increased 
proliferative potential and ultimately to clonal evolution and malignant progression. 
Several groups have reported mutations in the p53 gene in prostate cancer cells 
(Isaacs et al., 1991; Chi et al., 1994). (As described in section 1.2.9.iv, there is also 
evidence that p53 is directly involved in telomerase repression in normal cells); (v) 
chromosome 11 hybrids were selected because the loss of heterozygosity on both 
arms of chromosome 11 has been reported in prostate cancer (Dahiya et al., 1997); 
(vi) chromosome 21 hybrids were selected randomly. Telomerase activity was 
assessed in each of the hybrids at the same early growth stage, i.e. Passage 1, after 
transfer to mass culture using the commercially available TRAPeze kit. 
 
The initial plan was to screen all of the hybrids. However, the observed repression by 
chromosome 11 led us to focus on this chromosome and map the critical gene. 
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4.3.2 Phosphorimager scans of TRAP gels showing telomerase activity in clones 
of various hybrids obtained after transfer of normal human chromosomes. 
 
Figure 4.1: Levels of telomerase activity in hybrid clones generated by the transfer of normal human 
chromosome 3 into the PC-3 cell line. The corresponding histogram shows the level of telomerase 
activity relative to the internal control, S-IC. Control PC-3 values were obtained from mass cultures of 
PC-3 cells not subjected to MMCT. 
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Figure 4.2: Levels of telomerase activity in hybrid clones generated by the transfer of normal human 
chromosome 4 into the PC-3 cell line. The corresponding histogram shows the level of telomerase 
activity relative to the internal control, S-IC. Control PC-3 values were obtained from mass cultures of 
PC-3 cells not subjected to MMCT. 
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Figure 4.3: Levels of telomerase activity in hybrid clones generated by the transfer of normal human 
chromosome 10 into the PC-3 cell line. The corresponding histogram shows the level of telomerase 
activity relative to the internal control, S-IC. Control PC-3 values were obtained from mass cultures of 
PC-3 cells not subjected to MMCT. 
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Figure 4.4: Levels of telomerase activity in hybrid clones generated by the transfer of normal human 
chromosome 11 into the PC-3 cell line. The corresponding histogram shows the level of telomerase 
activity relative to the internal control, S-IC. Control PC-3 values were obtained from mass cultures of 
PC-3 cells not subjected to MMCT. 
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Figure 4.5: Levels of telomerase activity in hybrid clones generated by the transfer of normal human 
chromosome 17 into the PC-3 cell line. The corresponding histogram shows the level of telomerase 
activity relative to the internal control, S-IC. Control PC-3 values were obtained from mass cultures of 
PC-3 cells not subjected to MMCT. 
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Figure 4.6: Levels of telomerase activity in hybrid clones generated by the transfer of normal human 
chromosome 21 into the PC-3 cell line. The corresponding histogram shows the level of telomerase 
activity relative to the internal control, S-IC. Control PC-3 values were obtained from mass cultures of 
PC-3 cells not subjected to MMCT. 
 
ImageQuant analysis of phosphorimager scans of TRAP gels are represented as a 
histogram (Figs 4.1-4.6), showing telomerase activity in various hybrids obtained 
following MMCT of chromosomes 3, 4, 10, 11, 17 and 21 into PC-3 cells. A 
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summary comparing telomerase activity between the various hybrid clones and PC-3 
cells is shown in Table 4.1. 
 
In each set of hybrids, I found a proportion of clones that expressed low levels (less 
than 50% of the parent PC-3 cells) of telomerase activity, e.g. clones 11 and 13 
(2/13) of PC-3: chromosome 3 hybrids (Fig 4.1), and clones 1-4, clones 6, 13 and 14 
(7/17) of PC-3: chromosome 4 hybrids (Fig 4.2). The difference in telomerase 
activity between these hybrids could possibly be due to clonal variation that is 
normally observed when the parent line is seeded at clonal density and telomerase 
activity is measured randomly in selected clones. Savre-Train et al (2000) studied the 
level of telomerase activity and telomere length in telomerase-positive tumour-
derived human cell lines and clones of these cell lines and found clonal heterogeneity 
existed in both telomerase activity and telomere length in all the cell lines that were 
examined. 
 
Chromosome 10: PC-3 hybrid clones 8, 13, 14, and 18 (Fig 4.3) possessed very low 
levels of telomerase activity (less than 10% of the parent PC-3 cell line), as did 
chromosome 17: PC-3 hybrid clones 3 and 6 (Fig 4.5). Certainly there is a possibility 
that more than one normal human chromosome carries a sequence that appears to 
repress telomerase activity in prostate cancer as has been reported for HeLa, a 
cervical cancer cell line, by MMCT of normal human chromosomes 3 and 4 
(Backsch et al., 2001). However, the apparent level of strong telomerase repression 
in chromosome 11 hybrids was remarkably higher (40%) compared with 
chromosome 10 (18.7%) and 17 (12.5%) hybrids (Fig 4.4). 
 117 
A very high level of telomerase activity was observed in 56% (9/16) of chromosome 
21: PC-3 hybrid clones (Fig 4.6). The telomerase activity was at least 2 fold higher 
than the parent PC-3 cells in all the nine clones. There is a possibility that an 
unknown positive regulator of telomerase activity exists on chromosome 21. 
 
Table 4.1: A summary comparing the levels of telomerase activity in hybrids 
generated by MMCT of normal human chromosomes into PC-3 cells; the first 
column shows the percentage of hybrid clones that had less than 10% of telomerase 
activity of the parental PC-3 cell line. The second column shows the percentage of 
hybrid clones that had 20% lower telomerase activity than that of PC-3 mass 
cultures. 
Hybrids Percentage of hybrid clones 
with less than 10% 
telomerase activity of PC-3 
mass cultures 
Percentage of hybrid 
clones with 20% lower 
telomerase activity than 
that of PC-3 mass cultures 
PC-3/chr3 0 (0/13) 31 (4/13) 
PC-3/chr4 0 (0/17) 47 (8/17) 
PC-3/chr10 19 (3/16) 44 (7/16) 
PC-3/chr11 40 (6/15) 80 (12/15) 
PC-3/chr17 13 (2/16) 56 (9/16) 
PC-3/chr21 6 (1/16) 25 (4/16) 
 
The data shows that chromosome 11 was the most persuasive candidate for 
harbouring a telomerase repressor sequence. Due to the conventional TRAP being a 
semi-quantitative method, the decision was made next to measure hTERT mRNA 
quantitatively in the hybrids, since it has been shown that there is a strong correlation 
between hTERT mRNA expression levels and telomerase activity (Meyerson et al., 
1997). As will be seen in the following Chapters, hTERT analysis provided more 
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convincing evidence for a telomerase repressive sequence located on normal human 
chromosome 11. 
4.4 Discussion 
Screening the hybrid clones, generated by the individual transfer of normal human 
chromosomes into PC-3, for repressive effect on telomerase activity suggests that a 
telomerase repressor sequence is located on chromosome 11. Several groups have 
studied the effects of MMCT on telomerase repression by individual transfer of 
normal human chromosomes into telomerase-positive cancerous cell lines originating 
from various tissues. Different regions of normal human chromosome 3 have been 
reported to repress telomerase activity in breast, renal and cervical cancer cell lines 
(Cuthbert et al., 1999; Horikawa et al., 1998; Backsch et al., 2001 respectively). 
However, transfer of chromosome 3 into the prostate cancer cell line, PC-3, showed 
no convincing effect on telomerase activity. Collectively, studies carried out on other 
tumour cell lines suggest that genes regulating telomerase could be tissue-specific as 
proposed by Tanka et al (2005). These authors provided evidence from genetic 
complementation that different putative telomerase repressors were inactive in 
different types of cancers by whole cell fusion experiments involving two renal cell 
carcinoma cell lines (KC12 and RCC23) and a breast cancer cell line (21NT). In 
these studies fusion of KC12 and RCC23 generated hybrids with comparable 
telomerase activity to that of the parent cell lines, indicating that both renal 
carcinoma cell lines possessed the same defect. Fusion of 21NT cells with either 
KC12 or RCC23 cells produced a significant number of telomerase-negative hybrids, 
suggesting that the defect gene responsible for telomerase repression in the two renal 
cell lines differed from that in the breast cancer cell line. 
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In my study, further evidence that tissue-specific telomerase repressors are 
inactivated in different types of cancers emerged from the individual transfers of 
chromosome 10 and chromosome 4 into PC-3 cells. Normal chromosome 10 and 
chromosome 4 were relatively ineffective in reducing telomerase activity compared 
with chromosome 11, although chromosome 10 has been reported to repress 
telomerase activity in hepatocellular carcinoma (Nishimoto et al., 2001) and 
chromosome 4 in a cervical carcinoma cell line (Backsch et al., 2001). The fact that 
gene(s) on different normal human chromosomes appear to be able to repress 
telomerase activity in different tissues could indicate that not all the tumours have the 
same defective gene that regulates telomerase activity (Oshimura and Barret, 1997) 
and that some telomerase repressors may be subjected to inactivation in a tissue-
specific manner (Tanaka et al., 2005). Alternatively, there may be more than one 
target gene in a pathway regulating telomerase. Several cell lines from each cancer 
type would need to be analysed to establish this. 
 
In my study, telomerase activity was measured in hybrids generated by the transfer 
of normal human chromosomes into PC-3 cells. A significant level of telomerase 
repression in PC-3 chromosome 11 hybrids was observed at passage 1 in the absence 
of replicative senescence. Rapid senescence was recorded only in a few clones of 
different hybrids (see Table 3.1) and these clones were not analysed for telomerase 
activity due to the limited cell number. The most likely reason for not observing 
replicative senescence in a larger number of PC-3 chromosome 11 hybrids is that the 
hybrid cells were not cultured beyond passage one and that there may have been a 
delay in telomere shortening (approximately 150 to 200bp are lost with each cell 
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division) and the activation of replicative senescence, since our Q-FISH results (see 
section 5.3.2.) have shown that PC-3 cells have moderately long average telomere 
(5.6Kb). Hence, there is a significant probability that replicative senescence may 
have been observed if I had cultured the cells further than Passage 1. In this 
connection, Oshimura et al (1995) reported a higher growth potential of RCC23 
chromosome 3 telomerase repressed hybrids (at 23-43 population doublings) 
compared with that reported by Cuthbert et al (1999) in 21NT chromosome 3 
repressed hybrids (at 10-18 population doublings). The difference in growth potential 
observed in these renal and breast carcinoma cell lines could well have been due to 
the difference in original telomere lengths of the parent cell lines, which were 6kb 
and 3kb respectively. 
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Construction of a PC-3 recipient cell line ectopically 
expressing hTERT cDNA 
 
5.1 Introduction  
Unlike normal human cells, human tumour cells can sometimes be established as 
permanent immortal cell lines. The presence of active telomerase is thought to be 
responsible for tumour cell immortality (Kim et al., 1994). Several groups have 
cloned the genes encoding the two main components of telomerase, the hTR (Feng et 
al., 1995) and hTERT (Meyerson et al., 1997). Subsequent work has shown that only 
the expression of the hTERT gene encoding the catalytic component of telomerase 
correlated with telomerase activity (Takakura et al., 1999; Meyerson et al., 1997). 
hTERT mRNA was detected in telomerase positive cell lines and tumours but not in 
telomerase negative cells. Furthermore, the expression of hTERT mRNA was 
induced upon telomerase activation during cellular immortalization (Kilian et al., 
1997) and down-regulated when human promyelocytic leukaemia HL60 cells were 
induced to differentiate in vitro (Meyerson et al., 1997). These findings strongly 
suggested that hTERT mRNA expression is the rate limiting component of 
telomerase activity. 
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Subsequent studies have shown that the life–span of normal human cells can be 
extended by ectopically forcing the expression of telomerase by stable transfection of 
telomerase-negative cells with an hTERT cDNA construct (Counter et al., 1998; 
Bodnar et al., 1998). In my study, I wanted to ensure that I did not encounter 
replicative senescence when a normal human chromosome carrying a telomerase 
repressor sequence was transferred into the PC-3 cell line. Therefore, in the next 
phase of the project, PC-3 cells were stably transfected with an hTERT cDNA 
plasmid construct to ectopically express the hTERT gene. With the design of PCR 
primers that amplify cDNA sequence cloned from only immature (pre-spliced) 
endogenous hTERT mRNA, quantification of endogenous hTERT in the absence of 
replicative senescence would be possible. 
 
5.2 Materials and Methods 
5.2.1 Human telomerase reverse transcriptase (hTERT) plasmid construction 
Empty viral vector pBABE puro (5.05kb) and the viral construct pBABE puro 
hTERT were gifts from Professor Wynford-Thomas, Cardiff. A 4kb hTERT cDNA 
insert from pBABE puro hTERT was cloned into the EcoR1 cloning site of a 
mammalian expression vector, pCI-neo (Stratagene) to create PCI-neo hTERT (by 
Dr. Scott Ellis, Brunel Institute of Cancer Genetics) (Fig 5.1). The orientation of the 
hTERT cDNA insert was confirmed by sequencing the construct (which has to be 5’-
3’ with respect to the CMV promoter). 
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Figure 5.1: Diagram of pCI-neo vector. 
 
The pCI-neo carries the human cytomegalovirus (CMV) promoter region that 
promotes the expression of the cloned DNA insert. The neomycin 
phosphotransferase gene in the vector allows the transfected cells to be selected with 
the antibiotic G418. 
 
5.2.2 Stable transfection of PC-3 with hTERT plasmid construct using TfXTM-20 
liposomes 
PC-3 cells were plated at 1.0x 106 / 100mm dish, in triplicate in Ham’s F-12 medium 
containing 7% FBS and left to proliferate overnight. Six millilitres of SFM pre-
warmed to 37°C was placed into 3 tubes and 22.5µl of TfX20 reagent (Promega) was 
added to all the tubes; the first tube was the negative control, to the second tube 0.5-
1.0µg of the empty plasmid pCI-neo was added (positive control) and to the third 
tube 0.5-1.0µg of pCI-neo-hTERT was added (test). The content of the tubes were 
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vortexed immediately and left to incubate at room temperature for 10-15min. The 
culture medium was aspirated from the 3 dishes of PC-3 cells and the content of each 
tube was added. The plates were returned to the incubator for 1hour. Twelve 
millilitres of complete medium was then added to each dish and the dishes left to 
incubate overnight. The cells were split 1:6 and cultured for 3 days prior to selection 
with 400µg/ml of geneticin (G418). Cells were fed once a week until colonies 
appeared. Once picked, the clones were maintained in 200µg/ml of G418. 
Subsequently total telomerase activity and immature (pre-spliced) endogenous 
hTERT mRNA expression levels (see section 5.2.4.iii) were determined in all the 
clones by quantitative TRAP analysis and real time qRT-PCR respectively. 
 
5.2.3 Quantitative TRAP assay 
A quantitative method developed by Henning, et al (2003) was used for assaying 
total telomerase activity (endogenously and exogenously expressed). Cell samples 
were lysed in CHAPS lysis buffer and the protein concentration measured as for the 
conventional TRAP assay. The total volume of the reaction mixture was 
25µl/sample. Each reaction mixture consisted of 1µl of protein sample and 24µl of 
SYBR Green Mastermix, which contained 1x SYBR Green buffer, 0.1µg of TS 
primer (5′-AATCCGTCGAGCAGAGTT-3′) and 0.05µg of ACX primer 
(5′GCGCGG(CTTACC)3CTAACC-3′). 24µl of SYBR Green mastermix and 1µl of 
250ηg/µl protein sample was dispensed into each well of a microlitre plate. Each 
sample was assayed in triplicate. The PCR was performed on an ABI PRISM 7900 
HT Sequence Detection System. The reaction mixture was first incubated at 25°C for 
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20min to allow the telomerase in the protein extracts to elongate the TS primer by 
adding TTAGGG repeat sequence. PCR was then started at 95°C for 10min to 
activate the Taq polymerase followed by a two-step PCR amplification of 35 cycles 
at 95°C for 30s and 60°C for 90s. A standard curve was generated from serially 
diluted telomerase positive prostate cell line; PC-3 extracts (104 to 101 cells). The 
threshold cycle values (Ct) of the unknown samples were read off against the 
standard curve, and the level of telomerase activity compared to the number of PC-3 
cells. 
 
5.2.4 Determination of immature endogenous hTERT and GAPDH mRNA 
expression levels using real-time quantitative RT-PCR 
5.2.4.i Complementary DNA (cDNA) preparation  
DNase 1 treatment of RNA samples 
Total RNA was treated with DNase 1 (deoxyribonuclease 1, Amplification grade: 
Invitrogen, life technologies) prior to RT-PCR using the volumes of the reagents per 
sample as below: 
4µg of total RNA 
2µl X10 Buffer 
0.5µl of RNase inhibitor (RNase Out) 
2µl of DNase 1 
The reaction volume was made up to 20µl with DEPC treated water. The samples 
were incubated for 1hr at room temperature to digest single and double stranded 
DNA. The DNase 1 was inactivated by adding 2µl of 25mM EDTA solution to the 
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reaction mixture followed by incubation at 65oC for 15min. The samples were chilled 
on ice. 
 
First strand cDNA synthesis using SuperScriptTM11 for RT-PCR 
The following were placed in a PCR tube to reverse transcribe the GAPDH and the 
hTERT genes using gene specific primers: 
5µl of DNase treated RNA. 
1µl of reverse primer for GAPDH 3407 (100µM freshly diluted to 1:200) 
1µl of reverse primer for hTERT 13174 (100µM freshly diluted to 1:200) 
1µl of 10mM dNTP mix (10mM each of dATP, dGTP, dCTP, dTTP). 
4µl of water 
The above was incubated at 70oC for 10min in a PCR machine. The tubes were 
chilled on ice and the following was added to the tubes. 
4µl of X5 First Strand Buffer 
2µl of 0.1M DTT 
0.5µl of RNase Out 
1µl (40U) of SUPERSCRIPT II 
The final volume was made up to 20µl with DEPC treated water and the reaction 
mixture incubated at 42oC for 50min. The reaction was inactivated by heating at 
70oC for 15min. The resulting cDNA was stored at -20oC. 
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5.2.4.ii PCR amplification of GAPDH to check the quality of the cDNA 
This step was used to check the quality of the cDNA prepared. Forward and reverse 
primers for the GAPDH gene were used for this purpose. One microlitre of cDNA 
template was added to 1µl of primer mixture (8.3µM of forward primer 1457 
(5’GAAGGTGAAGGTCGGAGT 3’) and 8.3µM of reverse primer 
3407(5’GAAGATGGTGATGGGATTTC 3’)) and the final volume was made up to 
20µl with Reddymix Mastermix (ABGene). The samples were initially incubated at 
95oC for 5min followed by 30cycles of 95oC for 40sec denaturation, 55oC for 45sec 
annealing and 72oC for 45sec extension. A final extension step of 72oC for 10min 
was added. Ten microlitre product of the PCR reaction was loaded onto 2% agarose 
gel, made up in TBE buffer containing 5µl of 10mg/ml Ethidium Bromide, 10µl of 
1kb ladder was also loaded in order to estimate the size of the amplicon. The mini-
gel was allowed to run at constant voltage at 40V for approximately 90min and the 
gel visualized on Alpha Imager (Alpha Innotech Corporation). 
 
5.2.4.iii Quantification of immature endogenous hTERT and GAPDH mRNA 
levels using Real-Time PCR 
I used a quantitative RT-PCR assay developed by our collaborators (Ducrest et al., 
2001) to measure only the immature (pre-spliced) endogenous hTERT mRNA 
expression levels in the cDNA samples prepared from the hybrids. The primer pair 
that was used to amplify cDNA from immature nuclear endogenous hTERT spanned 
exon 2 and 256 nucleotides of intron 2. This immature nuclear hTERT correlated 
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with telomerase activity, indicating that hTERT RNA levels are regulated in the 
nucleus (Ducrest et al., 2001). 
 
To x1 TaqMan Mastermix (Applied Biosystems) 0.4µM of hTERT forward primer 
12896 (5’GAGCTGACGTGGAAGATGAGC 3' sequence localized at exon 2), 
0.4µM of hTERT reverse primer 13156 (5’GGTGAACCTCGTAAGTTTATGCAA 
3’ localized at intron 2) and 0.1µM of TaqMan probe was added. To 22.5µl of the 
prepared mastermix 2.5µl of the cDNA was added and placed into a well of a 
microtiter plate to give a final volume of 25µl. Each sample was assayed in triplicate. 
Thermal cycling conditions consisted of a step at 50oC for 2min, a denaturing step at 
95°C for 10min followed by 50 cycles at 95°C for 15s and 60°C for 1min (ABI 
PRISM 7900 HT Sequence Detection System). The number of hTERT copies in the 
unknown samples was determined by constructing a standard curve using dilutions of 
a plasmid of known concentration that had been converted into copy number for the 
hTERT gene. The hTERT plasmid used for this purpose was generated by cloning the 
PCR product, amplified by the primers 12896(fw) and 13174(rv) into PCR 2.1 
TOPO (by Dr Terry Roberts, BICGP). The PCR machine plots the cycle number at 
which the product is above the background (Ct) against the log of the number of 
template molecules. The efficiency of the assay is indicated by the slope of the line 
and the accuracy by linear regression coefficient of the standard curve. To determine 
the copy number of the GAPDH molecules in the samples, to 1X Sybr Green 
Mastermix (Applied Biosystems) 0.4µM of forward primer probe 1457 
(5’GAAGGTGAAGGTCGGAGT 3’ sequence localised at exon 1) and 0.4µM of 
reverse primer probe 3407 (5’GAAGATGGTGATGGGATTTC 3’ sequence 
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localised at exon 3) was added. To 22.5µl of the prepared mastermix 2.5µl of the 
cDNA was added. The thermal cycle conditions were the same as for the hTERT 
assay except the samples ran for 40 cycles. As for hTERT, the numbers of GAPDH 
copies in the unknown samples were determined by constructing a standard curve 
using dilutions of a plasmid of known concentration that had been converted into 
copy number of the GAPDH gene. The GAPDH plasmid was generated by cloning 
the PCR product, amplified by the primers 1457(fw) and 3407(rv) into PCR 2.1 
TOPO (by Dr Terry Roberts, BICGP). 
 
5.2.5 Quantitative Fluorescence In Situ Hybridization (Q-FISH) 
Q-FISH is a rapid technique used readily to measure the telomere length of 
individual chromosomes in a metaphase spread. It can also reveal any telomeric 
fusions that may have occurred. It has advantages over the traditional Southern blot 
method that only gives the average value of the terminal restriction fragments (TRF, 
which includes the telomeric and the sub-telomeric regions). 
 
5.2.5.i Slide preparation 
Freshly fed cells growing in logarithmic phase were incubated with 0.1µg/ml of 
colcemid for 2hr. The cells were trypsinized as normal and the pellet resuspended in 
approximately 200µl of the culture medium. Ten millilitres of hypotonic solution 
(75mM KCl) was added to the cells very slowly and the suspension allowed to 
incubate at room temperature for 30min. The cells were centrifuged at 1500rpm for 
5min. The supernatant was aspirated off and the pellet resuspended drop-wise in 
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15ml of freshly prepared fixative, consisting of Methanol: Acetic acid (3:1). The 
cells were incubated at room temperature for 30min and then centrifuged at 1500rpm 
for 5min. The last step of fixation was repeated 3 more times and finally the pellet 
resuspended in 1ml of fixative. Slides were rinsed in tap water and then dried with 
clean tissue prior to dropping 15µl of the cell suspension. Slides were aged overnight 
at 50oC on a heating block. 
 
5.2.5.ii Fixation of metaphase slides 
The slides were washed, whilst shaking in PBS at room temperature for 15min in a 
Coplin jar followed by fixation in 4% formaldehyde for 2min on the bench. The 
slides were then washed three times in PBS for 5min each on the shaker prior to 
incubating them in 1mg/ml of pepsin solution (50ml of water acidified with 0.5ml of 
1M HCl, pH 2.0, containing 10% pepsin solution) at 37oC for 10min. The slides were 
subsequently washed twice in PBS for 2min each on the shaker followed by fixation 
in 4% formaldehyde for 2min on the bench. The slides were washed three times in 
PBS for 5min each on the shaker before dehydrating them serially in 70%, 90% and 
100% ethanol for 5min each on the bench. Slides were left to air dry. 
 
5.2.5.iii Hybridization with the telomeric and centromeric probes 
Stock (1ml) hybridization mixture for the telomeric probe was made up of 700µl 
deionized formamide, 5µl blocking reagent (Boehringer Mannheim), 50µl MgCl2 
buffer ( 2.5M MgCl2, 9mM Na2HPO3, pH 7.0), 10µl Tris (1M, pH7.2), 152µl ddH2O 
and 83µl of PNA solution (6µl/ml FITC labelled C3TA2 peptide nucleic acid, PE 
 131 
Biosystem). The centromeric probe (ready to use) was purchased from DAKO. 
Twenty microlitres of the telomeric probe and 1µl of the centromeric probe were 
pipetted on each slide and a 22x50mm coverslip gently lowered on the mixture. The 
slides were denatured at 80oC for 3min on a heating block before placing them in a 
dark saturated chamber to incubate at room temperature for 2hr.  
 
5.2.5.iv Post-hybridization wash 
The slides were initially washed twice in 70% formamide (70ml formamide, 10ml 
2xSSC and 20ml ddH2O) in the dark for 15min to remove the coverslip and then 
three times in PBS for 5min each in the dark on the shaker. Slides were dehydrated 
by placing them sequentially into 70%, 90% and 100% ethanol for 5min each. 
Twenty microlitres of Vectashield with fluorescence DAPI mounting medium 
(Vector, Vectashield) was placed onto the slide and covered with a 22x50mm 
coverslip before sealing the edges with rubber cement.  
 
5.2.5.v Image capture 
Images of the metaphase spreads were examined on a digital fluorescence 
microscope (Zeiss Axioskop 2) with filters that detected DAPI (blue), FITC (green) 
and Cy3 (red). CCD camera (Jai) was used to capture the images and FishimagerI 
software (in situ imaging system (ISIS) Metasystems) was used to analyse the 
metaphases. The telomeric intensity is expressed relative to the centromeric signal. 
Ten metaphases were captured for each sample. 
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5.3 Results 
5.3.1 Stable transfection of PC-3 cell line with the hTERT plasmid construct 
When normal human chromosome 3 was transferred into 21NT, a breast cancer cell 
line, in our laboratory, 90% of the clones underwent replicative senescence after 
telomerase (hTERT) repression induced by the transferred chromosome. Initially the 
cells within the clones were found to proliferate normally with a slightly increased 
doubling time compared with that of the parental cell line. Subsequently, reduced 
growth rate was observed in these cells with morphological changes that are typical 
of senescence i.e. enlargement, multinucleation, vacuolation and positive 
senescence-associated (SA)-β-galactosidase staining (Cuthbert et al., 1999). 
Subsequent mapping experiments following chromosome 3 fragment transfer were 
conducted in a telomerized 21NT clone, 21NT/hTERT. Similarly, I wanted to ensure 
that I did not encounter senescence in my sets of PC-3 hybrids after MMCT of 
normal human chromosomes carrying telomerase repressor sequence. Therefore, as 
in our 21NT study, the PC-3 cell line was stably transfected with an hTERT plasmid 
construct to express the hTERT gene ectopically. We reasoned that if the transferred 
chromosome represses telomerase, then (as in the 21NT study) the clone may 
senesce. Providing telomerase ectopically would allow me to study hTERT 
transcriptional repression in the absence of senescence. 
 
Quantitative RT-PCR has become the most widely used technique for detecting and 
quantifying gene expression (mRNA) levels. It is a highly sensitive method for 
quantification of low abundance transcripts. For this reason the qRT-PCR technique 
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was used to determine the level of immature (pre-spliced) endogenous hTERT 
mRNA expression level in the transfected hybrid clones.  
 
Several critical factors that govern gene expression analysis by qRT-PCR were 
considered. DNA-free undegraded RNA and accurate assessment of the starting 
RNA is vital for accurate quantification. The reverse transcription step is known to 
cause most of the variability in RT-PCR, as the yield and quality of cDNA can be 
highly variable. Therefore, GAPDH, a housekeeping gene present in high abundance, 
was used as a reliable endogenous control of cDNA synthesis. The quantitative assay 
for hTERT mRNA expression in the hybrid clones was conducted using TaqMan RT-
PCR. TaqMan technology uses a gene-specific fluorescent probe that generates their 
fluorescence via hydrolysis of the probe by Taq polymerase’s 5’-3’ exonuclease 
activity. The hydrolysis separates fluorescein from a quenching dye and results in an 
increased fluorescein signal. GAPDH mRNA levels were determined by Sybr Green 
which is a non-sequence-specific fluorescent dsDNA binding dye. 
 
The efficiency of the GAPDH standard curve varied between 95-100% and the 
hTERT curve varied between 90-94%. The lower efficiency for the hTERT standard 
curve may possibly be due to primers not being fully optimized. It is generally 
recommended (by companies producing the primers) that the size of the amplicon 
should be between 100-150bp for qPCR reaction to be as close to 100% efficiency as 
possible and our hTERT primers produced an amplicon length of 260bp. However, it 
is also recommended that the efficiency of the qPCR reaction is at least 90% and our 
levels at 90% or higher was acceptable according to the guideline. 
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Figure 5.2: Typical images of real-time qRT-PCR amplification plots of (A) GAPDH mRNA; (B) 
hTERT mRNA. The dilutions of the GAPDH plasmid DNA used were 101-107 and the hTERT plasmid 
dilutions used were 101-106. The red line denotes the threshold level, a point at which the fluorescence 
signal from the sample exceeds the background fluorescence i.e. a point at which all samples have the 
same concentration of DNA. 
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Figure 5.3: Standard curves for (A) GAPDH; (B) hTERT constructed from the amplification plots in 
Fig 5.2. The slope of the line can be used to determine the exponential amplification which is  
10(-1/slope) and efficiency of the PCR reaction is (10(-1/slope))-1. The red diagonal lines are the unknown 
samples. 
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The 19 hybrids that were generated, following the transfection of the PC-3 cells with 
the hTERT plasmid construct, were subjected to hTERT mRNA expression analysis 
by qRT-PCR (Fig 5.4). Normalization of the samples was achieved by measuring the 
number of hTERT transcripts and expressing it relative to the number of GAPDH 
transcripts (Fig 5.4).  
 
 
Figure 5.4: The PC-3 cell line was transfected with the hTERT plasmid construct. G418 resistant 
clones were selected and cultured as separate cell lines. The immature endogenous hTERT mRNA 
expression levels were measured by real time qRT-PCR in the PC-3 clones in triplicates. 
 
I observed considerable variation in the normalized endogenous hTERT levels in the 
telomerized clones of PC-3 cells. This level of variation had been previously 
observed in 21NT, a breast cancer cell line that was also transfected with the hTERT 
plasmid construct in our laboratory (data not shown). Ducrest et al (2001) reported 
0.2 to 6 molecules of spliced hTERT RNA per cell (by using 2 sets of primer pairs 
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that amplified cDNA only from spliced hTERT RNA) in telomerase-positive cell 
lines whereas the number of hTERT RNA molecules was below the detection limit in 
telomerase-negative cells. In my study, expression of endogenous hTERT was 
completely undetectable in clones 4, 9, 10, 16 and 18 (Fig 5.4), whereas substantially 
higher levels of hTERT was observed in clones 7, 13, 15, 17 and 19 compared with 
the PC-3 cells. All the other clones expressed hTERT to at least the level seen in the 
parent PC-3 cells.  
 
Next, I selected the five G418 resistant clones (namely clones 7, 13, 15, 17 and 19) 
that expressed high levels of endogenous hTERT and subjected them to quantitative 
TRAP analysis in order to evaluate in each the expression of the transfected hTERT 
gene at the level of telomerase enzyme activity (Fig 5.5). Telomerase activity was 7 
fold higher in clone 15 compared with the parent PC-3 cells. Clones 7 and 17 
expressed a comparable level of telomerase activity to PC-3 cells whereas clone 13 
expressed reduced levels. Telomerase activity was absent in clone 19 as in GM847, a 
telomerase negative cell line used as a control. Clone 19 should have expressed some 
telomerase activity since the endogenous hTERT was 8 fold higher than the parental 
PC-3 cells (Fig 5.4). The variation in telomerase activity observed in the other clones 
may possibly reflect the differences in plasmid integration mechanisms. In stable 
transfections the plasmid becomes linear prior to inserting itself into the host 
genome. The number of copies of the transfected gene being inserted and the 
position where the plasmid opens up is random; hence these factors can govern gene 
expression leading to large variations in telomerase activity levels in different clones.  
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Figure 5.5: Expression of the transfected hTERT was assessed by measuring telomerase levels in the 
G418 resistant clones by quantitative TRAP. 
 
I selected clone 15 into which I could individually transfer normal human 
chromosomes and measure the effect of the transferred chromosomes on endogenous 
hTERT transcription, in an immortal background. The resulting hybrids would be 
prevented from undergoing replicative senescence since clone 15 ectopically 
expressed the highest level of telomerase activity after transfection with the hTERT 
plasmid construct. It also showed the second highest endogenous hTERT 
transcriptional levels. This particular clone was named PC-3/hTERT and it was 
grown in mass culture and a large stock of ampoules cryopreserved at a low passage 
number. 
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5.3.2 Quantitative Fluorescence In Situ Hybridization (Q-FISH) 
In order to investigate if there was a significant difference in the telomere lengths 
between the two types of cells, Q-FISH was performed on the wild type PC-3 cell 
line and the selected PC-3/hTERT clone (PC-3/hTERT 15). The average length of 
the telomeres in metaphase spreads of both samples were captured and measured by 
ISIS (in situ imaging system) software.  
 
Figure 5.6: Metaphase spreads prepared from PC-3 parental cell line (A) and the telomerized  
PC-3/hTERT cell line (B). Telomeres were labelled with FITC probe (green) and centromere of 
chromosome 2 was labelled with Cy3 probe (red). 
 
Ten metaphase spreads were captured and the average telomere length from each 
spread was used to determine the mean difference between PC-3 and PC-3/hTERT 
cell lines.  
 
 
 
 
 
A B A B 
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Table 5.1: The length of telomeres was measured in twenty-three pairs of 
chromosomes in each metaphase prepared from the wild-type PC-3 and the selected 
telomerized clone 15 (PC-3/hTERT) 
Number of metaphase Average telomere length 
in one metaphase of PC-
3 (Wild-type) cells (kb) 
Average telomere length 
in one metaphase of PC-
3/hTERT 15 cells (kb) 
1 4.503  7.68  
2 3.244  6.577 
3 2.915 5.414 
4 5.023 6.589 
5 5.062 8.190 
6 6.873 6.32 
7 4.389 5.99 
8 8.658 5.48  
9 8.016 9.46  
10 7.240 8.39  
Average telomere length 
calculated from 10 metaphases 
5.592 ±1.99 7.009 ± 1.35 
 
The average length of the ten metaphase spreads measured were 5.6 kb for PC-3 and 
7.01kb for PC-3/hTERT (Table 5.1). The unpaired t test showed the difference 
between the two cell lines is significant (p<0.05), and reflects the increased 
telomerase activity of the telomerized cells. 
 
5.4 Discussion 
In this part of the study, I wanted to construct a cell line that expressed high levels of 
endogenous hTERT mRNA and high total telomerase activity. So that transfer of 
normal human chromosome into such a cell line would allow me to measure, if any, 
reduction in the endogenous hTERT levels in the hybrid clones that would be 
generated, in the absence of senescence. 
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Maintenance of telomeres in most immortal cells derived from human cancers is 
achieved by endogenous expression of telomerase. In this study, the immortal PC-3 
cell line that, like most cancer cells, already expressed endogenous telomerase to 
maintain telomere length was forced to overexpress exogenous telomerase by 
transfecting the PC-3 cells with an hTERT cDNA construct and the changes in the 
telomere length was analysed by Q-FISH. The level of total telomerase measured by 
quantitative TRAP was 7 fold higher in the selected telomerized clone (PC-/hTERT) 
compared with the telomerase level observed in the parental PC-3 cell line (Fig 5.5).  
Similarly, the level of endogenous hTERT mRNA expression was approximately 10 
fold higher in the selected PC-3/hTERT clone compared with the parent PC-3 cells 
(Fig 5.4). The Q-FISH results showed that providing the catalytic subunit of 
telomerase exogenously produced significant lengthening of telomeres in the 
telomerized PC-3 cell line. I believe that this should permit the measurement of 
repressed endogenous hTERT mRNA levels in hybrids that would be generated by 
the transfer of normal human chromosomes, carrying a putative telomerase repressor 
sequence, into PC-3/hTERT in the absence of replicative senescence. 
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Repression of endogenous hTERT transcription by normal 
human chromosome 11 
 
6.1 Introduction  
Several studies have reported significant correlation between telomerase activity and 
immature hTERT mRNA expression levels in various cancerous cells, whereas other 
subunits of the telomerase were ubiquitously expressed in both normal and cancerous 
cells (Meyerson et al., 1997; Kirkpatrick et al., 2003; Snijders et al., 1998). 
Regulation of the hTERT gene at transcriptional, post-transcriptional, and 
translational levels is well documented but transcriptional deregulation of the hTERT 
gene is arguably the major mechanism activating telomerase in human cancers 
(Meyerson et al., 1997; Kilan et al., 1997). To date, the mechanism by which hTERT 
transcription is regulated in normal cells is largely unknown even though several 
general activators and repressors of hTERT transcription that act directly or indirectly 
on the 5’ promoter region have been identified by various groups (see section 1.2.9). 
 
Ducrest et al. (2001), in collaboration with our group, found a substantial number of 
hTERT RNA transcripts exclusively in the nucleus of telomerase positive cells that 
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had mainly retained intron 2. The level of this immature endogenous nuclear hTERT 
mRNA correlated with telomerase activity, indicating hTERT is regulated at the 
transcriptional level in the nucleus. The authors also demonstrated that our transfer of 
normal human chromosome 3 into 21NT (Cuthbert et al., 1999) completely abolished 
endogenous hTERT (immature nuclear hTERT RNA) even when the 21NT cells 
transfected with an hTERT cDNA plasmid construct were ectopically expressing the 
gene. In this study, I also wanted to identify a normal human chromosome that could 
down-regulate endogenous hTERT in telomerized PC-3 cells, as chromosome 3 could 
in 21NT cells by using the same methodology. 
 
6.2 Materials and Methods 
6.2.1 Transfer of normal human chromosomes into PC-3/hTERT cell line 
The MMCT method was performed as described in section 3.2.1. The only difference 
was the recipient PC-3/hTERT cell line. 
 
6.2.2 Determination of endogenous hTERT and GAPDH levels by qRT-PCR  
The synthesis of cDNA and the quantification of hTERT and GAPDH mRNA 
expression levels were measured by the methods described in sections 5.2.4.i and 
5.2.4.iii respectively. 
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6.3 Results 
The powerful method of quantitative RT-PCR allowed me to determine which 
normal human chromosome (if any) may carry a DNA sequence that regulates 
hTERT mRNA transcription. The qRT-PCR method permits reliable quantification of 
small differences in the transcript levels. Therefore, any change in endogenous 
hTERT in PC-3/hTERT hybrids containing the individually transferred normal 
human chromosome should be detectable. 
 
Chromosomes 3, 8, 10, 11, 13 and 17 were selected to be individually transferred 
into the telomerized PC-3 cell line so that the endogenous hTERT mRNA expression 
levels could be determined by qRT-PCR in the hybrids that would be generated. 
Chromosomes 8 and 13 were chosen instead of chromosomes 4 and 21, because in 
PC-3 cells I had shown earlier that chromosome 4 and chromosome 21 did not 
significantly repress telomerase activity when measured by the semi-quantitative 
TRAP assay (Figs 4.1 and 4.6). The reason for selecting chromosomes 8 and 13 was 
based on the fact that CGH studies have shown these chromosomes to be frequently 
altered in prostate cancer (Dong, 2001; Nupponen and Visakorpi, 2000). 
 
Clonal variation in the level of endogenous hTERT mRNA expression in the PC-
3/hTERT cells had to be determined first prior to measuring its level in hybrids that 
would be generated by the individual transfer of selected normal human 
chromosomes into the telomerized PC3/hTERT cell line by MMCT. I assessed the 
clonal variation by seeding the PC-3/hTERT cells at 104 per dish; the resulting clones 
were picked and assayed for endogenous hTERT mRNA level (Fig 6.1).  
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Figure 6.1: Histogram showing clonal variation in the endogenous hTERT mRNA levels observed in 
PC-3/hTERT cells. The last bar represents hTERT level in PC-3/hTERT mass cultured cells. 
 
The degree of clonal variation was evaluated from the control PC-3/hTERT clones. 
The average normalized hTERT and sd values of the 9 PC-3/hTERT clones were 
8.33 x 10-5 ± 5.5 x 10-5 and the values ranged between 2.96 x 10-5 and 1.91 x 10-4) 
(Fig 6.1). Comparison of endogenous hTERT mRNA expression levels between the 
control PC-3/hTERT clones and hybrid clones generated by the transfer of selected 
normal human chromosomes revealed chromosome 11 to be most effective in 
repressing endogenous hTERT transcription (Fig.6.2). This finding is consistent with 
my earlier results when chromosome 11 was identified as the most effective in 
repressing telomerase activity, measured by TRAP (Fig 4.4). 
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Table 6.1: A summary table showing; (i) the number of hybrid clones that expressed 
less than 50% or 10% endogenous hTERT transcript compared with the average 
hTERT expressed by the control PC-3/hTERT clones, (ii) the normalized mean and 
sd values of hTERT levels expressed by PC-3/hTERT chromosome 3, 8, 10, 11, 13 
and 17 hybrids and (iii) comparison of hTERT levels expressed by the hybrids with 
control PC-3/hTERT clones by unpaired “t” test.  
 
Hybrids Number of hybrids 
that expressed less 
than 50% of the 
average hTERT 
transcript expressed 
by PC-3/hTERT 
clones 
Number of hybrids 
that expressed less 
than 10% of the 
average hTERT 
transcript expressed 
by PC-3/hTERT 
clones 
Normalized 
hTERT levels
(mean and  
sd of clones) 
No of 
clones 
assayed 
Comparison of 
hTERT levels 
between the hybrids 
and PC-3/hTERT 
clones by unpaired 
“t” test. Column 
showing the 
p values 
PC-3/hTERT 3/9 (33.3%) 0/9 (0%) 8.33x10-5± 
5.55x10-5 
9 - 
PC-3/hTERT/chr3 6/20 (30%) 3/20 (15%) 2.13x10-4± 
4.06x10-4 
20 0.176 
PC-3/hTERT/chr8 14/30 (46.7%) 4/30 (13.3%) 1.29x10-4± 
3.15x10-4 
30 0.336 
PC-3/hTERT/chr10 2/14 (14.3%) 0/14 (0%) 5.46x10-4± 
5.91x10-4 
14 0.015 
PC-3/hTERT/chr11 18/20 (90%) 10/20 (50%) 2.31x10-5± 
4.4910-5 
20 0.0039 
PC-3/hTERT/chr13 7/15 (46.7%) 4/15 (26.7%) 6.28x10-4± 
1.17x10-3 
15 0.090 
PC-3/hTERT/chr17 4/10 (40%) 1/10 (10%) 1.41x10-4± 
1.55x10-4 
10 0.150 
 
In order to determine the level of endogenous hTERT repression by different sets of 
hybrids, I compared the hTERT expression levels of PC-3 chromosome 3, 8, 10, 11, 
13 and 17 hybrids with the control PC-3/hTERT clones. I found 90% (18/20) of 
chromosome 11 hybrids expressed lower hTERT than 50% of the average hTERT 
level expressed by PC-3/hTERT clones, i.e. the average hTERT level of 9 PC-
3/hTERT clones was 8.33 x 10-5 and 18/20 chromosome 11 clones expressed less 
than 4.16 x x10-5 hTERT transcripts (Table 6.1, column 2). Furthermore, 50% (10/20) 
of chromosome 11 hybrids expressed lower hTERT than 10% of the average PC-
3/hTERT clones. None of the other hybrids showed such strong repression of hTERT 
transcription as chromosome 11 hybrids. When the hTERT expression levels in PC-
3/hTERT chromosome 3, 8, 10, 11, 13 and 17 hybrids were compared statistically 
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with the control PC-3/hTERT clones by the unpaired t test, only chromosome 11 
hybrids showed a significant difference i.e. p=0.0039. Consistent with my earlier 
studies on telomerase activity, hybrid clones generated by the transfer of normal 
human chromosome 11 into the telomerized PC-3 cell line showed the most 
significant extent of apparent endogenous hTERT transcriptional repression 
compared with hybrid clones generated by the transfer of chromosomes 3, 8, 10, 13 
and 17 (Fig 6.2 and Table 6.1). 
 
Some clones generated by MMCT of chromosomes 3, 8, 10, 13, and 17 into PC-
3/hTERT cells expressed much higher levels of endogenous hTERT mRNA 
compared with any of the parent (PC-3/hTERT) clones. However, I did not observe 
such elevated levels of endogenous hTERT expression in any chromosome 11 PC-
3/hTERT hybrid clones (Fig 6.2), except for one clone that expressed higher hTERT. 
Similarly, TRAP analysis also revealed that some of the hybrid clones generated by 
the individual transfer of chromosome 3 (Fig 4.1), chromosome 10 (Fig 4.3) and 
chromosome 21 (Fig 4.6) into PC-3 possessed higher telomerase activity than the 
parent PC-3 cells. Currently, I cannot explain why these hybrid clones expressed 
such high levels of endogenous hTERT. There is a remote possibility that these 
chromosomes possess gene(s) that upregulate hTERT transcription. 
 
Next, transfer of chromosome 11 into PC-3/hTERT cell line was repeated 3 times to 
confirm this high level of hTERT repression. The hTERT levels in the hybrid clones 
were compared with the mean hTERT level (8.33 x 10-5 ± 5.5 x 10-5) expressed by 
the control PC-3/hTERT clones. It is shown as a red dotted line in figure 6.3.  
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A total of 52 PC-3/hTERT chromosome 11 hybrids were generated from three 
MMCT; out of which 11/52 (21%) clones had no detectable hTERT transcription. 
When the hTERT transcriptional levels of the average PC-3/hTERT clones (denoted 
as a red dotted line in Fig 6.3) were compared with PC-3/hTERT chromosome 11 
hybrids, forty six percent (24/52) of chromosome 11 clones displayed hTERT 
transcription level below 12.5% (hTERT/GAPDH value of 0.00001) of the control 
mean and in 79% (41/52) clones hTERT transcription was less than 50% of the 
control mean. Therefore the results so far strengthen my earlier hypothesis (Chapter 
4) that an hTERT repressor sequence is located on chromosome 11. 
 
6.4 Discussion 
I found hybrids generated only by the transfer of normal human chromosome 11 into 
the telomerized PC-3/hTERT cell line (that was also ectopically expressing the 
hTERT cDNA) appeared repressed with respect to endogenous hTERT mRNA 
expression levels, compared with monochromosomal hybrids constructed between 
PC-3/hTERT and chromosomes 3, 8, 10, 13, and 17. Only the difference between the 
control PC-3/hTERT clones and PC-3/hTERT chromosome 11 hybrids was 
statistically significant, p=0.0039. 
 
The advantage of measuring hTERT transcripts over telomerase activity is that the 
former is measured quantitatively using real time RT-PCR, whereas the latter is 
measured semi-quantitatively using the commercially available TRAP kit. However, 
the drawback with the hTERT transcription assay is the low number of hTERT 
transcripts in telomerase-positive cells. Ducrest et al (2001) reported less than 6 
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spliced hTERT RNA molecules per cell in telomerase-positive cells, while as 
expected these transcripts were below the detection limit in telomerase-negative 
cells. 
 
To my knowledge there has only been one published study of a direct comparison 
between telomerase activity and hTERT transcription in prostate tumour samples. 
Kamradt et al (2003) found no correlation existed between the two. Earlier, Liu et al 
(2001) showed transcriptional upregulation of hTERT expression in 94.4% of 
neoplastic cells obtained from prostate carcinoma tissue by laser capture 
microdissection which gave a purer population of cells. Kamradt et al (2003) used 
prostate cancer tissue samples that consisted of a mixture of different cell types. 
They claimed at least 70% were tumour cells. Therefore, the lack of correlation 
between telomerase activity and hTERT expression could have been due to the 
heterogeneity of the prostate tissue that they examined.  
 
In my study, I was unable to establish a direct correlation between telomerase 
activity and hTERT mRNA expression levels, because the hybrids in which the 
endogenous hTERT mRNA levels were measured were generated by the transfer of 
normal human chromosomes into an experimentally manipulated telomerized PC-3 
cell line that was ectopically expressing hTERT cDNA. However, I found the 
percentage of telomerase-repressed hybrids (constructed earlier-see Chapter 4, by the 
transfer of normal human chromosome 11 into PC-3 cells) was comparable with the 
percentage of hybrids that repressed endogenous hTERT mRNA transcripts measured 
by quantitative real time RT-PCR in hybrids generated by the transfer of 
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chromosome 11 into a telomerized PC-3 cell line. Eighty percent of PC-3 
chromosome 11 hybrids had lower telomerase activity compared with the parent PC-
3 cell line (see Table 4.1). Similarly, 85% of chromosome 11 hybrids expressed 
lower levels of endogenous hTERT mRNA transcripts compared with the average 
hTERT expression level in the parent PC-3/hTERT cell line (see Fig 6.3). 
 
The most interesting aspect of my study so far is that telomerase activity and hTERT 
expression both appear to be powerfully repressed by normal human chromosome 
11. This strongly suggests that telomerase activity is regulated at the transcriptional 
level by a gene or genes on normal human chromosome 11 and that this may be 
damaged in prostate cancer development. 
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Mapping a candidate hTERT transcriptional repressor 
sequence on human chromosome 11 using irradiation 
MMCT 
 
7.1 Introduction 
In Chapter 6, I used the standard MMCT technique to transfer individually whole 
human chromosomes into the PC-3/hTERT cell line and identified chromosome 11 
to be the most effective in down-regulating transcription of endogenous hTERT. This 
standard MMCT technique confirmed my earlier results (Chapter 4) that a gene of 
interest is present on the transferred normal copy of chromosome 11, but does not 
identify the region where the sequence is located. In order to identify the region on 
chromosome 11 carrying the hTERT repressor sequence, I employed an irradiation 
microcell-mediated chromosome transfer (XMMCT) technique. The reason for using 
XMMCT was to reduce the region of interest on chromosome 11 by randomly 
fragmenting the whole normal human chromosome prior to fusion with the recipient 
cells. In this way clones would be generated that contain smaller fragments of the 
transferred chromosome, aiding the identification of the hTERT repressor sequence. 
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7.2 Materials and Methods 
7.2.1 Irradiation Microcell Mediated Chromosome Transfer (XMMCT) 
Microcells were prepared as described in section 3.2.1 from donor cells seeded in 
24x25cm2 flasks. In order to generate radiation reduced monochromosome-11 
hybrids, these microcells were resuspended in 20ml of complete medium into a 50ml 
sterile conical flask. A small magnetic stirring-bar was placed into the cell 
suspension so that the microcells could be agitated whilst being exposed to 25 Grays 
of γ-radiation. The length of exposure was calculated from the data sheet for the 
cobalt-60 source. Thereafter, the microcells were centrifuged at 4500rpm for 5min 
and the cell pellet resuspended in 3ml of serum free Ham’s F-12 medium containing 
100µg/ml of PHA-P. The microcells were co-incubated with the recipient cells for 
25min at 37oC prior to fusion in the usual way. 
 
7.2.2 Reverse selection of the HyTk marker with ganciclovir 
Hybrids that were to be treated with ganciclovir (GCV) were cultured without 
hygromycin B for 16-24hr to allow a substantial number of cells to lose the 
chromosome carrying the HyTK selectable marker. The cells were trypsinized and 
plated out at 1x106 cells per P-100 dish and cultured in complete medium containing 
2µM GCV. Colonies were picked and cultured in complete medium without GCV. 
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7.2.3 Chromosome painting 
Chromosomes can be labelled with fluorophores in a way that permits individual 
identification. Sequences specific for a chromosome are converted into probes that 
are labelled with a fluorescent dye. Chromosomes can be detected by hybridizing 
them under FISH (Fluorescence In Situ Hybridization) conditions with chromosome 
paint probes, which results in specific labelling of that chromosome. The p- and q-
arms of a specific chromosome can be distinguished using arm-specific “paints”. 
Chromosomal translocations, breakages and other anomalies can be detected with 
this technique.  
 
7.2.3.1 Slide preparation 
In order to arrest the cells in metaphase 0.2µg/ml of colcemid was added to a plate of 
P-100 cells growing in logarithmic phase and incubated for 1hr in complete culture 
medium. Cells were trypsinized in 15ml conical tubes as normal and the supernatant 
aspirated off leaving behind 0.5ml. The pellet was flicked gently and 10ml of 75mM 
KCl (potassium chloride) pre-warmed to 37°C was added to the cells. The first 
millilitre of KCl was added very slowly onto the side of the tube whilst the content of 
the tube was being mixed. The cells were incubated at 37°C for 15min. One millilitre 
of cold fresh fixative, Methanol: Acetic acid, 3:1 was added drop-wise to the cells 
prior to spinning them at 1000rpm for 10min. The KCl was aspirated off leaving 
0.5ml in the tube. The loose pellet was flicked gently and 10ml of freshly prepared 
fixative was added drop-wise to the cells. The cells were incubated on ice for a 
minimum of 10min before spinning at 1000rpm for 10min. The fixative was pipetted 
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off and the cells washed three more times to remove all the proteins and lipids. 
Approximately 14µl of the cell suspension was dropped onto a slide that had been 
washed with deionized water. Slides were used within a couple of days; for longer 
storage (not more than 2 weeks) they were kept at -20°C.  
 
7.2.3.2 Fluorescence In Situ Hybridization (FISH) 
7.2.3.2.i Probe denaturation 
Ready prepared chromosome 11 p-arm specific paint probe directly labelled with 
FITC and q-arm specific paint probe directly labelled with TexasRed were purchased 
from XCAP-MetaSystems (Germany). Preparing hybridization mixture for a single 
slide involved pipetting 5µl each of the p-and q-arm specific probe into a sterile 
microcentrifuge tube. The probe was denatured by incubating at 75oC for 5min and 
then allowed to cool by briefly placing the tube on ice prior to incubating at 37oC for 
30min. The probe mixture was spun down briefly before hybridization. 
 
7.2.3.2.ii Denaturation of chromosome slides 
The slide to be denatured was immersed into denaturation solution (70% formamide 
in 2xSSC, pH 7.0, pre-warmed to 70oC) and incubated for 3min. The slide was 
transferred into ice cold 70% ethanol for 2min and then immersed into 90% and 
100% ethanol for 2min each. The slide was air dried prior to hybridization. It is 
crucial for the probe mixture and the slide to be denatured ready for hybridization 
within a couple of minutes of each other. The probe was carefully pipetted onto the 
slide and overlaid with a glass coverslip (22x22mm2). Rubber cement was used to 
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seal the edges of the coverslip before incubating the slide overnight in a humidified 
chamber at 37oC. 
7.2.3.2.iii Post-hybridization treatment 
The rubber cement was carefully removed and the slide placed in 1xSSC (pH 7.0-
7.5) pre-warmed to 75oC for 2min. The slide was washed twice in 2xSSC containing 
0.01% Tween20 (pH 7.0-7.5) for 1min at room temperature and then transferred into 
PBS for 2min at room temperature. Excess fluid was drained off and the slide 
allowed to air dry. Twenty microlitres of Fluorescence DAPI (Vector, Vectashield) 
was pipetted onto the slide and overlaid with a coverslip (22x22mm2). The coverslip 
was sealed with rubber cement, and the slide was examined under a fluorescence 
microscope (Axioplan 2 Imaging). 
 
7.2.4 Single copy FISH  
Metaphase slides were prepared as for chromosome paints (see section 7.2.3.1). 
7.2.4.1 Cutting the HyTK plasmid vector with restriction enzyme-Hae III 
In a 100µl reaction volume, 5µg of HyTK plasmid DNA was digested by adding 5U 
of Hae III restriction enzyme per microgram of DNA and 10µl of X10 buffer. The 
reaction mixture was incubated at 37oC for 2hr. The digested DNA was precipitated 
by adding 3M sodium acetate followed by ice cold 100% ethanol. The DNA pellet 
was resuspended in 10µl of DEPC water and the absorbance read at 260/280ηm to 
calculate the total amount of DNA recovered. 
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7.2.4.2 Labelling the digested DNA with Cy3 dUTP 
The digested and undigested plasmid DNA (250ηg DNA in 29µl volume) was mixed 
with 10µl of random 9-mer primers (Prime-ItR Fluor Fluorescence labelling kit-
Stratagene) and the mixture was incubated at 98oC for 5min in a heating block. The 
tubes were spun briefly before cooling the samples down on ice. 10µl reaction buffer 
(prepared by adding 1µl of Cy3 dUTP +11.5µl of 5X nucleotide buffer per sample) 
and 2µl (10U) of endonuclease free klenow was added to the tubes and the samples 
were mixed by pipetting. The tubes were incubated at 37oC for 20-30min. The 
reaction was stopped by adding 2µl of stop mix and the samples were stored in the 
dark at 4oC. To remove the unincorporated nucleotides by precipitation, Herring 
sperm DNA (15µg) (used as a carrier DNA to spin down with the probe as the 
concentration of the probe is too low to sediment by itself) was then added to all the 
samples. The DNA was precipitated by adding 1/10 volume of 3M sodium acetate 
followed by overnight incubation in ice cold 100% ethanol at -80oC. The samples 
were spun at 13,000rpm for 20min at 4oC. The pellet was washed with 70% ethanol, 
dried and resuspended in 10µl of hybridization buffer. The probes were stored at -
20oC in the dark and were used as soon as possible for a strong signal. 
 
7.2.4.3 Fluorescence In-Situ Hybridization (FISH) 
The DNA probes were denatured at 72oC for 5min followed by incubation at 37oC 
for 20min in the incubator. The slides were denatured in 70% formamide (4ml 
20xSSC, 8ml ddH2O, 28ml formamide) at 72oC for 2min followed by dehydration in 
70% ice cold IMS for 2min, then serially dehydrated in 80% , 90% and 100% IMS at 
room temperature for 2min each. The slides were air dried before 5µl each of the 
 159 
probe and chromosome 11 p-arm specific paint/18mmx18mm were mixed and 
applied onto each slide. The slide was incubated overnight at 37oC in a dark 
humidified chamber. The cover slip was taken off and the slide was washed with 
50% formamide (4ml 20xSSC, 16ml ddH2O, 20ml formamide) for 8min at 42oC 
followed by a wash in 2xSSC at 37oC for 5min and ST buffer (800ml ddH2O, 200ml 
20xSSC, 500µl Tween) at room temperature for at least 2min. 
 
7.3 Results 
7.3.1 Transfer of fragmented chromosome 11 by employing irradiation 
microcell-mediated chromosome transfer (XMMCT) technique 
In a similar gene transfer study using our MMCT panel, our collaborators Cosma et 
al (2003) exposed microcells to 50Grays (5krad) radiation to fragment the 
chromosomes; however, I was unable to produce any hybrid colonies at this dose. 
Experience from the breast (chromosome 3) project in our laboratory showed that 
exposure of microcells to 25Grays successfully generated colonies and this dose 
completely fragmented chromosome 3. Therefore, I used the same dose of radiation 
to fragment chromosome 11. I prepared microcells from A9HyTK 11 donor cells 
seeded in 24 x 25cm2 flasks, compared with 12 x 25cm2 flasks for whole 
chromosome transfers, to increase the number of colony formation. The colonies 
were selected in hygromycin B and the resistant clones were picked and their hTERT 
expression levels were measured. The XMMCT technique was expected to generate 
a mixture of hybrid clones that are hTERT repressed or non-repressed, depending on 
the chromosome 11 fragment that it acquires. 
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Figure 7.1: XMMCT (irradiation microcell mediated chromosome transfer). Microcells from 
A9HyTK11 donors were exposed to 25G gamma radiation prior to transfer into PC-3/hTERT cells. 
Endogenous hTERT mRNA expression levels were measured in the resulting clones. 
 
The majority of hybrid clones (14/20) expressed very low levels of endogenous 
hTERT mRNA levels compared with the parent PC-3/hTERT cell line (Fig 7.1). 
Thirteen out of twenty clones had almost completely silenced hTERT expression 
strongly indicating that the hTERT repressor sequence was still present on these 
fragments. I next embarked on chromosome painting using FISH (Fluorescence In 
Situ Hybridization) to determine whether the transferred chromosome 11 fragment 
was a discrete entity or, alternatively, had translocated onto a host chromosome or 
possibly a donor mouse chromosome during XMMCT. The FISH analysis was also 
performed to determine the number of chromosome 11 fragments that had been fused 
into each PC-3/hTERT hybrid clone. 
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7.3.2 Chromosome paints of microcell hybrids illustrating the presence of 
transferred fragment of chromosome 11. 
Metaphase spreads were prepared from the thirteen hybrid clones containing 
fragmented chromosome 11 that had strongly repressed endogenous hTERT mRNA 
expression levels. The chromosomes in the metaphase spreads were analysed by 
FISH using chromosome 11 arm-specific paints. Chromosome 11p was painted with 
FITC (green), 11q was painted with TexasRed (red) and DAPI (4', 6-diamidino-2-
phenylindole) painted all the chromosomes blue. 
 
 
Figure 7.2: PC-3/hTERT, the recipient cell line has 2 whole chromosomes 11, plus an additional copy 
of an 11q-arm translocated onto another chromosome. 
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Figure 7.3: A PC-3/hTERT cell line with the transferred fragment of chromosome 11 (PC-
/hTERT/fchr11, clone 1). The arrow is pointing at the fragment. Clone 1 was chosen randomly for 
further studies. 
 
Strongly repressed (hTERT mRNA) hybrid clones 1, 2, 3, 5, 7, 8, 9, 10, 12, 13, 16 
and 17 were found to possess a single, similar-sized fragment of chromosome 11 
(images not shown). All of these clones had a discrete fragment that possessed both 
the p- and the q-arms of chromosome 11. In fact the fragment was, in effect, a “mini-
chromosome” in all the hTERT-repressed clones that were examined. The probability 
that a discrete fragment of this kind was formed in all the 12 independently derived 
clones is low, as underscored by the fact that when microcells prepared from 
chromosome 3 were exposed to 25G gamma radiation prior to fusion into a 
telomerized breast cancer cell line (21NT/hTERT), chromosome 3 was found to be 
completely “shattered” and translocated onto other human chromosomes. Out of the 
54 clones of 21NT/hTERT containing fragmented chromosomes 3 that were 
collected, none of the clones possessed a discrete independent chromosome 3 
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fragment. This is in marked contrast to my findings in all the powerfully hTERT 
repressed PC-3/hTERT chromosome 11 hybrid clones.  
 
The similarities found between the 12 clones analysed by FISH may suggest that all 
these clones were derived from a single MMCT event. However, the possibility of 
these clones being satellites of a single colony is improbable because a P-100 dish of 
the recipient PC-3/hTERT cells that were fused with the irradiated microcells was 
split into 10 x P-100 dishes for selection with hyg B and on average only 2 to 3 
colonies per one P-100 dish were picked (see section 3.3.1). I do not have an 
explanation for the similarities observed between the clones at this stage but from the 
STS map (see Fig 8.2) it can be seen that regions of high gene densities 
(http://genecards.weizmann.ac.il/geneloc-bin/gene_densities.pl?chr=11&gc_id=GC11P065251) on 
chromosome 11 have been retained to form a mini chromosome. Since I did not 
observe any obvious differences in the fragment between the clones from the FISH 
analysis (i.e. total size of the fragment, differences in the length of p and q arms) 
clone 1 was selected randomly to be studied further. 
 
7.3.3 Reverse selection of the transferred fragment with ganciclovir 
The HyTK selectable marker on normal human chromosomes used in this study 
allowed for positive or negative selection (see section 3.1). Positive selection of 
transferred chromosome 11 in the recipient cells was carried out by culturing the 
cells in hygromycin B and negative selection was achieved by culturing the cells in 
ganciclovir (see section 3.1). Reverse selection of the HyTK marker, and hence the 
chromosome, should be accompanied by the loss of the hTERT repressed phenotype. 
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Clone 1, generated by the transfer of fragmented chromosome 11 into PC-3/hTERT 
cell line, was subjected to reverse (GCV) selection of the transferred fragment as it 
expressed very low levels of endogenous hTERT. Reverse selection of the fragment 
was achieved by culturing the cells without hygromycin B for 16hr allowing a 
proportion of the cells to lose the fragment. Thereafter, treatment of these cells with 
2µM ganciclovir permitted selection of cells that had lost the chromosome fragment. 
The clones that appeared were picked and assayed for hTERT expression. 
 
 
Figure 7.4: Reverse selection of the fragment from clone 1 of PC-3/hTERT/fragmented chr11 was 
achieved by treating clone 1 with 2µM GCV. Graph showing the generated clones assayed for 
endogenous hTERT mRNA expression levels. C-1 (green bar) untreated with GCV retains the 
fragment. 
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The majority (8/12) of the clones assayed had hTERT mRNA expression levels 
approximately equivalent to or higher than those observed in the parent PC-3/hTERT 
cell line. Two out of 12 clones remained low (Fig 7.4). The results provide 
independent confirmation that the repression of hTERT observed was due to the 
chromosome 11 fragment and its loss reverted the cells to their original endogenous 
hTERT phenotype. Loss of the fragment accomplished with ganciclovir treatment 
was confirmed by chromosome painting of metaphase spreads prepared from clone 1 
of PC-3/hTERT/fchr11 (Fig 7.5). 
 
 
Figure 7.5: Chromosome paint confirmed the loss of the fragment after GCV treatment. 
 
The loss of chromosome 11 fragment (shown by chromosome paints) with GCV 
treatment resulted in high levels of endogenous hTERT, however, a possible 
shortcoming in this part of my study is that I did not investigate the effect of GCV 
treatment on hTERT transcription in the parent PC-3/hTERT cells. 
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7.3.4 Localization of the HyTK marker on chromosome 11 fragment by single 
copy FISH 
Next, I wanted to show using direct visualization that the HyTK selectable marker 
was present on the transferred fragment. The HyTK plasmid DNA was digested with 
Hae III and labelled with Cy3 probe (red) prior to co-hybridization onto a metaphase 
spread with 11p arm specific (FITC-green) paint.  
 
 
 
Figure 7.6: The HyTK selectable marker labelled with Cy3 (painted red) can be identified on 
chromosome 11 fragment, in a metaphase spread prepared from clone 7 of PC-3/hTERT/fchr11 cells. 
The two chromosome 11p arms (normally present in PC-3/hTERT cells) are painted green (Image 
captured by Dr. Julio Masabanda, BICGP). 
 
From the above image the HyTK marker labelled with Cy3 (red) was clearly visible 
on the transferred chromosome 11 fragment. The Cy3 dye did not seem to co-
localize with the green FITC paint which is specific for chromosome 11p suggesting 
that the HyTK selectable marker is probably localized on the q arm of chromosome 
11. In our laboratory, the arm-specific paint available for chromosome 11q was 
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TexasRed and since the HyTK marker was labelled with Cy3, (both painting red), a 
decision not to paint chromosome 11q was taken in order to see the small HyTK 
signal on the fragment. 
 
7.4 Discussion 
Transfer of human sub-chromosomal fragments has been used successfully by the 
Brunel team, in collaboration, to identify several human disease genes (e.g. Zhu et 
al., 1998; Cosma et al., 2003; Coenen et al., 2004; Coelho et al., 2008). I used the 
XMMCT technique developed by Dowdy et al (1990) to investigate further and 
identify the region(s) on chromosome 11 that may be involved in hTERT regulation. 
One of the principal strengths and advantages of the MMCT technique is the capacity 
to generate segregant hybrids that have lost the DNA sequence of interest. 
Unfortunately, I was unable to isolate any spontaneous segregants in my system (all 
the hybrids collected were repressed with respect to endogenous hTERT 
transcription), possibly due to the HyTK selectable marker’s (close) proximity to the 
hTERT repressor sequence.  
 
It has been reported that exposure of microcells to gamma radiation prior to fusion 
into a recipient cell line may result in random deletions which can range from simple 
interstitial deletions to complex rearrangements. The deleted region and the size of 
the chromosomal fragments depend on the strength of the radiation dose (Hernandez 
et al., 1999). I chose to use a gamma irradiation dose of 25 Grays, which falls 
between the exposure strength of 50 Grays used by Cosma et al (2003) and 10 to 20 
Grays used by Cody et al (2007). In hindsight, a higher dose of 50 Grays should have 
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been used to obtain segregants which would have made fine mapping of the repressor 
region far easier. Due to a lower frequency of colony formation at 50 Grays, a lower 
dose of 25 Grays was selected for this study.  
 
Professor Newbold’s choice of tagging the normal human chromosome with the 
HyTK selectable marker proved extremely important to demonstrate clearly the 
presence of an hTERT transcriptional repressor sequence on a chromosome 11 
fragment. I believe I have convincingly demonstrated that reverse selection of the 
marker (hence the fragment) with GCV treatment was accompanied by elevated 
levels of endogenous hTERT expression, was comparable to that in or exceeding the 
parent cell line. This confirms the presence of the hTERT repressor sequence on 
chromosome 11 fragment. Szutorisz et al (2003) reported that only a proportion of 
GCV segregants which had lost the copy of transferred normal human chromosome 3 
into 21NT had re-expressed the hTERT gene. These authors suggested that additional 
changes were required for the re-expression of endogenous hTERT apart from the 
loss of the hTERT repressor sequence. However, I have successfully demonstrated 
the re-expression of hTERT transcription in more than 80% of my GCV-treated 
segregants, and these were confirmed to have lost the transferred fragment by FISH 
analyses. 
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Genetic and functional characterization of reduced 
chromosome 11 fragments to fine-map the hTERT repressor 
 
8.1 Introduction 
The next step in the project required the characterization of the DNA content of the 
normal human chromosome 11 fragment followed by the identification of regions 
where the hTERT transcriptional repressor may be located. Several studies have used 
polymorphic microsatellite markers to characterize the content of the transferred 
chromosome in human monochromosomal hybrids (Cuthbert et al., 1999; Cody et 
al., 2007). This procedure requires the assessment of the markers for informativeness 
by defining the allelotypes of both the donor hybrids and the recipient cells. I took a 
different approach; I characterized the fragment by transferring it from the human 
background into mouse A9 cells. The advantage of this transfer was that the resulting 
hybrids were heterospecific allowing much more effortless fine mapping of the 
fragment with STS markers and, since there are no other alleles, all STS markers 
could be used. In this study, I used a combination of MMCT, molecular and 
cytogenetic techniques to enable me to identify regions (by eliminating deleted 
regions) on the fragment that may carry the hTERT transcriptional repressor. 
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8.2 Materials and Methods 
8.2.1 Transfer of PC-3/hTERT fragmented chromosome 11 into A9 
Fragmented clone 1 of chromosome 11 (PC-3/hTERT/fchr11.1) that was selected to 
be studied further was transferred into A9 (recipient) cells by seeding Clone 1 cells at 
1.5x106 in 24x25cm2 flasks in Ham’s F-12 medium containing 20% FBS and 
100U/ml of hygB. The cells were cultured at 37°C and 6.5% CO2 in a fully 
humidified incubator for 24hr, after which 0.08µg/ml of colcemid was added to the 
cells. The cells were allowed to incubate for 48hr for micro-nucleation to occur. The 
fragment was transferred following the standard MMCT protocol and the hybrids 
were selected with 800U/ml of hyg B. The colonies that appeared were picked and 
thereafter cultured in half the dose of hyg B. 
 
8.2.2 Transfer of A9 containing fragmented chromosome 11 back into PC-
3/hTERT to confirm retention of the hTERT repressor sequence 
A9 cells containing the fragmented chromosome 11 were seeded at 1.25x106 cells 
into 48x25cm2 flasks in DMEM medium containing 20% FBS and 400U/ml of hygB. 
The cells were cultured at 37°C and 10% CO2 for 24hr prior to adding 0.05µg/ml of 
colcemid to the cultures for micro-nucleation to occur. The fragment in A9 
background was transferred back into PC-3/hTERT cells as above. Hybrids were 
gradually selected with 100U/ml of hygB for the first 3 days then the dose increased 
to 200U/ml until colonies appeared. Chromosome 11 fragments were maintained in 
the PC-3/hTERT hybrid clones with 100U/ml of hygB. 
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8.2.3 Identification of human chromosome by STS (Sequence Tagged Site) 
markers 
Human: rodent hybrids in which the transferred chromosome had to be identified 
were cultured in P-60 dishes as normal and harvested when 70 to 80% confluent. The 
culture medium was aspirated off and the cells were detached and spun at 1500rpm 
for 5min. The cellular pellets were resuspended in 1ml of PBS and transferred into a 
1.5ml microcentrifuge tubes. The pellets were washed twice in warm PBS and stored 
at -20oC until required for DNA isolation. DNA was isolated using the manufacture’s 
protocol (Promega Wizard DNA isolation kit). DNA was quantified using an 
Eppendorf BioPhotometer and diluted to 100ηg per µl in DEPC water. Polymorphic 
DNA markers were selected from the NCBI database and PCR conditions optimized 
on DNA prepared from 21NT, a breast cancer cell line. Twenty microlitre reaction 
mixtures were set up for PCR. They consisted of 1µl of 100ηg/µl of DNA, 1µl of 
10pmol of primer pair (Sigma, Dorset) and 18µl of ReddyMix (ABGene). The 
standard PCR cycle used was 94oC for 5min for initial denaturation, followed by 35 
amplification cycles of 94oC for 45 sec denaturation, 55oC for 45sec annealing and 
72oC for 45sec extension. A final extension step of 72oC for 10min was added. PCR 
amplification products were resolved on 2.0% agarose gel for approximately 1.5h at 
50V constant voltage in TBE (Tris borate EDTA) buffer. The gel was visualized on 
an Alpha Imager (Alpha Innotech Corporation). 
8.2.4 Extraction of cytoplasmic RNA 
Cells growing in log phase were harvested from 6 x P-100 dishes in 6ml of PBS. The 
cells were aliquoted into sterile 1.5ml microcentrifuge tubes and spun at 13000rpm 
for 1min. The supernatant was removed and 200µl of lysis buffer (140mM NaCl, 
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2mM MgCl, 0.5% nonidet P40 (IGEPAL; Sigma), 200mM Tris pH 8.5) was added 
on ice. The cell pellet was resuspended by pipetting and spun down immediately at 
13000rpm for 1min at 4oC. The cytoplasmic supernatant was transferred into a fresh 
microcentrifuge tube and the nuclear pellet discarded. TSE buffer, 300µl (0.5% SDS, 
5mM EDTA pH 8.0, 10mM Tris 8.5) was added to the supernatant and mixed 
thoroughly by shaking. Tris-equilibrated Phenol (500µl) was then added to the 
supernatant and mixed again before spinning at 13000rpm for 1min at 4oC. The 
phenol extraction on the aqueous phase was repeated two more times. Chloroform, 
500µl was added to the aqueous phase in fresh tubes and mixed well by vortexing. 
The tubes were spun at 13000rpm for 1min at 4oC. The aqueous phase from all the 
microcentrifuge tubes was combined in a sterile 13ml tube and 2.5 volume of ice 
cold ethanol was added. The RNA was left to precipitate overnight at -20oC. The 
sample was aliquoted into 1.5ml microcentrifuge tubes and spun at 13000rpm for 
20min at 4oC. The pellets were resuspended on ice in 10µl DEPC water and 
combined and stored at -20oC. 
8.3 Results 
8.3.1 Characterization of the transferred fragment of chromosome 11 by STS 
markers 
The next step towards identification of the hTERT repressor was to accurately map 
the gene sequence content of all the fragments in A9 hybrid clones in order to 
eliminate as much of the chromosomal gene-content as possible. For this purpose, we 
had adopted the rationale that transfer of this human fragment into a mouse 
background would enable us to use human STS (sequence tagged sites) markers of 
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high densities and hence facilitate accurate mapping. Therefore, I transferred PC-
3/hTERT/fchr11.1 (Clone 1) back into A9, a mouse fibroblast cell line, to map the 
fragment. Because the results of chromosome paints suggested the presence of both 
the p and q arms on the fragment, STS markers were selected (from the NCBI 
website) starting at the centromere region and radiating distally along both arms of 
chromosome 11. Twenty-two human: A9 hybrids were generated and STS mapped 
(initially only the first ten clones were mapped). All the hybrids were positive for the 
polymorphic marker D11S2365 except for clone 13. D11S2365 is the closest marker 
to the centromere at map position 53.5Mb. D11S2002 had a map position of 77.3 Mb 
and its sequence was absent in 5 of the 22 hybrids (Fig 8.1). 
 
D11S2365 
 
         -ve cont         A9              C-1                  C-2                 C-8  
 
 
  C-3           C-4         C-5         C-6        C-7          C-9          C-10 
 
 C-11   C-12   C-13  C-14   C-15   C-16   C-17   C-18  C-19   C-20   C-21   C-22   21NT  
 
D11S2002 
 
       C-1            C-2                C-3 C-4   C-5         C-6                C-7               C-8             C-9             C-10 
 
      C-11           C-12       C-13      C-14        C-15         C-16          C-17        C-18        C-19        C-20       C-21     C-22       21NT 
 
Figure 8.1: Structural analysis of the hTERT repressor on chromosome 11 fragments in the human: A9 
hybrids. Example of analysis with STS markers D11S2365 and D11S2002 is shown. 
 
The STS map (Fig 8.2) confirmed the presence of the heterochromatin rich 
centromere in all the hybrid clones except for Clone 13 (A9/fchr11.1.13). The STS 
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map shows the presence of telomeres on both the p and q-arms in most of the clones. 
Clone 9 (A9/fchr11.1.9) was the only clone without telomeres and Clone 13 had lost 
the telomeric region on the p-arm. Clone 5 (A9/fchr11.1.5) had some deleted loci on 
the p-arm at the telomeres. The map showed the presence of a much larger region of 
chromosome 11 on the fragment than I had anticipated from the roughly estimated 
size of the fragment from the FISH images. It suggests that complex rearrangement 
had occurred in the original Clone 1 (PC-3/hTERT/fchr 11.1) after the 25G gamma 
radiation exposure. The larger similar-sized deletions on both the p and q arms of the 
fragment in most of the twenty-two mouse: human hybrid clones were most probably 
due to the initial radiation, since they were all derived from a single clone (PC-
3/hTERT/fchr11.1). Smaller deletions in the fragment were possibly acquired by the 
MMCT of the fragment from the human PC-3/hTERT cell line into the mouse A9 
cells. The combined effects of gamma radiation exposure of the microcells followed 
by the MMCT of the resulting fragment probably resulted in broad variation in the 
marker content (and therefore gene presence) on these fragments. This was 
considered to be advantageous for narrowing down the region carrying our hTERT 
repressor sequence. 
 
The selection of STS markers from the NCBI website was random along the whole 
length of chromosome 11. However, I used expression primers to look for the 
presence of loci for specific genes of interest which have included the following 
HNRPUL, PHF21A, CREBL1, C11orf80, WT, NAT10, ZFPL1, SPDYC, KAT5, 
FOSL1, BRMS1, DRAP1, SART, KDM2A and EST1 (Fig 8.2). We were provided 
with a list of genes (as suggested by microarray data) which were differentially 
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expressed in my panel of hTERT repressed and non-repressed clones by Professor 
Colin Cooper (ICR UK) (see section 8.3.3 below). From this list, genes that had the 
potential to be involved in hTERT regulation were selected, i.e. genes involved in 
cell proliferation, senescence, differentiation, transformation etc. If the locus for the 
chosen gene was present on the human fragment in the mouse background then the 
same set of primers was used to determine its expression in my panel of hTERT 
repressed and non-repressed clones (see section 8.3.3 below) by quantitative real 
time RT-PCR.  
 
It should be emphasized that the construction of Figure 8.2 constituted a major part 
of the work in the latter part of my PhD project. Figure 8.2 is an extensive high-
density STS map of chromosome 11 fragments from irradiated hybrid Clone 1 (PC-
3/hTERT/fragmented chromosome 11.1) that was transferred into mouse A9 cells.  
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Figure 8.2: STS map of the 22 human: rodent hybrids selected from the transfer of clone 1 of PC-
3/hTERT/fchromosome11.1 into the mouse A9 cell line. D11S2365 (red) is the closest marker to the 
centromere. Filled circles indicate the presence of the locus and open circles indicate its absence. 
Expression primers were used for the following genes of interest; WT, NAT10, PHF21A, CREBL1, 
HNRPUL2, ZFPL1, SPDYC, KAT5, FOSL1, DRAP1, BRMS1, KDM2A and ETS-1. 
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8.3.2 Transfer of chromosome 11 fragment back into the PC-3/hTERT cell line 
to determine the presence of hTERT transcriptional repressor sequence 
 
The aim of individually transferring selected chromosome 11 fragments from the 
mouse A9 cells back into the human PC-3/hTERT cell line was to confirm that the 
hTERT repressor sequence on the fragment had been retained during the transfer. 
When I started fine mapping the fragment I did not expect to see such extensive 
variations between the fragments that was eventually observed in the 22 clones. I had 
initially only fine-mapped the first 10 clones (see section 8.3.1) and randomly 
selected A9/fchr11.1.8 and A9/fchr11.1.2 to be transferred first into the PC-3/hTERT 
cell line.  
 
Figure 8.3: Measurement of endogenous hTERT mRNA levels in hybrids generated from the 
individual transfer of (A) A9/chr11.1.8, (B) A9/chr11.1.2, (C) A9/chr11.1.9 and (D) A9/chr11.1.15 
fragment into PC-3/hTERT cell line. 
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Human TERT (hTERT) transcription was repressed in 10/12 A9/fchr11.1.8 clones 
(Fig 8.3; A). Four clones had no detectable hTERT expression and only clone 11 
expressed higher hTERT than the parent PC-3/hTERT cells, suggesting that the 
hTERT repressor had been retained on the fragment carried in the A9/fchr11.1.8 
clone. Compared with the A9/fchr11.1.8 results (Fig 8.3; A), I observed an even 
higher hTERT transcriptional repression in 11/12 clones that were generated by the 
transfer of A9/fchr11.1.2 into PC-3/hTERT cell line (Fig 8.3; B). Eight clones had 
completely silenced hTERT transcription, and only clone 7 had comparable hTERT 
transcription level to that of the parent PC-3/hTERT cells. Results from this transfer 
indicate that the hTERT repressor has been retained in A9/fchr11 1 2 clone. 
 
Development of the STS map revealed clone 9 (A9/fchr11.1.9) to be negative for a 
number of STS markers (Fig 8.2) and it was found to be considerably smaller than 
any of the other clones that were mapped thus far. Therefore, I decided to transfer 
A9/fchr11.1 9 next into PC-3/hTERT cell line. The hTERT expression levels were 
measured in the 13 clones that were generated. Once again, the hTERT mRNA 
expression levels observed were substantially lower in the majority (9/13) of the 
clones compared with the parent PC-3/hTERT cell line, suggesting that chromosome 
11 fragment in A9/fchr11.1.9 hybrid clone had also retained the hTERT repressor 
sequence (Fig 8.3; C). Next, I wanted to confirm the presence of human chromosome 
11 fragment in clone 9. Thus, metaphase spreads were prepared from A9/fchr11.1.9 
cells and painted with arm-specific chromosome 11 paints to show the presence of 
the human fragment in the mouse background. A single human fragment amongst the 
acrocentric mouse chromosomes was observed (Fig 8.4). 
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Figure 8.4: Image of A9/fchr11.1.9 metaphase spreads painted with arm-specific chromosome 11 
paints, showing the presence of the human chromosome fragment in the mouse A9 background. 11p is 
painted green and 11q red. 
 
A high level of hTERT repression in PC-3/hTERT/fchr11.1.9 clones (Fig 8.3; C) 
suggested that the hTERT repressor sequence may be located in the peri-centromeric 
region of normal human chromosome 11, a 5.4Mb region flanked by STS 
polymorphic markers D11S4420 and D11S2006 (Fig 8.2). In order to reduce the area 
around the centromere I selected clone 15 (A9/fchr11.1.15) to be transferred next 
into PC-3/hTERT cell line for analysis of repressive function. If positive for 
repressive activity this would reduce the region of interest by 1.3Mb as most of the 
q-arm just beneath the centromere has been deleted in this clone. 
 
The hTERT mRNA levels were measured in the 16 hybrid clones that were 
generated. Repression of hTERT transcription in 15 out of 16 clones was observed, in 
which 6 were completely silenced with respect to hTERT transcription and the rest 
expressed very low levels. Again, these results confirmed the presence of the hTERT 
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repressor sequence on this reduced fragment (Fig 8.3; D). The presence of the human 
chromosome 11 fragment in clone A9/fchr11.1.15 was confirmed by arm specific 
chromosome 11 paints (Fig 8.5). 
 
Figure 8.5: Image of the A9/fchr11.1.15 metaphase spread painted with arm-specific chromosome11 
paints, showing the presence of human chromosome 11 fragment which seems to have translocated 
onto a mouse chromosome. 
 
Further development of the STS map (Fig 8.2) revealed clone 13 to possess a deleted 
centromeric region. Therefore, I selected clone 13 to transfer next into PC-3/hTERT 
cell line because it would permit me to either include or eliminate the centromeric 
region as the location of the hTERT repressor sequence. 
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Figure 8.6: Measurement of endogenous hTERT mRNA levels in hybrids generated from the 
individual transfer of (A) A9/chr11.1.13 and (C) A9/chr11.1.4 fragment into PC-3/hTERT cell line. 
(B) Reverse selection of the fragment from clone 7 of PC-3/hTERT/fragmented chr11.1.3 was 
achieved by treating clone 7 with 2µM GCV. Graph showing the generated clones assayed for 
endogenous hTERT mRNA expression levels. Clone 7 (second last bar) with the fragment remains 
repressed. 
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Transfer of clone 13 into PC-3/hTERT cell line, as with the previously analysed 
fragments, showed high level of repression in 70% (7/10) of the clones (Fig 8.6; A).  
 
In order to confirm the presence of the hTERT repressor sequence on the fragment in 
clone 13 I randomly selected clone 7, from all the other clones that had undetectable 
level of hTERT, for reverse selection of the fragment. GCV treatment of clone 7 
resulted in 6/14 clones having higher or equal levels of hTERT compared with the 
PC-3/hTERT cell line (Fig 8.6; B). Eleven out of fourteen clones had higher hTERT 
than the untreated clone 7 and 3 clones displayed very low undetectable levels. One 
possible reason for clones 6, 10 and 14 failing to revert is that the HyTK selectable 
marker on the fragment had been lost or mutated in these clones and the hTERT 
repressor sequence had been retained. These results suggest that reverse selection of 
the fragment, hence the hTERT repressor sequence, in clone 7 with GCV treatment 
can revert the cells back to the original endogenous hTERT expression phenotype as 
in the parent PC-3/hTERT cell line. 
 
Clone 4 (A9/fchr11.1.4) was selected from the STS map to be transferred next into 
the PC-3/hTERT cell line with the intention to eliminate the p-arm of chromosome 
11 from the possibility of retaining the hTERT repressor sequence. High levels of 
hTERT repression were observed in 11 out of 13 clones (Fig 8.6; C) indicating the 
presence of an hTERT repressor sequence on A9fchr11.1.4 hybrid clone.  
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Table 8.1: Summary of the total number of clones collected from the six microcell 
transfer (MMCT) experiments of the human chromosome 11 fragment from mouse 
A9 cells into the human PC-3/hTERT cell line (in the order in which they were 
performed). 
 
From Fig 8.2 
(STS map) 
Human 
chromosome 11 
fragment clone 
Designation of 
A9 fragment 
donor cell line 
Reason for 
transfer 
Number 
of clones 
collected 
Number of 
highly 
repressed 
hTERT 
clones 
8 A9/fchr11.1.8 Random 12 10/12 (83%) 
2 A9/fchr11.1.2 Random 12 11/12 (92%) 
9 A9/fchr11.1.9 Smallest fragment. 
Both telomeres 
missing 
13 9/13 (69%) 
15 A9/fchr11.1.15 Negative between 
58.3-59.5Mbp on 
q-arm 
16 14/16 (88%) 
13 A9/fchr11.1.13 Centromere and 
the p-telomere 
missing 
10 7/10 (70%) 
4 A9/fchr11.1.4 No positive STS 
markers on the p-
arm between 10.8- 
44.3Mbp 
13 11/13 (85%) 
 
I found that individual transfer of chromosome 11 fragments produced higher 
proportion of clones that showed endogenous hTERT repression compared with the 
clones in which a whole chromosome 11 was transferred (Fig 6.2). This may be due 
to the formation of a “telescoped” chromosome (when microcells containing whole 
chromosome 11 were originally exposed to gamma radiation for XMMCT) having 
the HyTK marker closer to the hTERT repressor sequence. Thus far, in these 
experiments, I have been unable to identify a negative fragment (i.e. a fragment that 
had lost the hTERT repressor sequence). All six transfers produced clones in which 
the majority repressed endogenous hTERT levels (Table 8.1). This result would be 
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expected if the HyTK marker and the hTERT repressor sequence had by chance 
become closely juxtaposed. 
 
I used the results from individual transfers of chromosome 11 fragments from A9 
clones 2, 4, 8, 9, 13 and 15 into PC-3/hTERT cell line (i.e. that had all retained the 
hTERT transcriptional repressor sequence) to inform a more detailed analysis of the 
STS map (Fig 8.2) in order to narrow down the region of interest (i.e. hTERT 
repressor) on chromosome 11. The positive results with clone 9 eliminated the 
possibility that the hTERT repressor is located in the telomeric regions of the p and q-
arms. Transfer of clone 13 also eliminated the telomeric region of the p-arm, in 
addition to the centromeric region, and transfer of clone 4 excluded the p-arm of 
chromosome 11. From these six selected transfers I have identified 3 possible regions 
of interest on chromosome 11 where the hTERT repressor may be located. The first is 
a 0.72Mb region, map position 64.70Mb to 65.42Mb (11q13.1). The second and third 
regions are flanked by a single STS marker at 69.71Mb (11q13.3) and 127.32Mb 
(11q24.3) (Fig 8.7). 
 
Figure 8.7: Sections of the STS map highlighting the 3 possible candidate regions where the hTERT 
repressor sequence may reside. 
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8.3.3: Selection of endogenous hTERT repressed and non-repressed clones to 
construct a panel against which the genes of interest could be tested 
A number of hTERT repressed and non-repressed hybrids were selected from the 
individual transfers of human chromosome 11 fragment in mouse A9 clone 2, 8, 9, 
and 15 (A9/fchr11.1.2, A9/fchr11.1.8, A9/fchr11.1.9 and A9/fchr11.1.1) into PC-
3/hTERT cell line (Fig 8.8), to construct a panel against which the genes of interest 
could be tested. The panel consisted of eight clones that had highly repressed hTERT 
transcription and six clones that did not show repressed hTERT. 
 
 
Figure 8.8: Construction of a panel consisting of hTERT repressed and non-repressed (labelled with 
X) hybrid clones selected from MMCT of clones 2, 8, 9 and 15 from mouse A9 cells into human PC-
3/hTERT cells. 
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8.3.4: Identification of the differentially expressed genes (by microarray) in the 
minimal region of clone 13, as defined by CGH 
At this stage of the project we collaborated with Professor Colin Cooper’s team at 
the Institute of Cancer Research (ICR) UK to try to identify the hTERT repressor 
sequence on the fragment. They used the comparative genomic hybridization (CGH) 
technique to analyse the copy number on the DNA fragment in clones 2, 8, 9, 13 and 
15 and microarray technology was used in an attempt to identify genes that were 
differentially expressed in our panel of hTERT repressed and non-repressed clones in 
the regions of the fragment as determined in these five clones by CGH. 
 
I provided genomic DNA from A9 parent cells and from clones 2, 8, 9, 13 and 15 
(A9/fchr11.1.2, A9/fchr11.1.8, A9/fchr11.1.9, A9/fchr11.1.13 and A9/fchr11.1.15) 
which contained the human chromosome 11 fragment in mouse A9 background to 
Professor Cooper’s team for CGH analysis. I also provided the cytoplasmic RNA 
from the two sets of hybrid clones from the panel of hTERT repressed and non-
repressed clones and the ICR team synthesized complementary DNA (cDNA) and 
tagged each set with different colour fluorochromes, namely Cy 3 (red) and FITC 
(green). These test samples when co-hybridized to arrays spotted with either normal 
oligonucleotide or cDNA clones (representing specific genes) gave a ratio of the 
intensity of the fluorochromes. Any abnormal ratios represented a difference in RNA 
expression levels between the hTERT repressed and non-repressed clones. A list of 
up and down-regulated genes in the two sets of hybrids was generated with the 
Aglilent microarray and Affymetrix exon microarray using the minimum region on 
A9/fragmented chromosome 11.1 clone 13. (A9/fchr11.1.13). 
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The two minimum regions identified by the ICR team were both on the q-arm of 
chromosome 11. The first region was between 61037739-70771300bp and the 
second was the q telomeric region between 126851379-134340191bp (Fig 8.9).  
 
 
Figure 8.9: The two minimum candidate regions for harbouring the hTERT repressor, as defined by 
CGH by Professor Cooper’s team are highlighted in black. The three candidate regions I have 
identified by STS mapping, highlighted in red, all fall within these two regions. 
 
Noticeably, the three much smaller regions I had independently identified all fall 
within the two minimum regions identified by Prof Cooper’s team. They also 
identified six microRNAs, namely has-mi-612, has-mi-1237, has-mi-192, has-mi-
548k, has-mi-194-2 and has-mi-611 in the minimum regions. Two out of the six 
miRNAs were in my first candidate region and a third was just outside my second 
candidate region (Fig 8.9). 
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8.4 Discussion 
The MMCT transfers of carefully selected A9: human chromosome 11 XMMCT 
clones (that showed variations in DNA content in the human fragment) back into PC-
3/hTERT cells allowed three regions of interest to be identified, all on the q-arm of 
chromosome 11 (Fig 8.7). Individual transfers of clones 4, 9, and 13 from this set 
have been invaluable in identifying the long arm of chromosome 11 as carrying the 
hTERT transcriptional repressor sequence. The largest of the three regions that has 
been identified is 0.72Mb, map position 64.70Mb to 65.42Mb (11q13.1). The second 
and third regions were flanked by a single STS marker at 69.71Mb (11q13.3) and 
127.32Mb (11q24.3). The genes in these regions are listed in Fig 8.4.1. 
 
One of the three regions that have been identified as the possible location for the 
hTERT repressor sequence on the chromosome 11 fragment will contain the HyTK 
selectable marker. I have previously shown the presences of the HyTK on the q-arm 
of chromosome 11 by single copy FISH (see section 7.3.4). 
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Figure 8.10: The list of genes in the three candidate regions obtained from the NCBI website. 
 
Independent verification of our very original findings was corroborated (in 
collaboration with ICR) by Professor Colin Cooper’s team. They performed CGH 
(comparative genomic hybridization) analysis on the A9/fchr11.1.13 clone and their 
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data confirmed our STS observations that both the centromeric region and the 
telomeric region on the p-arm are deleted in Clone 13. Using this clone allowed them 
to define two minimum regions which may carry the hTERT repressor. The first 
minimal region is between 6107739-70771300bp and the second is between 
126851379-134340191bp on the q-arm of chromosome 11. Interestingly, my first 
candidate region between 64.70Mb-65.42Mb and the second region flanked by a 
single STS marker at 69.71Mb fell into Prof. Cooper’s first region and my third 
candidate region fell into their second region (see Fig 8.9). Professor Cooper’s team 
also identified six microRNAs (miRNA) within their defined regions. The miRNA-
612 (map position 64.9Mb) falls within my candidate region. Two of the miRNAs, 
namely miRNA-192 (map position 64.4Mb) and miRNA-548K (map position 
69.8Mb) fall just outside my first and second candidate regions respectively. 
 
More than 50% of miRNA genes have recently been identified in genomic regions 
associated with cancer. These non-protein coding RNAs that are approximately 20-
25 nucleotides long can inhibit gene expression at the post-transcriptional level by 
either cleaving the target mRNA or having a high degree of complementation to the 
mRNA at the 3’ untranslated end (reviewed in Zhang et al., 2007; Pasquinelli et al., 
2005). However, in my study I have been trying to identify a repressor that functions 
at the transcriptional level. Therefore, there will probably be no urgency to examine 
the expression profiles of the three miRNA in our panel of hTERT repressed and 
non-repressed clones. 
 
 
 191 
          
 
 
 
Identification of potential hTERT repressor genes from the 
minimal chromosome 11 region of interest: KAT5 as an 
attractive candidate 
 
9.1 Introduction 
In this section of the study, genes that could possibly repress hTERT expression were 
identified by two means. First, I used the NCBI website to select plausible genes 
(from the total number of genes listed in my three candidate regions) i.e. that were 
either known or predicted to be involved in regulating cell proliferation, 
differentiation, transformation etc and hence had the potential to mediate hTERT 
repression. The expression levels of these genes were measured in my panel of 
hTERT repressed and non-repressed hybrids (see Chapter 8), using the real time 
qRT-PCR relative quantification method. Second, a list of differentially expressed 
genes, as determined by microarray data, in my hTERT panel was provided by 
Professor Cooper. Those genes that showed the most significant difference between 
the repressed and non-repressed clones were selected for measurement of hTERT 
expression levels by qRT-PCR. 
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9.2 Materials and Methods 
9.2.1 Real-time qRT-PCR-relative quantification 
The real-time qRT-PCR relative quantification method was used to measure the 
expression levels of the selected genes in the panel of hTERT repressed and non-
repressed clones. This method compares the Ct value of a target gene with an internal 
housekeeping gene in a single sample. I used this method to analyse changes in gene 
expression in my panel of hTERT repressed and non-repressed clones relative to the 
parent PC-3/hTERT cell line.  
 
The Mastermix for the target gene (gene of interest) was prepared by adding an 
optimized concentration of the forward and reverse primer probes to 1xSybr Green 
(Applied Biosystems) and the Mastermix for the endogenous gene, GAPDH was 
prepared by adding 0.4M forward primer probe 1457 
(5’GAAGGTGAAGGTCGGAGT 3’ sequence localized at exon 1) and 0.4µM 
reverse primer probe 3407 (5’GAAGATGGTGATGGGATTTC 3’ sequence 
localized at exon 3) to 1XSybr Green. To 24µl of the prepared mastermix (containing 
the primers for the target gene or the endogenous GAPDH) 1.0µl of cDNA was 
added in each well of a microtiter plate in triplicate. Thermal cycling conditions 
consisted of a step at 50oC for 2min, a denaturing step at 95°C for 10min followed by 
45 cycles at 95°C for 15s and 60°C for 1min (ABI PRISM 7900 HT Sequence 
Detection System). The results were analysed by the relative quantification (∆∆ Ct) 
study assay using the SDS 2.1 software. The expression level of the target gene in the 
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hTERT repressed and non-repressed clones was plotted relative to the level measured 
in PC-3/hTERT cells (Fig 9.1). 
 
9.3 Results 
The NCBI website (http://www.ncbi.nlm.nih.gov/mapview/maps.cgi?taxid=9606&chr=11) 
listed 50, 14 and 3 genes in the first, second and third candidate regions respectively. 
A list of all the genes (and their known or predicted functions) in the three candidate 
regions is outlined in Table 9.1. 
 
Table 9.1: A list of all the genes and their functions as published on the NCBI and 
GeneCards (http://www.genecards.org/) websites. The genes in bold text have been 
tested against the hTERT panel (see section 8.8). 
First candidate region at 11q13.1; map position 64.70Mb to 65.42Mb (0.72Mb). 
 
Gene  Known or predicted function of the gene 
ZFPL1 Required for cis-Golgi integrity and efficient ER to Golgi transport. Involved in 
the maintainance of the integrity of the cis-Golgi. 
LOC100130348 Not known 
C11orf2 Required for both Golgi structure and vesicular trafficking, and ultimately lipid 
transport. 
LOC100287251 Not known 
LOC100131416 Not known 
TM7SF2 Involved in the conversion of lanosterol to cholesterol. 
ZNHIT2 Not known 
FAU This gene encodes a fusion protein consisting of the ubiquitin-like protein fubi 
at the N terminus and ribosomal protein S30 at the C terminus. It has been 
proposed that the fusion protein is post-translationally processed to generate 
free fubi and free ribosomal protein S30. Fubi is a member of the ubiquitin 
family, and ribosomal protein S30 belongs to the S30E family of ribosomal 
proteins. The function of fubi is currently unknown and ribosomal protein S30 
is a component of the 40S subunit of the cytoplasmic ribosome. 
MRPL49 Mammalian mitochondrial ribosomal proteins are encoded by nuclear genes and 
help in protein synthesis within the mitochondrion.  
LOC100287960 Not known 
SPDYC Promotes progression through the cell cycle via binding and activation of CDC2 
and CDK2. 
CAPN1 Calcium-regulated non-lysosomal thiol-protease which catalyze limited 
proteolysis of substrates involved in cytoskeletal remodelling and signal 
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transduction.  
SLC22A20 Organic anion transporter that mediates the uptake of estrone sulfate. May act 
as an odorant transporter. 
POLA2 May play an essential role at the early stage of chromosomal DNA replication 
by coupling the polymerase alpha/primase complex to the cellular replication 
machinery. 
CDC42EP2 May act downstream of CDC42 to induce actin filament assembly leading to 
cell shape changes.  
DPF2 May be a transcription factor required for the apoptosis response following 
survival factor withdrawal from myeloid cells. Might also have a role in the 
development and maturation of lymphoid cells. 
TIGD3 The exact function of this gene is not known. 
SLC25A45 SLC25A45 belongs to the SLC25 family of mitochondrial carrier proteins. 
FRMD8 Not known 
NCRNA00084 Not known 
MALAT1 Not known 
SCYL1 Regulates COPI-mediated retrograde traffic. Has no detectable kinase activity 
in vitro. Isoform 6 acts as transcriptional activator. It binds to three different 
types of GC-rich DNA binding sites (box-A, -B and -C) in the beta-polymerase 
promoter region. It also binds to the TERT promoter region. 
LTBP3 May play critical roles in controlling and directing the activity of TGFB1.  
SSSCA1 Might play a role in mitosis. Could be a centromere-associated protein. May 
induce anti-centromere antibodies. 
FAM89B Not known 
EHBP1L1 Not known 
KCNK7 Probable potassium channel subunit. No channel activity observed in vitro as 
protein remains in the endoplasmic reticulum. May need to associate with an as 
yet unknown partner in order to reach the plasma membrane.  
MAP3K11 Activates the JUN N-terminal pathway. Required for serum-stimulated cell 
proliferation and for mitogen and cytokine activation of MAPK14 (p38), 
MAPK3 (ERK) and MAPK8 (JNK1). Plays a role in mitogen-stimulated 
phosphorylation and activation of BRAF, but does not phosphorylate BRAF 
directly. Influences microtubule organization during the cell cycle. 
PCNXL3 Not known 
SIPA1 GTPase activator for the nuclear Ras-related regulatory proteins Rap1 and Rap2 
in vitro, converting it to the putatively inactive GDP-bound state.  
RELA NF-kappa-B is a pleiotropic transcription factor which is present in almost all 
cell types and is involved in many biological processes such as inflammation, 
immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-
B is a homo- or heterodimeric complex formed by the Rel-like domain-
containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and 
NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes 
and the individual dimers have distinct preferences for different kappa-B sites 
that they can bind with distinguishable affinity and specificity. Different dimer 
combinations act as transcriptional activators or repressors, respectively.  
KAT5 Catalytic subunit of the NuA4 histone acetyltransferase complex which is 
involved in transcriptional activation of select genes principally by acetylation 
of nucleosomal histones H4 and H2A. This modification may both alter 
nucleosome-DNA interactions and promote interaction of the modified histones 
with other proteins which positively regulate transcription. This complex may 
be required for the activation of transcriptional programs associated with 
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oncogene and proto-oncogene mediated growth induction, tumor suppressor 
mediated growth arrest and replicative senescence, apoptosis, and DNA repair. 
NuA4 may also play a direct role in DNA repair when recruited to sites of DNA 
damage. Directly acetylates and activates ATM. In case of HIV-1 infection, 
interaction with the viral Tat protein leads to KAT5 polyubiquitination and 
targets it to degradation. 
RNASEH2C Non catalytic subunit of RNase H2, an endonuclease that specifically degrades 
the RNA of RNA: DNA hybrids. Participates in DNA replication, possibly by 
mediating the removal of lagging-strand Okazaki fragment RNA primers during 
DNA replication. Mediates the excision of single ribonucleotides from DNA: 
RNA duplexes. 
LOC100288054 Not known 
KRT8P26 Not known 
DKFZp761E198 Not known 
OVOL1 Putative transcription factor. Involved in hair formation and spermatogenesis. 
May function in the differentiation and/or maintenance of the urogenital system. 
SNX32 Not known 
CFL1 Controls reversibly actin polymerization and depolymerization in a pH-sensitive 
manner. It is the major component of intranuclear and cytoplasmic actin rods. 
MUS81 May be required in mitosis for the processing of stalled or collapsed replication 
forks. 
EFEMP2 The protein encoded by this gene contains four EGF2 domains and six calcium-
binding EGF2 domains. This gene is necessary for elastic fiber formation and 
connective tissue development. Defects in this gene are cause of an autosomal 
recessive cutis laxa syndrome. 
CTSW May have a specific function in the mechanism or regulation of T-cell cytolytic 
activity. 
FIBP May be involved in mitogenic function of FGF1. 
CCDC85B Functions as a transcriptional repressor. May inhibit the activity of CTNNB1 in 
a TP53-dependent manner and thus regulate cell growth. May function in 
adipocyte differentiation, negatively regulating mitotic clonal expansion. 
FOSL1 The Fos gene family consists of 4 members: FOS, FOSB, FOSL1, and FOSL2. 
These genes encode leucine zipper proteins that can dimerize with proteins of 
the JUN family, thereby forming the transcription factor complex AP-1. As 
such, the FOS proteins have been implicated as regulators of cell proliferation, 
differentiation, and transformation.  
C11orf68 Not known 
DRAP1 The association of the DR1/DRAP1 heterodimer with TBP results in functional 
repression of both activated and basal transcription of class II genes. This 
interaction precludes the formation of a transcription-competent complex by 
inhibiting the association of TFIIA and/or TFIIB with TBP. Can bind to DNA 
on its own. 
TSGA10IP Not known 
SART1 May play a role in mRNA splicing. May also bind to DNA. 
 
Second candidate region flanked by a single STS marker at 69.71Mb (11q13.2) 
Gene Function 
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CCND1 Essential for the control of the cell cycle at the G1/S (start) transition. 
FLJ42258 Not known 
ORAOV1 Not known 
FGF19 May be involved in brain development during embryogenesis. 
LOC100129779 Not known 
FGF4 Can transform NIH 3T3 cells from a human stomach tumour (hst) and from 
karposi's sarcoma (KS3). It has a mitogenic activity. 
FGF3 Could be involved in ear development. 
LOC100127946 Not known 
TMEM16A Acts as a calcium-activated chloride channel. Required for normal tracheal 
development. 
FADD Apoptotic adaptor molecule that recruits caspase-8 or caspase-10 to the activated 
Fas (CD95) or TNFR-1 receptors. The resulting aggregate called the death-
inducing signalling complex (DISC) performs caspase-8 proteolytic activation. 
Active caspase-8 initiates the subsequent cascade of caspases mediating 
apoptosis. 
PPFIA1 May regulate the disassembly of focal adhesions. May localize receptor-like 
tyrosine phosphatases type 2A at specific sites on the plasma membrane, 
possibly regulating their interaction with the extracellular environment and their 
association with substrates. 
CTN May contribute to the organization of cell structure. The SH3 motif may 
function as a binding region to cytoskeleton. Tyrosine phosphorylation in 
transformed cells may contribute to cellular growth regulation and 
transformation. 
SHANK2 May play a role in the structural and functional organization of the dendritic 
spine and synaptic junction. 
C11orf76 Not known 
 
Third candidate region flanked by a single STS marker at 127.32Mb (11q24.2-3) 
Gene Function 
LOC100132514 Not known  
LOC387820 Not known 
ETS1 ETS transcriptions factors, such as ETS1, regulate numerous genes and are 
involved in stem cell development, cell senescence and death, and 
tumorigenesis. The conserved ETS domain within these proteins is a winged 
helix-turn-helix DNA-binding domain that recognizes the core consensus DNA 
sequence GGAA/T of target genes (Dwyer et al., 2007 ). Transcription factor. 
 
Next, the expression levels of the above genes needed to be analysed. In the first 
phase of the investigation, genes that could potentially repress hTERT transcription 
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were selected to be tested against the panel of hTERT repressed and non-repressed 
clones (see section 8.3.3). 
 
I am currently confirming the validity of some of the candidate genes selected from 
the microarray data. A number of genes that may possibly be involved in 
transcriptional repression of hTERT were tested first against this panel but to date I 
have been unable to identify a gene that was differentially expressed between the 
hTERT repressed and non-repressed hybrid clones by the real time qRT-PCR 
method. The genes that have been tested so far include HNRPUL, CREB3L1, 
PHF21A, C11orf80, ETS1, WT1, SUV420H1 (variant 1 and 2), ZFPL1, FOSL1, 
DRAP1 and SART. An example of the expression level of PHF21A in my hTERT 
repressed and non-repressed clones is given in Fig 9.1. 
 
Figure 9.1: Real-time qRT-PCR relative quantification of PHF21A gene in hTERT repressed (black) 
and non-repressed (red) hybrid clones. 
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9.4 Discussion 
9.4.1 Potential candidate genes for repressing hTERT transcription 
The candidate regions that have been identified on chromosome 11 as possibly 
carrying the hTERT transcriptional repressor sequence excluded the MEN1 gene 
(located at 11q13 map position 64.34Mb). MEN1 encodes menin, a protein that acts 
as a tumour suppressor in endocrine neoplasia. Menin is thought to suppress hTERT 
by possibly mediating its effects through interaction with JunD and/or NF-ĸB at the 
hTERT promoter region (Lin and Elledge, 2003). Recently, it has been shown that 
over-expression of menin decreases hTERT transcription in a cell type specific 
manner (Hashimoto et al., 2008). Therefore, it may be possible that menin does not 
have any repressive effects on hTERT transcription in MMCT experiments with 
prostate cancer cells. The locus for the MEN1 gene was absent in all the 22 clones 
(see Fig 8.2). So menin can be confidently eliminated as the repressor involved in 
PC-3/hTERT repression. 
 
ETS1 was another gene (located at 11q23.3, map position 127.88Mb) just outside the 
third candidate region that had the potential for repressing hTERT transcription. The 
ETS1 protein belongs to a family of transcription factors involved in cellular 
proliferation, senescence, apoptosis, and tumorigenesis. Interestingly, recent studies 
have shown that the ETS1 protein inhibits telomerase activity by binding directly to 
the hTERT promoter region in K562 cells, a human myeloid erythroleukemia cell 
line (Dwyer J et al., 2007). I had initially eliminated EST1 as a possible candidate for 
repressing hTERT transcription because its locus was missing from clone 9 (see Fig 
8.2). However, because of its reported involvement in hTERT repression I tested the 
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expression levels of EST1 in my panel of hTERT repressed and non-repressed clones 
(see section 8.8) and found no difference in the two sets of samples (data not shown). 
 
9.4.2 Search for putative tumour suppressor gene(s) in my candidate regions 
from the literature 
Loss of heterozygosity (LOH) studies has played an essential role in identifying 
putative tumour suppressor genes on chromosomal regions from where genetic 
material has been lost in a non-random fashion from cancer tissues. LOH is a very 
common event in epithelial cancers. A literature survey for LOH on chromosome 11 
revealed that both arms are implicated in prostate carcinoma. Dahiya et al (1997) 
compared LOH on chromosome 11 in microdissected samples from normal prostate 
epithelium with invasive carcinoma from the same patients. They reported four 
deleted regions at 11p15, 11p12, 11q22, and 11q23-24. LOH was observed in 25% 
and 39% of tumours at 11p15 and 11p12 respectively. The percentage of tumours 
with LOH at 11q22 and 11q23-24 was higher at 66% and 47% respectively. 
 
 
Figure 9.2: Part of my STS map showing the two deleted regions of the q-arm of chromosome 11 in 
human prostate cancer as defined by Dahiya et al (1997). 
 
 200 
I also used the two STS markers, D11S898 and D11S940 at 11q22, used by Dahiya 
et al (1997). I found both markers to be negative for all of the 22 A9 clones (hybrids 
containing human chromosome 11 fragment in mouse A9 background, see Fig 8.2). 
Therefore, I eliminated this region as potentially possessing the hTERT repressor 
sequence (Fig 9.2). D11S1818 (map position 108.78Mb) was another marker used by 
Dahiya et al (1997), but unfortunately I have a gap in STS markers between 
105.06Mb to 111.97Mb. So, it is possible that I may have missed the region around 
108Mb. However, Prof. Cooper’s team did not identify the 11q22 region as a 
potential location for the hTERT repressor (their second minimum region was 
between 126.8Mb-134.3Mb). Therefore I can conclude with some degree of 
confidence that 11q22 is not the region of interest. 
 
Dahiya et al (1997) used three STS markers at 11q23-24, namely D11S924, 
D11S1336, and D11S912. Map positions for these markers are 119.4Mb, 122.6Mb, 
and 128.6Mb respectively. D11S912 is the only marker that falls in Prof. Cooper’s 
second minimum region (Fig 8.9) and it is just outside my third candidate region. 
Therefore, the possibility that our gene of interest may be located at 11q23-24 is 
slim. 
 
Dumur et al (2003) performed a genome-wide search for LOH in prostate cancer 
using human SNP microarray technology. They studied a cellular model which 
consisted of a prostate cell line and its tumourigenic sub-line and they also analysed 
prostate cancer patients. Their results from the cellular model showed LOH between 
11q21.1-11q24.2 in the prostate tumourigenic sub-line. Other deletions were on 
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chromosomes 3p12-p22.1, 19p13.12, and 19q13.42. The authors observed LOH at 
11q23.3 in 33% of the prostate cancer patients. Interestingly, once again the region 
between 11q21.1-11q24.2 falls in the region defined by both Prof. Cooper’s team (by 
using array CGH) and mine (by using STS mapping). The 11q23.3 locus, deleted in 
33% of prostate cancer patients is the location of the ETS1 gene which has already 
been eliminated (see above). 
 
Admittedly, there are gaps in my STS markers in the region between 11q21-11q24.2. 
However, if more STS markers could be tested for the presences of sequence in these 
gaps then perhaps clone 9 could prove to be even more invaluable than it has already 
been in further narrowing the region on 11qter, as it possesses the smallest 
chromosome 11 fragment.  
 
9.4.3 hTERT repressor - a possible chromatin remodelling factor 
Several groups have investigated the nuclease-sensitive sites in the region of the 
hTERT gene in order to identify the mechanisms that regulate hTERT expression in 
normal and cancerous cells. Szutorisz et al (2003), in close collaboration with our 
group, reported chromosome 3 to transcriptionally repress hTERT by remodelling the 
chromatin structure of the hTERT gene at intron 2 in a breast cancer cell line into a 
more “closed” conformation. Reverse selection of transferred chromosome 3 with 
GCV treatment resulted in reverting to an open chromatin structure. In another 
report, Wang and Zhu (2003) identified a DNase I hypersensitive site near the 
hTERT transcription initiation site in telomerase positive cells. The authors also 
demonstrated that the treatment of telomerase negative cells with histone deacetylase 
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inhibitor trichostatin A (TSA) induced hTERT transcription and increased chromatin 
sensitivity to DNase I treatment. The authors concluded that the endogenous 
chromatin environment plays a vital role in the regulation of hTERT expression 
during cellular immortalization. Therefore, gene(s) that may be involved in 
epigenetic regulation through altering the chromatin structure would make excellent 
candidates in my study. 
 
9.4.4 The KAT5 gene, a credible candidate? 
There are three histone modifying genes listed in Professor Cooper’s first region 
between 61.08Mb-65.42Mb. These are KAT5, a histone acetyltransferase (HAT), 
BRMS1, a histone deacetylase (HDAC) and KDM2A, a histone demethylase (see Fig 
8.9). However, I eliminated the BRMS1 and KDM2A genes on the basis that both loci 
were deleted in clone 9. Clone 9 has been extremely useful in narrowing the regions 
of interest as it is the smallest fragment at approximately 16 Mb (Fig 8.2). Therefore, 
from my data the most likely candidate gene in the three defined regions is KAT5. 
 
It is well established that HDACs function as repressors of gene expression by 
removing the negatively charged acetyl groups from the histone NH2 terminal 
domains resulting in a tighter chromatin structure. This type of chromatin 
remodelling makes it difficult for the gene to be transcribed (reviewed by Zhang and 
Dent, 2005). Therefore, a simple scenario in my study would be that the hTERT 
repressor sequence encodes a HDAC that could catalyse the deacetylation of histones 
on the hTERT regulatory sequence leading to hTERT repression. The BRMS1 gene 
(encodes a HDAC) exists in very close proximity to my first candidate region, at a 
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distance of 0.44Mb away, but the BRMS1 gene has already been eliminated as a 
possible hTERT repressor. The KAT5 (K(lysine) acetyltransferase 5), encoding a 
HAT is the only chromatin remodelling gene in my three candidate regions. HATs 
generally function as activators of gene expression. Acetylation by HATs neutralizes 
the positive charge on the lysine residues resulting in an open chromatin structure 
that allows transcription factors to gain access to the regulatory sequence (reviewed 
by Zhang and Dent, 2005). 
 
Several HATs have been identified since their first discovery in the mid-nineties in 
Tetrahymena. The A-type nuclear HATs are divided into four families based on their 
conserved sequence within the HAT domain. The KAT5 gene encodes an A-type 
nuclear HAT that belongs to the MYST family of protein (reviewed in Marmorstein 
and Trievel, 2009). In humans, the MYST family consists of five proteins, namely 
TIP60, MOF, HBO1, MOZ and MORF, all of which contain a highly conserved 
MYST domain that is composed of an acetyl-CoA binding motif and a zinc finger 
(reviewed by Avvakumov and Cote, 2007; Yang, 2004). These members of the 
MYST family also contain various other structural subunits. Consequently, 
considerable diversity exists within this group of HATs (Yang, 2004). 
 
A great deal of variation exists not only in the structural organisation of MYST 
proteins but also in their biological function. MYST proteins are involved in a 
number of nuclear processes such as DNA repair and apoptosis and they are also 
associated with cancer (reviewed by Avvakumov and Cote, 2007). There is evidence 
to suggest that the MYST family of HATs function as coregulators of transcription 
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i.e. TIP60 can act as transcriptional corepressor for TEL and STAT3 and coactivator 
for androgen receptor and c-Myc (reviewed by Yang, 2004). From these published 
reports of structural and functional complexities in the MYST proteins, it is possible 
that the HAT protein encoded by the KAT5 gene may function as a repressor when 
recruited to the hTERT promoter region to regulate transcription. 
 
The credibility of the KAT5 gene being an hTERT repressor comes from the breast 
cancer project that ran in parallel to my prostate study in our laboratory (Cuthbert et 
al., 1999). Chromosome 3 was identified as possessing an hTERT repressor sequence 
when transferred into a telomerized breast cancer cell line, 21NT/hTERT (Ducrest et 
al., 2001). A candidate region, flanked by a single STS marker D3S4066 (map 
position 47.14Mb) on the p-arm of chromosome 3, was identified as the possible 
location for the hTERT repressor sequence. Seven genes were listed in this region 
and on examination SETD2 (SET domain containing protein 2) was the most likely 
candidate based on the biological function of these genes. Sarakbi et al, (2009), in 
collaboration with our group recently reported significantly lower levels of SETD2 
expression in breast carcinoma. Furthermore, the SETD2 transcripts decreased with 
increasing tumour stage. Recently, using copy number analysis, we have 
demonstrated allele loss of SETD2 in breast cancer cell lines, including intragenic 
microdeletions (Roberts et al., in preparation). 
 
The SETD2 gene encodes a histone methyltransferase that specifically methylates 
lysine-36 of histone H3, and methylation of this residue is associated with active 
chromatin (reviewed in Zhang and Dent, 2005). Precisely how SETD2 is involved in 
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regulating gene transcription is not known but recently Xie et al (2008) reported that 
the interaction of SETD2 with p53 could regulate the activity of p53 as a 
transcription factor. The authors demonstrated that overexpression of SETD2 
upregulated the transcript of p53. Alternatively, knock down of endogenous SETD2 
expression with RNA interference resulted in opposite effects. Therefore, their 
findings suggest that the interaction of SETD2 with p53 could selectively regulate its 
downstream effector genes. 
 
The fact that both KAT5 and SETD2 genes are identified as potential hTERT 
transcriptional repressors in prostate and breast cancer cell lines respectively is 
highly interesting, as they are both histone modifying enzymes that transcriptionally 
regulate gene expression. Even though the exact mechanism of how the products of 
these genes regulate transcription is unknown, it has been proposed irrespectively 
that they both interact with p53 to regulate downstream effector genes (Sykes et al, 
2006; Xie et al., 2008). 
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General discussion 
Lack of telomerase activity as a result of hTERT transcriptional repression in normal 
human cells suggests the existence of telomerase repressor genes that tightly regulate 
its activity. Conversely, elevated and dysregulated telomerase activity in cancerous 
and immortal cells indicates that there are defects in telomerase regulation, possibly 
resulting from the inactivation of hTERT transcriptional repressors. The hTERT 
transcriptional regulation is highly complex and still largely uncharacterized. Hence, 
identification of hTERT repressor(s) would be an essential step in understanding how 
telomerase is regulated in normal and cancerous cells. In the work described in this 
thesis, I have tried to locate an hTERT transcriptional repressor sequence that 
regulates telomerase activity in prostate cancer through genetic complementation 
studies. 
 
Using the MMCT technique, genes located on different chromosomes have been 
implicated in repressing telomerase activity in tumour cells originating from a range 
of human tissues. Thus far, there are no reports of a gene that may be involved in 
repressing telomerase activity in prostate cancer cells. Furthermore, the literature 
survey performed at the start of this study provided no indication which, if any, 
chromosome may possibly carry a prostate cancer telomerase repressor gene (or 
genes). Therefore, I generated hybrids to screen the whole genome for repressive 
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function via the individual transfer (by MMCT) of normal human chromosomes into 
PC-3, a prostate cancer cell line. As a result of this work, the data generated has 
convincingly shown that chromosome 11 harbours a telomerase repressor sequence.  
 
Previous reports demonstrated telomerase repression by MMCT of normal human 
chromosome 3 into breast, renal and cervical cancer cell lines (Cuthbert et al., 1999; 
Horikawa et al., 1998; Backsch et al., 2001 respectively). However, chromosome 3 
had no repressive effect in the present study when it was transferred into PC-3 cell 
line. MMCT of chromosome 10 and chromosome 4 into PC-3 cells were also 
comparatively ineffective in repressing telomerase even though chromosome 10 was 
reported to have repressed telomerase activity in a hepatocellular carcinoma 
(Nishimoto et al., 2001) and chromosome 4 in a cervical carcinoma cell line 
(Backsch et al., 2001). These findings support the theory that not all the tumours 
have the same defective gene that regulates telomerase activity (Oshimura and 
Barret., 1997) and that telomerase repressors may be subject to inactivation in a 
tissue specific manner (Tanaka et al., 2005). 
 
A more forward approach towards identifying telomerase repressor gene(s) located 
on a normal human chromosome is to measure hTERT, the catalytic subunit of 
telomerase. In order to identify repressor sequences that mediate hTERT 
transcription, I adopted the method reported by our close collaborators Ducrest et al 
(2001). They had previously shown a substantial number of hTERT RNA transcripts 
that had mainly retained intron 2, were present exclusively in telomerase positive 
cells and the level of this immature nuclear hTERT correlated with telomerase 
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activity. Furthermore, transfer of normal human chromosome 3 into 21NT, a breast 
cancer cell line completely abolished the expression of immature endogenous hTERT 
in cells that were ectopically expressing the hTERT gene. In my study, I have shown 
hybrid clones generated by the individual transfer of normal human chromosomes 3, 
8, 10, 13 and 17 into PC-3 cells transfected with an hTERT cDNA plasmid construct 
did not effectively repress immature endogenous hTERT, in marked contrast to 
hybrid clones constructed by the transfer of human chromosome 11 into PC-3 cells 
that were ectopically expressing hTERT. These results further substantiate the 
involvement of genes located on chromosome 11 in telomerase repression. 
 
To further localize the telomerase repressor region on chromosome 11, I employed 
the XMMCT technique to randomly fragment whole chromosome 11 prior to fusion 
into the recipient cells (Dowdy et al., 1990). The advantage of this technique is that it 
can generate a variety of hybrids in which the irradiated transferred chromosome can 
range from simple interstitial deletions to complex rearrangements resulting in a 
mixture of repressed and segregant hybrids and therefore I thought it would prove to 
be highly useful in fine mapping the region of interest. Perhaps an even more 
effective method of isolating the telomerase repressor region may have been a 
technique where the donor chromosome is truncated prior to transfer into the 
recipient cell line, as specific regions on the target chromosome can be removed 
using homologous DNA sequence (Abe et al., 2010). However, this technique 
requires previous knowledge of the regions that can be truncated on the target 
chromosome and since the hTERT repressor in my study could be located anywhere 
along chromosome 11, I could not utilize this technique. 
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Use of arm-specific chromosome paints identified the transferred chromosome 11 
fragment as an independent entity in the highly repressed hTERT hybrids. To show 
that the hTERT repressive effect was due to the transferred chromosome 11 fragment, 
I made use of the HyTK selectable marker on the fragment. Reverse selection of the 
HyTK marker hence the transferred fragment from a randomly selected hTERT 
repressed hybrid was achieved by treating the cells with ganciclovir (GCV). I have 
convincingly demonstrated that the loss of the fragment from hybrids, shown by 
chromosome painting, was accompanied by elevated levels of endogenous hTERT 
expression comparable or exceeding those in the parent PC-3/hTERT cells, this 
confirmed the presence of an hTERT repressor sequence on the fragment. 
 
Using a novel approach in an effort to locate the hTERT repressor, I generated 
heterospecific hybrids by transferring an hTERT repressed fragment from human PC-
3/hTERT cells back into mouse A9 to allow fine mapping of the fragment with STS 
markers. From my STS map, I made use of the DNA variations observed in the 
resulting human: mouse A9 monochromosomal hybrids by performing another round 
of MMCT of carefully selected clones (fragments) back into PC-3/hTERT cells. 
DNA sequence, common to the fragments that repressed hTERT transcription led to 
the identification of three small regions on the q-arm of chromosome 11 as the 
location of hTERT repressor sequence. The fact that all the fragments tested for 
hTERT repression were positive was a disappointment. The only plausible 
explanation for this is that the hTERT repressor sequence by chance lies in very close 
proximity to the HyTK selectable marker. 
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In my study, the genes of interest on 11q include the MEN1 and EST genes located at 
11q13 and 11q23.3 respectively, both implicated in hTERT transcriptional repression 
(Lin and Elledge, 2003; Dwyer et al., 2007), were eliminated because they fall out of 
my three candidate regions. Dahiya et al (1997) reported four deleted regions on 
chromosome 11 in microdisected prostate carcinoma tissue. However, it is unlikely 
that any of the four regions are of interest as two of the deletions are on 11p and the 
other two are at 11q22 and 11q23-24, both of which also fall outside my candidate 
regions. There are no known tumour suppressor genes in my candidate regions; 
therefore possible candidate genes, based on their known or predicted functions as 
published on the NCBI website, were tested for differential expression in a panel that 
consisted of a mixture of hybrids that had repressed and non-repressed hTERT 
transcription. Thus far, I have been unable to identify a gene from my list of 
candidates that is expressed in the repressed but not in the non-repressed hybrids, in 
my panel. 
 
Studies have shown that remodelling the chromatin structure at either the hTERT 
gene or its promoter may play an important role in its regulation (Szutorisz et al., 
2003; Wang and Zhu, 2003). Concurrent work on the breast project in our laboratory 
has identified SETD2, a histone methyltransferase located on chromosome 3p as a 
strong candidate hTERT transcriptional repressor. Similarly, KAT5, a histone 
acetyltransferase in my first candidate region could therefore be a plausible candidate 
for repressing hTERT expression in a prostate cancer cell line. 
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In our laboratory, recent work performed on the breast cancer cell lines 21NT and its 
telomerized sub-line, 21NT/hTERT, transfected with SETD2 plasmid construct, has 
shown an inverse relationship between SETD2 and endogenous hTERT expression 
levels i.e. results have shown that hybrids that expressed high levels of SETD2 
expressed low endogenous hTERT levels (Roberts et al., in preparation). Further 
functional analyses are required to confirm the validity of SETD2 involvement in 
hTERT repression. However, preliminary data from the breast project makes KAT5 a 
very credible candidate in my study since the probability of locating histone 
modifying genes in relatively small regions of both chromosomes 11 and 3 in two 
completely separate mapping exercises in different cell lines would be remote. 
Identifying the hTERT repressor sequence in either case may provide important clues 
to the mechanism that regulates telomerase activity through transcriptional repression 
of hTERT. 
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Summary and conclusion 
I have performed a novel and an in depth study in an effort to identify and locate a 
telomerase repressor sequence involved in prostate cancer by using genetic 
complementation. Firstly, I identified chromosome 11 as possessing a telomerase 
repressor sequence by carrying out TRAP analysis on hybrids generated by the 
individual microcell transfers of normal human chromosomes into PC-3 cells. 
Secondly, I identified chromosome 11 as possessing an hTERT transcriptional 
repressor sequence, using the real-time qRT-PCR method, in hybrids generated by 
the transfer of normal human chromosomes into a PC-3 cell line that was ectopically 
expressing hTERT cDNA. 
 
I have successfully narrowed down the region of interest on chromosome 11 by 
employing the XMMCT technique. I have convincingly demonstrated that reverse 
selection of chromosome 11 fragment with GCV treatment of a randomly selected 
gamma irradiated hybrid, that expressed very low levels of immature endogenous 
hTERT, generated clones in which the hTERT mRNA levels were comparable to (or 
higher than) those observed in the parent cell line. The loss of the fragment, resulting 
in elevated levels of hTERT transcription, strongly suggested the presence of the 
repressor sequence on the fragment.  
 
The use of molecular and cytogenetic studies has positively identified three small 
regions on the q-arm of chromosome 11 as being strong candidates where the hTERT 
transcriptional repressor may be located. Our collaborators at ICR, Professor Colin 
Cooper’s team, also independently identified two regions on the q-arm of 
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chromosome 11 as possessing the hTERT repressor sequence by using CGH analysis 
and microarray technology on my samples. Therefore, from this study I can conclude 
that the location of the hTERT repressor sequence involved in prostate cancer is on 
the q-arm of chromosome 11. 
 
The NCBI website listed 50, 14 and 3 genes in my first, second and third candidate 
regions respectively. The most plausible candidate gene that I have identified, in my 
first region, is KAT5, a histone modifier. It’s credibility as a potential hTERT 
transcriptional repressor is based on the recent identification of SETD2, (another 
histone modifying gene) as a probable repressor of hTERT transcription in breast 
cancer cell lines in our laboratory. 
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Future work 
KAT5, a histone modifying gene- a candidate hTERT repressor 
I have identified KAT5, a histone modifying gene belonging to the MYST family of 
HATs, as a plausible candidate for repressing hTERT transcription. If continuing the 
project, I would measure the expression levels of KAT5 in my panel of hTERT 
repressed and non-repressed hybrid clones. If I observed differential expression of 
KAT5 in the two sets of hybrids then the next step would be to examine the function 
of KAT5 by cloning it into an appropriate expression vector and transfecting the gene 
into the PC-3/hTERT cell line. The expression levels of KAT5 and endogenous 
hTERT would be measured by real-time qRT-PCR in the resulting hybrid clones. If a 
significant number of clones expressed high levels of KAT5 and low levels of hTERT 
then KAT5 could be investigated further for its involvement in hTERT repression. 
Further confirmation of KAT5’s involvement would be verified by knocking down its 
expression by using small interfering RNAs (siRNAs) that specifically target the 
mRNA transcript. Finally, expression and the structural integrity of the gene would 
then be investigated in prostate carcinoma tissue and cell lines. 
 
If KAT5 is not an hTERT repressor 
In the event of not observing repression of hTERT in the KAT5 transfected clones, 
several different approaches could be employed to identify the hTERT repressor 
sequence. By using the NCBI database I could further investigate the genes in the 
three candidate regions that I identified (Table 9.1). There are over 50 genes in the 
first candidate region. Genes that may possibly be involved in telomerase regulation 
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i.e. cell cycle regulators; senescence and apoptosis etc would be investigated in the 
first phase of the study. If a selected gene is present on the human chromosome 11 
fragment then the expression profile of that gene would be investigated in my panel 
of hTERT repressed and non-repressed clones. 
 
Transfer of a fragment from an hTERT non-repressed clone back into A9 
Another approach that could be adopted in locating the hTERT repressor sequence on 
the fragment would be to transfer the chromosome 11 fragment from one of the non-
repressed hTERT clones in the human PC-3/hTERT cells back into A9 cells for fine 
structure mapping. Prior to transfer, I would need to know if the fragment exists as a 
discrete entity or if it had translocated onto another human chromosome. Transfer of 
a discrete fragment into A9 would favour fine mapping of the resulting clones with 
STS markers. Loss of markers (loci) in the clones compared with the original parent 
clone would together further pinpoint the probable location of the hTERT repressor. 
As a start, I have already used chromosome painting (FISH) to analyse all the non-
repressed hybrids and selected a panel clones from which the fragment can be 
transferred into A9 cells. 
 
Single-nucleotide polymorphism (SNP) genotyping 
A recently developed technique called single-nucleotide polymorphism (SNP) is 
increasingly being used for identifying gene(s) associated with a variety of diseases. 
This technique makes use of the fact that SNPs are the most common form of 
sequence variation, approximately occurring in one base pair in a thousand when 
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alleles from two chromosomes are compared. SNPs are stable genetic markers and 
over a million SNPs are available for genotype studies in humans. It would be 
possible to use this technique to look for SNPs in our hTERT repressed and non-
repressed clones. I would initially be interested in analysing only the long arm of 
chromosome 11 for SNP in the regions independently defined by us and Professor 
Cooper’s team as the region where the hTERT repressor may be located. A number 
of SNP markers spanning the regions on the q-arm of chromosome 11 would be 
selected and any differences in the marker content between the two sets of samples 
may again further refine localization of the hTERT repressor sequence. 
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Appendix 
 
The MMCTs performed in this study and the nomenclature used for the 
generated hybrid clones 
Hybrids generated from the transfer of normal human chromosome 11 in telomerized 
PC-3 (PC-3/hTERT) cells were symbolized as PC-3/hTERTchr11, followed by the 
clone number, i.e. PC-3/hTERT/chr11.1, PC-3/hTERT/chr11.2 etc. 
 
 
 
Hybrids generated by the transfer of fragmented (by exposing microcells containing 
whole chromosome 11 to 25G gamma radiation) chromosome 11 prior to fusion in 
PC-3/hTERT cells were symbolized as PC-3/hTERT/fchr11, followed by the clone 
number, i.e. PC-3/hTERT/fchr11.1, PC-3/hTERT/fchr11.2 etc. 
 
 
 
Clone 1 from PC-3/hTERT/fchr11 (PC-3/hTERT/fchr11.1) hybrid was selected 
randomly to be treated with GCV. 
 
 
 
Reverse selection of the fragment from PC-3/hTERT/fchr11.1 confirmed the 
presence of an hTERT transcriptional repressor sequence by quantitative real time 
RT-PCR and FISH. Therefore, PC-3/hTERT/fchr11.1 was investigated further. 
 
 
 
The PC-3/hTERT/fchr11.1 hybrid was next transferred into A9, to generate hybrid 
clones for fine STS mapping. The resulting hybrids were symbolized as A9/fchr11.1 
followed by the clone number, i.e. A9/fchr11.1.1, A9/fchr11.1.2, A9/fchr11.1.3 etc, 
in 22 clones that were collected. 
 
 
 
Selected hybrids clones from the STS map i.e. A9/fchr11.1.4, A9/fchr11.1.9, 
A9/fchr11.1.13 etc were individually transferred back into PC-3/hTERT cell line. 
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The hybrids generated, for example from the transfer of A9/fchr11.1.9 were 
symbolized as PC-3/hTERT/fchr11.1.9 followed by the clone number, i.e. clone 1 
was designated PC-3/hTERT/fchr11.1.9.1, clone 2 was designated PC-
3/hTERT/fchr11.1.9.2 etc. 
 
 
 
The hTERT repressed and non-repressed hybrid clones generated by the selected 
individual transfers of the fragments from mouse A9 cells back into human cells 
were used to construct a panel in which the genes of interest could be tested. 
 
 
